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ABSTRACT 
 
Protein families are comprised of numerous sequences that adopt a similar three-
dimensional structure and functional properties. The superfamily of cytochromes P450 are 
an excellent example of a common structural scaffold being utilized for a variety of 
biological functions. This functional diversity is achieved in Nature through millions of 
years of evolution to create new and diverse sequences. We have used site-directed 
recombination guided by the computation algorithm SCHEMA to create an artificial family 
of cytochromes P450 in the laboratory. Members of this family possess unique properties 
such as altered activity profiles, increased thermostability and the ability to accept new 
substrates. 
 
We developed screening tools for the rapid analysis of hundreds of individual P450s. These 
high-throughput assays include the 4-aminoantipyrine (4-AAP) assay which is capable of 
detecting the hydroxylation of an aromatic ring. High-throughput carbon monoxide binding 
facilitates the rapid detection of P450s that correctly incorporate a heme cofactor and are 
thus properly folded and potentially functional. Finally, a substrate binding assay which 
measures a spectral shift that occurs when a substrate binds in a P450 active site is 
described.  
 
Fourteen double-crossover chimeras created from the bacterial P450s CYP102A1 and 
CYP102A2 were constructed to calibrate the P450 scaffold for SCHEMA, a computational 
algorithm used to minimize structural disruption in chimeric proteins. We found that only 
chimeras with high levels of structural disruption as measured by SCHEMA were 
vii 
 
unfolded. Among the fourteen chimeras we also observed three different activity profiles 
based on peroxygenase kinetic assays with the substrates p-nitrophenoxydodecanoic acid 
(12-pNCA), 2-phenoxyethanol and allyloxybenzene.  
 
We applied this calibration to create an artificial family comprising ~3,000 chimeric heme 
P450 proteins that correctly fold and incorporate a heme cofactor by recombining three 
cytochromes P450 at seven crossover locations chosen to minimize structural disruption. 
Members of this protein family differ from any known sequence at an average of 72 and by 
as many as 109 amino acids. Most (>73%) of the properly folded chimeric P450 heme 
proteins are catalytically active peroxygenases; some are more thermostable than the parent 
proteins. A multiple sequence alignment of 955 chimeras, including both folded and not, 
was analyzed using logistic regression analysis (LRA) to identify key structural 
contributions to cytochrome P450 heme incorporation and peroxygenase activity and 
suggests possible structural differences between parents CYP102A1 and CYP102A2. 
 
Thirty-four members of this artificial family were assayed for functional diversity on a set 
of eight substrates. P450 chimeras were able to exceed the parents in total activity on all 
eight substrates and were grouped into five different groups based on activity profiles using 
K-means clustering. Activity profiles on eight substrates were then performed in high 
throughput to produce a data set of 330 chimeras. The mean percent standard deviation of 
the activity assays showed the reproducibility of these high-throughput data and further 
analysis may reveal information about sequence-structure-function relationships.  
viii 
 
The products of the catalytic reactions of four chimeric P450s with substrates of human 
P450s, some of which are drug compounds, were analyzed by HPLC in order to determine 
their identity. Chimeras were able to produce authentic human metabolites of 
chlorzoxazone, zoxazolamine and propranolol, showed peroxidase acitivty on 4-
aminobiphenyl and produced an unknown product with tolbutamide. Finally, the 
peroxygenase activity of a mutant P450 heme domain is able to be further altered and 
enhanced using directed evolution. After two rounds of directed evolution and screening 
with the 4-AAP assay, we found mutants with altered substrate specificities and an overall 
enhancement of activity.  
 
The design and high-throughput methodologies described here can be used to create 
artificial protein families and to discover new and useful protein sequences. Like natural 
protein families, artificial protein families can be used to identify regions of protein 
sequence and structure that are important for folding and function. This is especially useful 
for analyzing protein families with few members or for validating tools for structure 
prediction and for protein sequence-structure-function analysis. Artificial protein families 
are also rich in sequence diversity and can provide sources of novel protein function. Using 
the high-throughput methodologies described here, chimeric P450s with enhanced activity, 
altered activity profiles, and the ability to hydroxylate drug-like compounds to produce 
authentic human metabolites were discovered in our artificial family of P450s. These 
methodologies will hopefully be extended to the study of other protein families and to the 
creation and discovery of increasingly valuable protein catalysts. 
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Chapter 1 
 
Introduction and thesis summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
Proteins are linear chains of amino acid that fold into specific three-dimensional 
structures (protein folds) that enable them to perform various biological functions critical 
for life. They have evolved over the past few billion years to comprise an enormous 
diversity of sequences, estimated at 5 x 1010 unique protein sequences [1]. However, 
there are postulated to only be on the order of one to ten thousand folds that are adopted 
by these many sequences [1-4]. These protein folds are therefore encoded by a multitude 
of amino acid sequences and each sequence is able to utilize that same fold for different 
biological functions. Sequences with similar folds are often grouped into protein families 
which are used to derive additional information about these protein folds and sequences. 
It is the functional diversity found within a single protein fold and the knowledge that can 
be extracted from protein families that has motivated the work described here. 
 
An excellent example of functional diversity and sequence differentiation is found in the 
cytochromes P450 superfamily of enzymes. In Nature, cytochromes P450s are capable of 
a variety of biological functions such as the breakdown of xenobiotics, primary 
catabolism, and steroid and other secondary metabolite biosynthesis [5,6]. The P450s that 
perform these myriad functions evolved by natural selection from a common ancestor 
which appeared hundreds of millions of years ago [7]. There now exist an enormous 
number of unique P450 sequences with over 5,000 known members of this family [8]. 
These P450s are highly variable at the amino acid sequence level (often less than 15% 
amino acid identity) yet their three-dimensional structures are well conserved [9,10]. 
Figure 1.1 exemplifies the functional and sequence diversity found in cytochromes P450 
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and illustrates how Nature has utilized the P450 fold for a variety of biological functions 
by diversifying its amino acid sequence. 
 
 
 
Figure 1.1. The diversification of an ancestral P450 sequence has led to new, divergent 
sequences with various biological functions but a well-conserved three-dimensional 
structure. CYP101 (red) is involved in the utilization of camphor as a carbon source in 
bacteria [11]. CYP3A4 (green) and CYP107A1 (orange) are involved in the defense of 
their host organisms by breaking down xenobiotics such as drugs or toxins and 
synthesizing antibiotics, respectively [12,13]. CYP51 (blue) is involved in cellular 
communication by synthesizing steroids [14]. The number in red shows the variability of 
the protein sequences as percent of amino acids which are different in a pairwise 
sequence alignment using ClustalW [15]. 
 
 
We sought to mimic the diverse functions found in a single protein fold by creating a 
large number of new P450 sequences in the laboratory using protein recombination 
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guided by the computational algorithm SCHEMA [16]. The result was the creation of an 
artificial family of cytochromes P450 which contains many new and diverse sequences 
that possess a variety of useful and interesting properties.  
 
Chapter 2 provides background information on protein diversity, current methods for 
creating protein diversity in the laboratory, and fundamentals of cytochromes P450. 
Chapter 3 describes high-throughput assays we developed in order to rapidly characterize 
the P450s created by recombination. Methods for detecting aromatic ring hydroxylation, 
a substrate binding event and heme incorporation are described. In Chapter 4, SCHEMA 
structural disruption is calibrated against the P450 scaffold by creating seventeen 
individual double-crossover chimeras between the heme domains of CYP102A1 and 
CYP102A2 (A1 and A2). SCHEMA is a computational algorithm used to further 
improve the likelihood of creating folded proteins by minimizing structural disruption 
upon recombination. The double-crossover chimeras were assayed for their ability to 
correctly fold and incorporate a heme cofactor and only chimeras with a higher level of 
structural disruption were not folded. The chimeras also showed a wide range of 
thermostabilities and possessed novel activities and substrate specificities relative to the 
parental proteins. 
 
Guided by the calibration in Chapter 4, we created an artificial family of cytochromes 
P450 using SCHEMA-guided, site-directed recombination of the three bacterial P450 
heme domains, A1, A2 and CYP102A3 (A3) in Chapter 5. This family contains 
thousands of new and diverse chimeric P450 sequences which differ from any known 
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P450 by 72 amino acid substitutions on average. Using logistic regression analysis (LRA) 
of 955 of these sequences we determined which sequence elements contribute to a 
chimeric P450s ability to fold and correctly incorporate its heme cofactor. We found that 
some of the new P450s are also more thermostable than any of the starting parents. 
Activity measurements on 2-phenoxyethanol and p-nitrophenoxydodecanoic acid (12-
pNCA) showed at least 73% of the chimeric P450s are catalytically active. LRA analysis 
of chimeras for which the activity on 12-pNCA was determined identified portions of the 
sequence contributing to this activity. Further analysis led to the construction of site-
directed mutants that identified residues previously unknown to be important for catalytic 
activity. 
 
Chapter 6 describes functional characterization of members of the artificial library on 
eight substrates and shows we can produce a large data set for further analysis. K-means 
clustering of 34 chimeras showed they separated into five groups based on activity 
profiles. This demonstrates that chimeric P450s can be functionally different from each 
other and from any of the parental proteins. The characterization of select chimeras 
towards substrates of human P450s, some of which are drug compounds, is described in 
Chapter 7. Chimeric P450s show activity on chlorzoxazone, propranolol, zoxazolamine, 
tolbutamide and 4-aminobiphenyl. The authentic human drug metabolites of 
chlorzoxazone, propranolol and zoxazolamine were shown to be shown to be produced 
by some of the chimeras using HPLC analysis. Chapter 8 describes the directed evolution 
of a mutant P450 peroxygenase for improved production of drug metabolites of 
propranolol. This chapter demonstrates that once activity on these important drug-like 
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molecules is found it can be further modified and improved using directed evolution. We 
were able to shift activity to the more active 5-hydroxypropranolol product as well as 
increase total production. We also demonstrate the potential utility of a bioconversion 
done with a P450 heme domain driven by hydrogen peroxide and its ability to produce 
comparable quantities of authentic drug metabolites to other methods. 
 
By creating and analyzing an artificial family of cytochrome P450s, we have made 
advances in the field of protein engineering and further demonstrated the utility of the 
cytochrome P450 scaffold for biocatalysis. The use of site-directed recombination guided 
by SCHEMA demonstrates that thousands of new proteins can be created in the 
laboratory. These new sequences can be analyzed as a traditional protein family would to 
derive information about the new and starting proteins. Proteins created in this manner 
can also vary functionally and perform useful chemical reactions such as the 
hydroxylation of drug compounds into their authentic human metabolites. These 
properties can then be further improved from the newly discovered sequence using 
directed evolution. This general protein design, creation and discovery should be 
applicable in the creation of other new enzymes with desirable properties. 
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A. Natural protein diversity 
Proteins are key building blocks of life and involved in virtually all aspects of cellular 
structure and function. They serve a variety of biological roles including the binding of 
nearly any conceivable molecule, catalyzing myriad chemical reactions, providing 
structure to living cells, allowing motion, and acting as sensors and switches. Their 
diversity stems from the nearly infinite number of ways these linear polymers can be 
assembled from the twenty amino acids. For instance, an average protein with length of 
200 amino acids has 20200 different possible sequences. The space of all possible 
sequences, termed protein sequence space, is vast and for all intents and purposes 
infinitely large [1-3]. The frequency of sequences which form useful proteins in this 
space, however, is extremely low [4-6]. These useful sequences generally define a protein 
fold, a well-defined three-dimensional structure that gives a protein its properties.  
 
Roughly three to four billion years ago [7], an early form of life happened upon a useful 
protein sequence which likely accelerated its rate of reproduction, possibly by enhancing 
the replication of a prebiotic nucleic acid [8,9]. Since then, this ancestral protein sequence 
has diversified and evolved through the process of natural selection to serve a variety of 
functions [10]. Protein sequences found in Nature are not randomly distributed 
throughout sequence space and this is used to group them into functionally or structurally 
related groups [11]. In the 1960s, the concept of protein families and superfamilies was 
introduced in order to better understand protein evolution and function [12]. A family of 
proteins is a group of closely related sequences and a superfamily is two or more related 
families. This has been expanded to more hierarchical systems which consider a proteins 
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three-dimenstional structure first, then sequence and functional similarity [13,14]. By 
grouping proteins into families, various bioinformatic tools can be applied to learn about 
the proteins in general as well as the individual members. Generally a set of sequences 
are aligned using multiple sequence alignment tools such as ClustalW [15,16]. Topics 
such as residues contributing to enzymatic activity [17,18], ligand binding [19], protein 
structure [20-22], and protein evolution [23,24] can be explored.   
 
B. Artificial protein diversity 
Artificial protein diversity consists of the new protein sequences created by humans. The 
number of sequences created this way pales in comparison to that found in Nature, but 
there has been much progress with the creation of ever more complicated proteins as well 
as those with folds not yet found in Nature [25]. To create new protein sequences, 
researchers must either modify existing sequences, design specific sequences from 
scratch, or search among random or semi-random sequences [26,27]. The former is 
generally the most successful and has found utility in the modification of enzymes for 
industrial purposes [28,29]. And indeed, biocatalysts are used in large-scale industrial 
applications including the production of acrylamide and nicotinamide with nitrile 
hydratases [30], pulp kraft-bleaching and recycling of paper [31], antibiotic synthesis 
[32], and the synthesis of biopolymers [33].  
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B.1 Modification of existing sequences 
New protein sequences can be created from existing sequences by selectively mutating an 
amino acid to another specific amino acid or by randomly mutating portions of the entire 
sequence and screening or selecting for sequences with the desired properties. Generally, 
the goal of such experiments is to improve specific protein properties such as stability or 
activity. When targeting specific residues information from a variety of sources is 
employed such as structural information [34], comparison with other protein sequences 
[35] or from experimentally derived information (e.g. importance in substrate specificity) 
[36,37]. Successful inversion of enantioselectivity [38,39] and activity enhancements 
[34,40,41] are a few examples of successes achieved with targeted mutagenesis.  
 
Computational protein design is another form of targeted mutagenesis that employs 
different algorithms to choose the specific amino acid residues to be altered. The 
mutations selected in this manner generally have a higher success rate as they are pre-
screened by the computer. Early computational design efforts aimed to repack the 
hydrophobic cores of proteins to increase stability or to optimize other structural elements 
[42], eventually leading to fully automated computational sequence selection tools [43-
45]. Since these early efforts, numerous other properties have been designed including 
the stabilization of normally unstable portions of proteins [46], optimization of interfaces 
[47,48], and the binding of metals [49] or other cofactors [50-53].   
 
Unlike targeted mutagenesis, directed evolution does not require large amounts of 
information about structure or function to be successful. Instead an algorithm similar to 
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that used by Nature, natural selection, is employed [54]. Directed evolution involves the 
creation of a large number of variations of a gene of interest (a.k.a parental gene). These 
groups of genes with new sequences are termed ‘libraries’ and are screened or selected 
for an individual sequence with a desired property [55]. These improved variants are then 
used as parents for the next round of evolution and iterations of this cycle are repeated 
until the desired result is achieved. Numerous methods to create variant genes for 
directed evolution have been developed such as error-prone PCR, where a gene is 
randomly mutated, or DNA shuffling, where multiple genes are broken and reassembled 
into new sequences [27,56]. Directed evolution can be used to evolve a protein in 
unnatural conditions and for features which Nature may not evolve for but may be 
necessary for industrial or medical purposes [57,58]. The new proteins discovered in this 
fashion often contain very unpredictable sequence changes, for example mutations on the 
proteins surface can affect substrate specificity. Directed evolution has been used to alter 
and improve many properties of enzymes including thermostability [59-61], organic 
solvent resistance [62,63], enantioselectivity [64-66], increased activity [67,68], 
functional expression [69], and altered substrate specificity [70-72]. 
 
More recently, a synergy between targeted design and directed evolution has been 
demonstrated. By combining design and directed evolution, Park and co-workers were 
able to introduce β-lactamase activity into the αβ/βα metallohydrolase scaffold of 
glyoxalase II [73]. The design was used to choose mutations which gave the protein a 
very low level of the new activity, followed by rounds of directed evolution to find 
mutations to rapidly improve this activity. The creation of a biologically functioning 
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enzyme from a protein without any known enzymatic activity serves as another example 
of the potential [74-76]. In this experiment, Dwyer et al. began with ribose-binding 
protein and converted it to function as a triose phosphate isomerase using computational 
design. The designed molecule had a rate enhancement of 105 over the background 
reaction and after a few rounds of directed evolution by random mutagenesis was able to 
support E. coli growth under gluconeogenic conditions on glycerol [75]. 
 
B.2 Searching among random sequences and de novo design 
The creation of libraries of random or semi-random protein sequences followed by 
screening or selection for folded or functional proteins has been successful in discovering 
interesting sequences with basic functions. For instance, isolation of proteins with simple 
functions such as the binding of adenosine triphosphate have been isolated from a pool of 
random sequences [77]. Methods which attempt to increase the frequency of useful 
sequences in these large libraries such as a ‘binary patterning’ have accelerated the 
discovery of de novo proteins. Binary patterning takes advantage of the structural 
periodicity of polar and nonpolar amino acids in protein secondary structures. The first 
success was in creating a four-helix bundle using amphipathic α-helices which have a 
repeating periodicity of 3.6 residues per turn [78]. This methodology was extended to 
beta-sheet proteins were this same strategy yielded proteins which self-assembled into 
large fibrils similar to the amyloid fibrils found in neurodegenerative diseases [79,80]. 
Another method to increase the frequency of promising sequences is to use a reduced set 
of amino acids that improves the frequency of secondary structural elements. For 
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example, isolation from random sequences consisting mainly of random combinations of 
glutamine, leucine, and arginine yielded folded structures with native-like folds [81]. 
 
Computational design can also be used to design sequences de novo. Instead of searching 
among a pool of sequences, a computational algorithm is used to design a single 
sequence that is predicted to fold or function. As this is a very computationally 
demanding problem, the complexity of sequences that can be designed is limited by 
accessible computational power. As such, some of the first computationally designed 
proteins were very simple proteins such as four-helix bundles that displayed circular 
dichroism spectra characteristic of α-helices but were not uniquely folded structures 
[82,83]. More recently, computational protein design has been used to design a protein 
fold not present in the Topology of Protein Structure server [25]  
 
B.3 Protein recombination 
Protein recombination is a powerful tool in the creation of new protein sequences. Since 
it will serve as a primary means here, the methods and background will be discussed in 
more detail. Recombination has been shown to be an effective search strategy in other 
fields such as animal breeding, computer programming and economics [84-86]. Many of 
the ideas behind the use of recombination to alter protein properties in the laboratory 
stem from the observation of alternative splicing and the presence of introns and exons in 
Nature [87-89]. Alternative splicing takes place when exons present in an organism’s 
genome are differently assembled in order to modify a proteins sequence and potentially 
function. The exon theory of proteins takes this a step further and postulates that during 
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evolution, proteins acquired functional diversity by combining the exons encoded by 
early proteins [88,89]. A search for these protein building blocks or Nature’s protein lego 
set still continues [90]. 
 
Protein recombination refers to the division and reassembly of the nucleotide sequence 
encoding two or more parent proteins and reassembling them into new sequences (Figure 
2.1). The new proteins created in this manner are referred to as chimeras. The advantage 
of recombination over other methods such as random or targeted mutagenesis is that one 
is able to create a much larger number of sequence changes while still retaining a high 
frequency of folded and potentially interesting proteins. Using random mutations, one 
can make approximately five amino acid substitutions before the fraction of functional 
proteins in a library drops below 10% [91,92]. In contrast, recombination is much more 
conservative and allows at least an order of magnitude more substitutions while retaining 
the same frequency of functional proteins [93]. The main reason for this is the new 
proteins contain sequence changes which have effectively been prescreened by Nature to 
be compatible with a given structure [94]. The larger number of sequence changes allows 
one to explore more distant regions of protein sequence space and potentially functional 
space [94].   
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Figure 2.1. In vitro recombination showing three parental proteins and genes being 
recombined to form numerous chimeric offspring.  
 
 
Numerous methodologies exist for in vitro protein recombination. One of the most well 
known, DNA shuffling, relies on stretches of DNA sequence identity to randomly 
reassemble gene fragments of parental genes into chimeras [68,95,96]. It works by 
breaking the DNA of different parent genes into pieces and reassembling them in a PCR 
reaction. Variant proteins with a few mutations each can be recombined in this manner in 
order to find the most favorable combinations of the mutations or to eliminate deleterious 
ones [97]. Alternatively, a method referred to as family shuffling uses naturally occurring 
protein sequences as the parent enzymes [94,98]. Family shuffling takes advantage of the 
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diversity found in homologous genes from nature and has assisted in the creation of 
enzymes with increased activity [94,99], higher stabilities[100], and altered substrate 
activities [101-103]. More distant regions of sequence space, that is regions that are not 
connected by single amino acid changes, are sampled by this approach. It is thought that 
this may allow for the discovery of other functional regions of sequence space. However, 
DNA shuffling and other annealing based methods suffer from only allowing the use of 
parental proteins with high levels of sequence identity (>70%) and crossover locations 
biased towards regions of highest sequence identity. Other annealing based methods 
include RACHITT [104], StEP [105], heteroduplex formation [106], synthetic shuffling 
[107], ADO [108] and DOGS [109]. 
 
To overcome the issues of crossover bias and high parental similarity requirements, 
sequence-independent recombination methods have been developed. Methods such as 
SHIPREC [110], ITCHY [111] and SCRATCHY [112] rely on direct DNA ligation 
rather than annealing, allowing for the creation of chimeras from very divergent parents 
but resulting in a higher frequency of deletions and frameshifts. Of these three methods, 
only SCRATCHY is able to create more than a single crossover in each chimera. Another 
method, SISDC, uses the insertion of tag sequences to specify crossover locations and is 
less susceptible to the problems resulting from direct ligation. It also allows the crossover 
locations to be specified and is able to incorporate multiple crossovers [113]. Finally, full 
gene synthesis can be used to assemble chimeric sequences [114].  
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To complement these construction methods are a number of design strategies by which 
libraries of chimeras can be further optimized. The methods FAMCLASH and 
OPTCOMB seek to minimize the number of unfavorable clashes in the resulting 
chimeras by examining evolutionary sequence information [115] and OPTCOMB [116]. 
IPRO uses energy-based scoring functions to improve overall library quality [117]. 
SCHEMA, which is used in the work described here, uses structural information from the 
parental proteins in order to design optimal libraries. Using the 3D structure of one of the 
parent proteins, SCHEMA identifies pairs of amino acids that are interacting (e.g., 
residues within a cutoff distance of 4.5 Å) and determines the net number of interactions 
broken when a chimeric protein inherits portions of its sequence from different parents 
[118]. SCHEMA has been shown to increase the frequency of folded proteins by 
choosing crossover points which minimize structural disruption [119,120]. 
 
C. Cytochromes P450 
Cytochromes P450 are a fascinating family of enzymes due to their importance in fields 
such as the creation and administration of medicines, the evolution of every family of life 
and their future promise for biotechnology and ‘greener’ chemistry. P450s are ubiquitous 
in Nature and constitute one of the most diverse enzyme superfamilies. They are most 
well known for their role in oxidative chemistry whereby an oxygen atom is inserted into 
a C-H, C-C, C-N or N-H bond leading to epoxidations, S-oxidations, N-hydroxylations 
and dealkylations. Other reactions which are catalyzed include but are not limited to 
reductions, desaturations, ester cleavages, ring expansions, ring formations, aldehyde 
scission, dehydration, coupling reactions, ipso attacks, one-electron oxidations, cis-trans 
 19
bond rearrangements, oxidative cleavage and rearrangements [121-123]. The diverse 
functions of these enzymes stems from their heme cofactor (protoporphyrin IX) seen in 
Figure 2.2A. The heme is covalently bound to an axial cysteine ligand and is housed in a 
generally hydrophobic active site which allows for the binding of a diverse array of 
substrates. This heme cofactor is also what provides P450s with their name since P450 is 
derived from the unusual Soret band with a maximum absorption near 450 nm that is 
present upon CO difference spectroscopy (Figure 2.2B). 
 
 
 
Figure 2.2. Basic features of a P450. A) Chemical structure of protoporphyrin IX, the 
heme cofactor found in cytochromes P450. B) Soret band at 450 nm observed using CO 
difference spectroscopy on the ferrous–CO complex. 
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C.1 P450 Nomenclature 
A nomenclature system was designed for the large number of P450 sequences based on 
evolutionary divergence were P450 genes are grouped into families and subfamilies [124-
128]. A P450 protein from one family generally shares ≤ 40% amino acid identity with a 
P450 protein from another family although there are exceptions [129]. Members of 
different families are though to have diverged from one another roughly 600 – 900 
million years ago. P450s with 55% or greater amino acid sequence identity are then 
grouped into subfamilies and are approximated to have diverged from one another with 
the past 150 million years. Cytochromes P450 are abbreviated CYP which is then 
followed by their family and subfamily designations. For example, CYP3A4 is the fourth 
member of the A subfamily in family 3. Ranges of family numbers are assigned to 
different species with CYP1-49 belonging to animals, CYP51-70 belonging to fungi, 
CYP71-99 representing plant P450s and CYP101 and higher are for bacterial P450s. 
However, due to the rapid increase in known P450s this numbering system has now been 
extended to the hundreds and even thousands [128]. 
 
C.2 Diversity in the cytochromes P450 superfamily 
Stemming from their ability to perform numerous chemical reactions and bind a variety 
of molecules, cytochromes P450 perform an enormous number of biological functions. In 
microbes, P450s function in secondary metabolism, signaling and catabolism. The most 
well known role of P450s in bacteria is in the catalysis of the first metabolic step in the 
metabolism of some carbon sources. Generally, a P450  hydroxylates an inactivated 
carbon compound which serves to solubilize the molecule as well as to initiate its 
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degradation. They facilitate a large number of molecules as carbon sources such as 
hydrocarbons [130], alkanes [131-135], and polycyclic hydrocarbons such as 
benzo[a]pyrene [136] and camphor [137,138]. Specific P450s that allow bacteria to 
utilize chemicals in the environment as energy sources include CYP101  [139,140], 
CYP108 [141], CYP111 [142,143] which are from different Pseudomonas sp. and 
CYP176A [144] from Citrobacter braakii. 
 
The majority of P450 research is directed towards the 57 found in humans due to their 
critical roles in the synthesis of steroids and other signaling molecules as well as the 
breakdown of xenobiotics such as drugs and other environmental chemicals [145,146]. In 
fact, P450s are required to synthesize all steroids found in humans and assist in the 
metabolism of over 90% of currently prescribed drugs making them extremely interesting 
to the pharmaceutical industry [147,148]. Of the P450s important in drug metabolism, 
CYP3A4 does the majority of the work and is responsible for 30% of phase I metabolism 
[149]. Understanding P450s role in drug metabolism is critical to producing safe and 
effective drugs. Their variability in activity and expression from individual to individual 
can result in drastic differences in dosage requirements. For example, the expression of 
CYP2D6, which is important in drug metabolism, can vary over four orders of magnitude 
[150]. Inhibition of a P450 by a drug can lead to exaggerated pharmacological effects of 
another drug whose elimination or activation depends on the inhibited enzyme. This may 
cause build up of the drug in the patient or prevent the drug from being converted to its 
active form, both leading to therapeutic failure [151]. Understanding this metabolism can 
also lead to new and improved drugs since numerous drugs form active metabolites with 
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superior properties [152]. A well known example of this is with the anti-histamine drug 
terfenadine (Seldane) [153]. Approved by the FDA it went on the market in the early 
1990’s, however, it was soon discovered that it caused heart problems. It was then found 
that the active form of terfenadine was not the chemical that was ingested but the 
metabolite created by CYP3A4. This molecule turned out to also be less toxic and was 
approved by the FDA and introduced onto the market as fexofenadine, better know as 
Allegra™ [154]. Similar examples include the hypertension drug mibefradil and the 
asthma drug furafylline [155,156].  
 
The genetic polymorphisms found in human P450s are one of the major contributors to 
individuals drastically different responses to drugs and other chemicals [157]. For 
instance, variable activities of CYP1A2 in humans is partially responsible for our 
different responses to caffeine since the rate of this enzyme can vary [158]. These 
variability’s also make P450s of great interest to the medical community since numerous 
diseases are associated with defects in P450s. For example, a missing or damaged P450 
involved in the processing of steroids or vitamins can have devastating health effects 
[159]. P450s are associated with diseases such as hypercholesterolaemia [160], coronary 
artery disease [161] and hypertension [162]. They are also key enzymes in cancer 
treatment and cancer formation since they can activate procarcinogens or inactivate 
carcinogens [163] as well as activate or inactivate cancer drugs [164]. 
 
In plants, P450s are involved in the biosynthesis of lignins, terpenes, alkaloids and a 
variety of other secondary compounds that act as plant defense agents [165-168]. Since 
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plants are sessile and cannot move away from danger, they require a large battery of 
P450s for defense. Whereas humans have 57 functional P450 genes, Arabidopsis 
thalianis has 246 (roughly 1% of genes) [169,170] and rice has a whopping 356 
functional P450s [171]. An interesting example of insecticides and bactericides formed 
by P450s is the molecules DIBOA and DIMBOA, found in rye and maize, respectively 
[172-174]. Their biosynthesis involves four distinct P450s, each involved in a different 
synthetic. Additionally, plants use P450s in a variety of biosynthetic pathways of both 
central and secondary metabolites  
 
Another form of diversity in P450s is their redox systems. There are numerous types of 
electron transfer components utilized by P450s as well [175,176]. Most bacterial and 
mitochondrial membrane P450s are termed class I P450s. Class I P450s have a reductase 
system with two components, a flavin adenine dinucleotide (FAD)-containing reductase 
and an iron-sulfur protein [177]. The class II P450s are typically membrane-bound 
eukaryotic microsomal P450s which interact with a single reductase containing both 
flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) cofactors. There 
are some soluble class II P450s, as is the case with CYP102A1. Self-sufficient P450s, 
that is those that require no additional proteins since they utilize oxygen-containing 
substrates and do not require exogenous electrons, make up class III P450s. Class II 
P450s with all of the protein components fused into a single polypeptide chain are also 
sometimes grouped into this class [178,179]. A more recently discovered class IV 
consists of the catalytic heme domain fused to an FMN- and 2Fe-2S cluster-containing 
reductase similar to that found in dioxygenases [178,180,181]. In these systems, the flow 
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of electrons is from NADH to FMN to 2Fe2S cluster to heme domain. Artificial systems 
for supplying electrons have also been developed including electrochemical methods 
[182] and artificial cofactors such as cobaltocene [183] and cobalt (III) sepulchrate [184]. 
 
Due to the great interest in P450s, numerous x-ray crystal structures have been solved. 
Bacterial P450s were the first structures to be determined since they are highly soluble 
and easier to crystallize.  To date the structures for CYP101A1 (P450cam) [185-187], 
CYP102A1 (P450BM3)  [188-190], CYP108A1 (P450Terp) [191,192], CYP107A1 
(P450eryF)   [193-195], CYP119A1 [196], CYP154C1 [197], CYP152A1  (P450BSβ) 
[198], CYP175A1  [199], CYP121A1 [200], CYP107L1 (P450PikC) [201], CYP154A1 
[202], CYP167A1 (P450epoK) [203], P450 OxyC [204], P450 OxyB  [205], CYP199A2  
[206] and CYP2R1 [207] have been solved. CYP55A1 (P450Nor) [208] and CYP51 [209] 
from fungus have been determined. The structures of mammalian P450s include CYP2C5 
[210-212], CYP2C9 [213,214], CYP3A4 [215,216], CYP2B4 [217,218], CYP2C8 [219], 
CYP2A6 [220], CYP2D6 [221]. 
 
C.3 P450 evolution 
It is thought that the first ancestral P450 genes may have arisen in a prokaryote about 3.5 
billion years ago [126]. There is strong evidence that all P450s are derived from this 
common ancestor due to their sequence similarity [222,223] and conservation of 
predicted secondary structure and hydrophobicity profiles [224]. The early function of 
P450s is still open to debate and has been postulated to be involved in the detoxification 
of oxygen as its levels began to increase to what we see today [225], a role in steroid 
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metabolism, assimilation of chemicals [129] or as peroxidases [224]. Regardless of their 
original biological function, P450s have rapidly diverged through gene duplications 
followed by divergence and ultimately fixation along with lateral gene transfer 
[129,226,227]. 
 
During more recent evolution over the past 800 million years, plant-animal and plant-
insect warfare has aided the diversification of P450s [165]. As animals and insects began 
to ingest plants, the plants responded by synthesizing new metabolites that are toxic to 
their consumers. In response, animals and insects developed new enzymes capable of 
breaking down these toxins [129,228]. P450s were critical in this escalation. An example 
of how P450s affect plant-animal interactions is illustrated by CYP6B1 and CYP6B8 
from the butterfly species Papilio polyxenes and Helicoverpa zea, respectively. The 
generalist, H. zea, is capable of consuming hundreds of types of plants compared to the 
specialist P. polyxenes which only feeds on furanocoumarin-containing plants. This is 
directly facilitated by their P450s with CYP6B8 showing a much broader substrate 
specificity allowing it to breakdown the insecticides present in a larger number of plants 
and therefore allow its host to feed on more plants. In contrast, CYP6B1 could only 
breakdown a small number of insecticides and therefore its host could only consume a 
small number of plants [229].  
 
The rapid diversification of P450s has led to an extremely high variance in their primary 
sequences. The two most well conserved sequences among all P450s are within the K-
helix and at the heme-binding site. The K-helix has an EXXR charged pair were X can be 
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any amino acid. The heme-binding site contains the ‘signature sequence’ of all P450s, 
FXXGXXXCXG which contains the cysteine that ligates the heme cofactor. With 
thousands of different P450s there are variations at each position except the critical 
cysteine. Other conserved features of different sub groups of P450s can be found but are 
less prominent [128,230]. However, despite having very low sequence identities ranging 
from 10 – 30 % between families [125], P450s possess the same tertiary structure and a 
well-conserved heme-binding core [231-233]. For example, a set of nine P450s which 
share between 10 and 27% amino acid sequence identity has over 28% of their C-alpha 
carbons withn a root-mean-square deviation (RMSD) of 2 Å demonstrating their high 
level of structural conservation [233].  
 
C.4 P450 mechanism and catalytic cycle 
The overall reaction catalyzed by cytochromes P450 can be seen in equation (1): 
 
OHPNADROHHPNADHORH 22 )()( ++→+++ ++    (1) 
 
The subsrate, RH, can be a tremendous number of molecules with a vast chemical 
diversity.  The archetypal P450 reaction involves insertion of an oxygen atom into an 
unactivated C-H bond although many heteroatoms are possible targets [123].  P450s are 
capable of many other different types of reactions. The overall mechanism involves the 
combination of oxygen and substrate to produce a water molecule and a mono-
oxygenated product facilitated by a protoporphyrin IX cofactor (heme). The central 
concepts of the catalytic cycle have been appreciated since early 1970 although specific 
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reaction intermediates are still up for debate. The structures of some of these reaction 
intermediates have been elucidated using x-ray crystallography in the CYP101 system 
[186,234-236] as well as with other spectroscopic methods [237-241]. 
 
The mechanism of cytochrome P450 catalysis has been the subject of numerous reviews 
[123,242-246] and is summarized here in Figure 2.3. The catalytic cycle begins with the 
enzyme in its resting state [I] with iron in the ferric state and the iron spin state typically 
low-spin (although some substrate-free P450s are high-spin [247,248]). The distal sixth 
ligand of the heme in this resting state is a water molecule [249]. When substrate binds, 
the water molecule is displaced, resulting in the iron spin-state equilibrium to become 
predominantly the high-spin ferric state [II] [250]. This results in the redox potential of 
the heme becoming less negative. In CYP101 and CYP102A1, for example, binding of 
substrate shifts the redox potential from -303 mV to -173 mV [250] and from -370 mV to 
> -270 mV [251], respectively. The redox potential shift allows the appropriate reductant, 
putidaredoxin (-240 mV) for CYP101 and the FMN- and FAD-reductase (-216 mV) for 
CYP102A1 for example, to provide reducing equivalents to the heme. The ferric iron 
moves to the ferrous state [III] while remaining high-spin. This is followed by 
preferential oxygen binding to the high-spin ferrous state with a rate constant of 1.7 x 106 
M-1 s-1 producing a high-affinity complex (KD = 0.6 μM in CYP101) [248,252]. This 
complex, however, is unstable and in equilibrium with a ferric-superoxide species, 
Fe3+O2.- (IV) [253-256]. This ferric-superoxide species is favored by protonation of the 
superoxy anion and is facilitated in P450s by the presence of exchangeable protons in the 
heme environment. The second reduction yields a negatively charged ferric-peroxo and is 
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generally thought to be rate limiting in most P450s [V]. Protonation of this ferric-peroxo 
species is rapid, forming Fe3+OOH [VI]. A second protonation is quickly followed by 
heterolysis of the O-O bond forming reactive oxygen species equivalent to Compound I 
[VII] [257-259] and release of water. A thiolate-ligated nonheme oxoiron(IV) complex 
[Fe+4(O)(TMCS)]+ [260] as well as electronic paramagnetic resonance studies [261] 
supports the structure shown in [VII]. Interestingly it was found that in the absence of the 
thiolate ligand, the [Fe+4(O)(TMCS)]+ complex was an oxo-atom transfer agent (two-
electron oxidant). The axial thiolate altered the reactivity into a hydrogen-atom 
abstraction agent (one-electron oxidant), consistent with P450 chemistry. This is an 
electron-deficient complex which is thought to abstract a hydrogen atom or an electron 
from the substrate resulting in collapse of this intermediate and generation of the product, 
ROH [VIII]. This product is then released, returning the enzyme to its resting state [I]. 
  
 
 29
 
Figure 2.3. P450 catalytic cycle, see text for details. 
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The P450 catalytic cycle is not perfect, however, and there at least three branch points 
were side reactions may occur (Figure 2.3). These branch points are often referred to as 
uncoupling steps. The first uncoupling reaction that can occur during the cycle is the 
‘autoxidation shunt’ were the oxy-ferrous species [IV] is autoxidized producing a 
superoxide anion and returning the enzyme to its resting state [I] [262,263]. In CYP101, 
the oxy-P450 complex autoxidizes with a rate constant of 0.01 s-1 at 20 °C [252]. The 
presence of substrate increases the half-life ten to twentyfold [252,253]. The second side 
reaction is the ‘peroxide shunt’ were the coordinate peroxide [V] or hydroperoxide anion 
[VI] dissociates from the iron forming hydrogen peroxide [264]. This completes an 
unproductive cycle in which the two-electron reduction of oxygen occurs without product 
formation. The peroxide shunt, however, may be exploited in the reverse direction 
eliminating the need for O2 and NAD(P)H. This is discussed in more detail in the next 
section. A third side reaction  the ‘oxidase shunt’ were the ferryl-oxo intermediate [VII] 
wherein the ferryl-oxo intermediate is oxidized to water instead of oxygenation of 
substrate [265]. This results in the four-electron reduction of dioxygen with the net 
formation of two water molecules.  
 
C.5 The ‘peroxide shunt’ pathway 
The two electrons used during the catalysis are generally supplied by one molecule of 
NAD(P)H, although the second electron transfer can be facilitated by cytochromes b5 
[266,267]. Alternatively, P450s are capable of utilizing oxygen and two electrons from 
peroxide to perform catalysis via the ‘peroxide shunt’ pathway (see equation 2).  
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OHRROHOOHRRH '' +→+             (2) 
 
Figure 2.3 shows that the peroxide shunt pathway bypasses a large part of the catalytic 
cycle. Numerous sources of peroxide such as organoperoxides or hydrogen peroxide may 
support the reaction, however this depends on the individual P450s. This pathway is 
thought to utilize a similar reactive oxygen species [242,268] produced by varying routes 
depending on the peroxide species, substrate and individual P450. Homolytic cleavage of 
peroxide has been shown to occur with peroxyphenylacetic acid [269], cumene 
hydroperoxide [270-272] while heterolytic cleavage has been shown with butylated 
hydroxytoluene [273]. The specific P450 and substrate also has an effect on how 
peroxide is utilized [272,274]. Additionally, a number of oxidants other than 
hydroperoxides such as peroxy acids, iodobenzene and sodium chlorite can be utilized 
[275-277].  
 
NAD(P)H utilizing P450s generally have high Km values for peroxides, with ranges from 
15 to 250 mM have been reported [67,277-279]. Some P450s such as CYP152A1 and 
CYP152B1 (P450BSβ and P450SPα, respectively) appear to naturally function as 
peroxygenases [198,280-284]. They hydroxylate near the carboxyl group of a fatty acid 
substrate which is thought to be stabilized by a nearby arginine residue similar to 
peroxidases. This presumably assists in peroxide activation by increasing the polarity of 
the active site. As such, CYP152A1 and CYP152B1 have low Km’s for H2O2 at 21 μM 
[285] and 72 μM [198], respectively. 
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The utilization of peroxide can cause different products to be made compared to the 
NAD(P)H driven reactions. For example, CYP1A2 catalyzes the activation of the 
heterocyclic aromatic amine 2-amino-3-methylimidazo[4,5-f]quinoline to genotoxic 
metabolites in the presence of peroxides [286]. P450s found in guinea pig liver were able 
to more efficiently catalyze hydroxylation at thermodynamically less reactive positions of 
arachidonic acid than the NADPH-dependent reaction [287]. P450s in rat liver 
microsomes showed different substrate specificities when using NADPH/O2 versus H2O2 
[288]. Reaction rates of CYP3A4 and CYP2D6 were able to be increased when using 
peroxide donors in place of the natural electron [289]. 
 
C.6 The CYP102 family 
Members from the CYP102 family are employed in the studies here. Currently, there are 
thirteen known members of the CYP102 family with six members of the CYP102A 
subfamily (CYP102A1 – CYP102A6). CYP102’s are class II P450s with a FAD- and 
FMN-reductase fused to the heme-binding domain [290]. The most well understood of 
the family and favored model system of our laboratory, is CYP102A1. The common 
name of CYP102A1 is P450 BM3, as it is the third P450 isolated from Bacillus 
megaterium [291]. Its sequence was first reported in 1989 causing much excitement in 
the field due to its potential use as a more accessible model system for understanding 
aspects of the membrane-associated human P450s [292]. CYP102A1 hydroxylates or 
epoxidates numerous substrates, but shows the highest activity (~17,000 min-1 [293]) on 
long-chain fatty acids at the omega-1-3 positions [293-295]. In Nature, its thought to play 
a role in the detoxification of polyunsaturated fatty acids such as linoleic acid [296,297].  
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Of the thousands of P450s, CYP102A1 is one of the best studied and frequently 
engineered. Several features make CYP102A1 such a popular P450 system [298]. The 
first is that it has the fastest known catalytic rate for P450 enzymes. This is thought to be 
a result of the fusion of the reductase domain and catalytic domain within the same 
polypeptide chain [299,300]. Although it can function when the heme and reductase 
domains are separated and mixed together, but at much lower efficiency [301]. 
Additionally, its large hydrophobic active site enables it to accept a variety of other, non-
natural substrates [302].  Additionally, the numerous X-ray crystal structures that are 
available assist in understanding [188-190]. It is also easy to genetically manipulate and 
expresses well at levels of  up to 1,000 mg/ml [298]. 
 
CYP102A1 has been engineered to accept and be more active on a variety of substrates. 
Early efforts aimed at improving activity on compounds similar to the natural fatty acid 
substrates. For instance, reversing the charge at the mouth of the active site allowed for 
increased activity on alkyltrimethyl ammonium compounds [303] and the activity 
towards shorter fatty acids was enhanced using targeted mutations [304]. Directed 
evolution of CYP102A1 led to a triple mutant (F87V/L188Q/A74G) able  to oxidize a 
variety of substrates such as indole, alkanes, cycloalkanes, arenes, fluorene, acenaphthene 
and polycyclic, aromatic hydrocarbons [305-307]. Other triple mutants could hydroxylate 
polycyclic aromatic hydrocarbons such as fluoranthrene [308] and alkoxyresorufins 
[309]. Starting with wild-type CYP102A1, activity on octane was improved [310], 
followed by activity on gaseous alkanes such as propane and ethane [311,312].  Even 
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increases in the regioselectivity for the terminal position of octane [313] and epoxides 
[314,315]. Six amino acid mutations led to a 300-fold increase in activity on the 
carotenoid intermediate, β-ionone [316]. Engineering efforts have more recently targeted 
more commercial-like processes such as activity in organic solvents [62] and activity on 
valencene for fragrance production of (+)-nootkatone [317] 
 
CYP102A2 and CYP102A3 are the next best characterized members of the CYP102 
family [318,319]. Discovered in Bacillus subtilus, they share roughly 65% amino acid 
identity to CYP102A1 and are also fatty acid hydroxylases but prefer substituted fatty 
acids and have altered regioselectivity relative to CYP102A1 [319,320]. CYP102A2 has 
been evolved using error-prone PCR to exhibit modified substrate specificity with 
increased activity. The mutant discovered was proline 15 to serine, a residue likely not in 
direct contact with the substrate but in shaping the active site [321]. CYP102A3 was 
engineered using mutations that had been previously been made in CYP102A1 [307] to 
broaden its substrate specificity, especially towards aromatic compounds. Interestingly, 
one of these sequence changes was already present in CYP102A3. The mutations in 
CYP102A3 had similar effects, conferring activity on octane and naphthalene [322]. 
CYP102A3 has also been engineered for increased terminal hydroxylation of octane 
[307]. 
  
C.7 P450s and recombination 
Breaking and reassembling P450s is not a new idea and is actually inspired by Nature 
were it is used to alter the function of or target a P450 to different cellular locations [323-
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329]. For example, CYP3A7 is the most abundant P450 in human liver during fetal 
development and plays an important role in the metabolism of endogenous hormones, 
drugs and other potentially toxic chemicals [330,331]. Interestingly an alternately spliced 
variant comprised of exons from CYP3A7 and the pseudogene CYP3AP1 displays 
altered enzymatic activity and tissue distribution [329]. Another example of altered 
function is CYP4F3 which be modified by incorporating alternate exons [328]. Chimeric 
P450s can also be detrimental; unequal crossing over between CYP11B1 and CYP11B2 
causes type I familial hyperaldosteronism [332]. 
 
Numerous studies have created chimeras of P450s for the exploration of novel functions 
as well as the study of the particular enzymes involved.  For example, replacement of 
small stretches CYP102A1 with segments of roughly ten amino acids from the insect  
CYP4C7 produced enzymes capable of forming a new product from a previously 
accepted substrate [333]. Chimeric enzymes constructed by swapping domains between 
P450s and the heme enzyme nitric-oxide synthase proved to be able to either perform 
hydroxylation or produce nitric oxide [334,335]. Other examples of altered 
regioselectivities include chimeras between CYP2C2 and CYP2C1 which acquire 21-
progesterone hydroxylase activity while retaining their activity on lauric acid [336]. 
Interestingly, replacing only the 28 carboxy-terminal residues of CYP2C2 with those 
from CYP2C14 created a chimeric P450 capable of novel 16β-hydroxylation of 
testosterone [337,338]. A study in which CYP1A1 and CYP1A2 were randomly 
recombined using DNA shuffling yielding a library in which 11.8% of the chimeras 
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analyzed were functional on naphthalene [96]. The DNA-shuffled chimeric P450s 
exhibited altered substrate specificities [339]. 
 
Numerous studies have used chimeragenesis to study P450s and identify functionally 
important regions of their sequence [340-348]. In fact, replacement of ten residues of 
CYP2C5 with those from CYP2C3 increased the solubility of CYP2C5 [349], leading to 
the determination of its crystal structure, the first ever of a microsomal P450 [210]. 
Similarly, the solubility of CYP1A2 was increased using recombination with CYP102A1, 
who share only 16% amino acid identity while retaining catalytic activity [110]. 
Chimeras between CYP2B5 and CYP2B4 aided in determining amino acid residues 
responsible for these enzymes regioselectivity on androstenedione [348]. Another 
example is were  a segment of CYP2C5 important for substrate binding was identified by 
examining chimeras made using CYP2C5 and CYP2C4 [347]. Other chimeric P450s 
reported in the literature include those between CYP2E1 and CYP101 [350], CYP11A1 
and CYP27 [351], and CYP2C9 and CYP101 [352], between CYPC17 from humans and 
rats [353]. 
 
Finally, numerous fusions between P450 heme domains and non natural reductases have 
been constructed [354-358]. Of notable interest is the fusion of 2C11 from rat with the 
reductase from CYP102A1 [355]. 2C11 was not able to hydroxylate arachidonic acid 
when mixed separately with the CYP102A1 reductase, however, upon fusion was able to 
hydroxylate this substrate.  A fusion of human CYP2E1 with the CYP102A1 reductase 
showed levels of activity equivalent the wild-type enzyme without the addition of lipids 
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or detergents [354]. The utility of this enzyme was shown in its production of the human 
metabolite of chlorzoxazone. 
 
C.8. Applications of  cytochromes P450 
Cytochromes P450 have numerous potential applications [302,359,360]. One of the most 
famous and well publicized examples is the incorporation of P450s from petunias into 
transgenic ‘blue’ carnations [361] and slightly less ‘blue’ roses [362]. More practically, 
the ability of P450s to perform difficult C-H bond hydroxylation gives them many uses in 
stereo- and regio-selective hydroxylation for the production of bulk and fine chemicals. 
Use of P450s in the synthesis of leukotoxin B [363] and construction of an engineered 
yeast for the biosynthesis of hydrocortisone from a simple carbon source [361] 
demonstrate specific examples. Cytochrome P450 proteins also show promise in 
bioremediation [364]. Since one natural function is to facilitate the breakdown of 
chemicals, new P450s could be discovered or engineered for specific applications. For 
instance, an engineered CYP101 variant was able to oxidize the pollutant polychlorinated 
benzene [365].  
 
As mentioned, P450s have great importance in the synthesis and discovery of drugs. For 
example, cytochrome P450 Taxadiene 5α-hydroxylase was cloned and functionally 
expressed in yeast to perform the first oxygenation step in the biosynthesis of Taxol [366-
368]. Similarly, the conversion of compactin to pravastatin, a hypocholesterolaemic 
compound, is catalyzed by a P450 from Mucor hiemalis [369]. In drug development, 
P450s may be used for combinatorial biocatalysis whereby they are used to produce 
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libraries of new molecules that can be screened for useful compounds, e.g. introduction 
of P450 variants into antibiotic producing strains and screening them for their ability to 
kill other microorganisms [302] or the generation of new protein kinase inhibitors based 
on the indigoid scaffold [370]. Novel metabolites of warfarin and an angiotensin II 
antagonist not typically produced by humans were produced using fungal P450s 
[371,372]. Such novel metabolites may possess enhanced drug properties. Finally P450s 
can be used to activate pro-drugs [373] at a specific target, such as a tumor cell. These 
serve as a few of the many examples of applications for natural and engineered 
cytochromes P450. 
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Chapter 3 
High-throughput assays for analysis of cytochromes  
P450 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The majority of this chapter is adapted from two book chapters: Otey CR (2003) High-
throughput carbon monoxide binding assay for cytochromes P450. Methods Mol. 
Biol. 230: 137-139, and Otey CR, Joern JM (2003) High-throughput screen for 
aromatic hydroxylation. Methods Mol. Biol. 230: 141-148. They are reprinted with 
permission from Humana press. The goal of these chapters is to provide a high level of 
detail so the methods can be easily reproduced. This detail is facilitated by frequent 
annotation of the methods in the form of ‘notes’ which are found at the end of this 
chapter. Additionally, I would like to thank John M. Joern for his work on the Gibbs’ 
assay and assistance in adapting it to P450s and to Philip Romero for work on the 
substrate-binding assays.  
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A. Introduction 
Central to any directed evolution experiment is an effective high-throughput screening or 
selection method. These methods allow an experimenter to test anywhere from one 
hundred to millions of clones per day for specific properties. Due to the great interest in 
the research and engineering of cytochromes P450 described in Chapter 2, a variety of 
methods amenable to high-throughput have been developed. Examples of these 
colorimetric, fluorescent and spectroscopic methods are listed in Table 3.1. The majority 
of these assays were developed to more efficiently test the inhibitory properties of 
potential drugs on human P450s, while others have been used in the study or alteration 
and improvement of a variety of P450 properties. However, most of these assays focus on 
a single substrate and do not offer information about P450s other than their enzymatic 
properties. In this chapter, new assays appropriate for the measurement of the ability of a 
P450 to fold, bind a substrate and hydroxylate a variety of substrates are discussed. These 
methods are applied herein and have subsequently been utilized in other studies [1-3].    
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Table 3.1. Cytochrome P450 assays amenable to high-throughput screening. 
Substrate or reagent Applicable P450s Assay descriptiona References 
NAD(P)H 
Any NAD(P)H utilizing 
P450, applied to 
CYP102A1, CYP102A2 
Monitor decrease in absorbance at 340 
nm from conversion of NAD(P)H to 
NAD(P)+. 
[4-7] 
Naphthalene CYP101 
Phenolic products of naphthalene 
coupled by HRP to form fluorescent 
products, ex 350 em 450 . 
[8,9] 
4-Nitrophenol substituted 
substrates CYP102A1 
Substrates such as 12-pNCA;  monitor 
increase of absorbance due to 4-
nitrophenol formation at 398 or 410 nm. 
[5,10-12] 
7-Ethoxycoumarin CYP1A1, CYP1A2 Measure fluorescence: ex 360, em 450. [13,14] 
3-Cyano-7-
methoxycoumarin 
CYP1A1, CYP1A2, 
CYP2C6, CYP2C11, 
CYP2E1, CYP2B6 
Measure fluorescence: ex 410, em 460. [15-17] 
3-Cyano-7-
ethoxycoumarin 
CYP1A2, CYP1A1, 
CYP2A6 Measure fluorescence: ex 410, em 460. [15,18-20] 
7-Methoxy-4-
trifluoromethylcoumarin 
CYP2C9, CYP2E1, 
CYP2C6, CYP2C11 Measure fluorescence: ex 410, em 538. [15,19,20] 
7-Ethoxy-4-
trifluouromethylcoumarin 
CYP1A2, CYP2E1, 
CYP2B6 Measure fluorescence: ex 400, em 500. [17,19,21] 
7-Benzyloxy-4-
trifluormethylcoumarin 
CYP3A4, CYP2B1, 
CYP2B6, CYP3A1, 
CYP3A2, CYP3A4 
Measure fluorescence: ex 410, em 538 [15,19,20] 
7-Methoxy-4-
(aminomethyl)-coumarin CYP2D6 Measure fluorescence: ex 390, em 460. [20] 
3-[2-(N,N-diethyl-N-
methylamino)ethyl]-7-
methoxy-4-
methylcoumarin 
CYP2D6, CYP2D2 Measure fluorescence: ex 390 em 460. [15,19] 
7-Methoxyresorufin CYP102A1 Measure fluorescence: ex 430, em 580. [22,23] 
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7-Ethoxyresorufin CYP102A1, CYP1A2 Measure fluorescence: ex 530, em 580. [23-27] 
7-Pentoxyresorufin CYP102A1 Measure fluorescence: ex 530, em 580. [23] 
7-Benzyloxyresorufin CYP102A1 Measure fluorescence: ex 530, em 580. [23,26] 
7-Benzylresorufin CYP102A1, CYP1A1, CYP1A2, and CYP2B1 Measure fluorescence: ex 530, em 580. [15,23,28] 
3-Cyano-7-
ethoxyresorufin 
CYP1A2, CYP2C9, 
CYP2C19, and CYP2D6 Measure fluorescence: ex 420, em 485. [28] 
Dibenzylfluorescein CYP2C8 Measure fluorescence: ex 485, em 538. [15,19,23,26] 
7-Benzyloxyquinoline CYP1A1, CYP2D1, CYP3A1, and CYP3A2 Measure fluorescence: ex 410, em 538. [15] 
P450-Glo luminescent 
substrates 
CYP1A1, CYP1A2, 
C1B1, CYP2C8, 
CYP2C9, CYP3A4, and 
CYP3A7 
Substrates are conjugated to luciferin 
which is a substrate for luciferase that 
emmits a luminescent signal. 
[29] 
Purpald CYP102A1 
Detects formaldehyde which can be 
formed by hydroxylation of surrogate 
ether substruates, e.g. hexyl methyl ether 
and dimethyl ether. Measure absorbance 
at 550 nm. 
[30] 
4-(p-nitrobenzyl)pyridine 
(NBP) CYP102A1 
Detection of terminal epoxides. Measure 
absorbance at 580 nm. [31,32] 
Indole 
2E6, 2C19, 2A6, 
CYP102A1 and 
CYP2W1 
Indigo is converted to indole, indiribun, 
indigoids, etc. which are colored 
compounds. 
[33-40] 
2-Amino-3,5- 
dimethylimidazo[4,5-
f]quinoline (MeIQ) 
CYP1A2 
Genotoxicity assay in which N-
hydroxyation of MeIQ creates a 
mutagen which causes reversion of a 
LacZ- straint to LacZ+ allowing cell 
growth on minimal lactose media. 
[22,25] 
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Diazo Blue B CYP1A1 and CYP1A2  
Detection of hydroxlated naphthalene or 
other phenolic prodcts. Measure 
absorbance at 490 nm. 
[41,42] 
11-Deoxycortisol CYP11B1 
Conversion of 11-deoxycortisol to 
cortsiol followed by addition of sulfuric 
and acetic acids which creates a yellow; 
fluorescent dye, ex 475 em 525. 
[43] 
LC/MS/MS 
CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, and 
CYP3A4 
Two substrate cocktails which are 
incubated with a mix of P450s and then 
pooled and analyzed using LC/MS/MS. 
[44] 
Carbon chains, e.g. fatty 
acids and alkanes CYP102A3 
 Measure terminal hydroxylation of 
alkanes by monitoring the depletion of 
NADH at 340 nm caused by alcohol 
dehydrogenase activity, which is 
specific to primary alcohols. 
[45] 
a Abbreviations: horse radish peroxidase, HPR; p-nitrophenoxydodecanoic acid, 12-pNCA; excitation wavelength 
(nm), ex; emission wavelength (nm), em. 
 
 
B. High-throughput carbon monoxide difference spectroscopy 
The high-throughput carbon monoxide binding assay monitors the folding properties of a 
P450 by employing the spectroscopic properties of the noncovalently bound 
protoporphyrin IX in the P450 active site. This heme has an available sixth coordination 
site that is able to tightly bind carbon monoxide when the heme iron is in the ferrous 
state.  Difference spectroscopy using carbon monoxide yields a spectral peak at 
approximately 450 nm characteristic of a correctly-folded cytochrome P450 when 
comparing bound and unbound forms [46,47]. This peak is referred to as a Soret band 
since it is in the blue region of the absorption spectrum of a heme protein. Binding of 
carbon monoxide in the presence of a catalytically inactive form of a cytochrome P450 
yields a spectral peak at 420 nm [48-50]. Thus CO binding effectively assays for the 
presence of a correctly-folded cytochrome P450, an incorrectly-folded P420, or a lack of 
either. Carbon monoxide binding assays are typically performed in single cuvette format 
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[51] but are easily modified for high-throughput in microtiter plates (Figure 3.1A). This 
method is useful in assaying a library of cytochrome P450s for folded and possibly 
functional proteins while eliminating misfolded or low-expressing variants.  It can also be 
used to rapidly determine the P450 concentration of multiple samples or the relative 
expression levels of individual clones in a library of P450 variants.  
 
 
Figure 3.1. Spectroscopic assays developed for cytochromes P450.  (A) A 96-well plate 
showing the CO difference spectra from a library of cytochromes P450. The 
characteristic Soret peak in the folded chimeras is present near 450 nm. The range 400 to 
500 nm is shown with an absorbance range of -0.1 to 0.1.  (B) Type I binding spectra 
resulting from the heme domain of wild-type CYP102A1 with 0, 94, 177, 333, and 632 
µM lauric acid. The resulting spin-shift results in a decrease in absorbance near 415 nm 
with an increase near 395 nm. Range 350 to 500 nm with an absorbance range of 0.2 to 
0.6 is shown.  (C) Increasing difference spectra from Type II substrate binding with 3 µM 
of P450 mutant 2C11 (see chapter 6) titrated with 100, 200, 300, 333, 666, 1000 and 
2000 µM serotonin. The Type II spectra results in an increase in absorbance near 430 nm 
with a concomitant decrease near 415 nm. Range 330 to 600 nm is shown with an 
absorbance range of -0.1 to 0.1. 
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B.1 Materials 
1.   100 mM sodium hydrosulfite in 1.3 M phosphate buffer, pH 8.0 prepared fresh for   
       each experiment. 
2.   50 mM phosphate buffer, pH 7.3. 
3.   96-well microtiter plates: R-96-OAPF-ICO (Rainin, Emeryville, CA). 
4.   Carbon monoxide tank with an appropriate regulator that allows for slow and  
      controlled bubbling into liquids. 
5.   Carbon monoxide chamber: a container in which 96-well microtiter plates can be  
      placed and where a vacuum can be created followed by a slight pressurization. It  
      should be an easily sealed container with at least one hose connection or stopcock   
      valve. A vacuum oven will work (Fisher Scientific) as well as a desiccator made of  
      polycarbonate. A 3-way stopcock, C-clamps and vacuum grease may also be  
      necessary (see Note 1.1).  
7.   Spectrophotometer/plate reader (Model Spectra max Plus 384, Molecular Devices,  
      Synnyvale, CA).  Software Softmax Pro 3.1.1. 
8.   Benchtop centrifuge that can accommodate 96-well microtiter plates: Allegra 25R     
      Centrifuge (Beckman Coulter, Fullerton, CA). 
 
B.2  Methods 
1.   Add 40 μL of the 100 mM sodium hydrosulfite solution into wells of a 96-well  
      microtiter plate (see Note 1.2).   
2.   Add 160 µL of enzyme solution per well and mix (see Note 1.3). Enzyme solution  
      can be either purified enzyme or extract from a cell lysis reaction after centrifugation    
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      and removal of cell debris (see Note 1.4). 
3.   Blank plate reader, taking both baseline spectra and particular wavelengths (see Note   
      1.5). Put plate into the carbon monoxide chamber and pull a vacuum with a vacuum   
     pump to roughly 350 mbar. Fill the container with carbon monoxide until a positive     
     pressure is obtained and seal the container for at least eight minutes (see Note 1.6). 
4.   Remove the plate and record spectra from 400-500 nm and at specific wavelengths       
      (see Note 1.5). 
5.   Using A450 and A490, P450 concentrations can be determined using Beer’s Law:  
A= εcl and the extinction coefficient, ε450-490 = 91 mM-1 cm-1 . (see Note 1.7). 
 
C. High-throughput substrate binding (spin-shift) assay 
The second assay also employs the heme cofactor and monitors the spectral shifts that 
occur upon substrate binding by cytochromes P450. As discussed in chapter 1, when a 
substrate enters the P450 active site it displaces a water molecule as the sixth ligand of 
the heme cofactor causing a shift from low to high spin in the heme iron. This can result 
in three specific types of binding spectra; Type I, reverse Type I and Type II [52,53]. 
Type I binding spectra show a decrease in the absorption peak of the low-spin state at 
414-420 nm and increase in the high-spin state at 385-395 nm (Figure 3.1B). Reverse 
Type I shows the opposite, with an increase around 420 nm and decrease around 390 nm. 
The cause is postulated to be displacement of the distal ligand and substrate binding to a 
hydrophobic region of the active site [54,55]. Type II binding spectra are thought to occur 
when a substrate ligates to the heme iron, a common mechanism of P450 inhibitors [56]. 
Type II binding causes a decrease in absorbance around 390 to 405 nm and an increase at 
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about 425-435 nm. These changes are caused by a simultaneous shift to longer 
wavelengths for each spin state and a change in the spin-state equilibrium from low to 
high (Figure 3.1C). 
 
The goal of this assay is to obtain a binding curve and approximate a binding constant for 
multiple clones using either clarified cell lysate or purified protein and the substrate of 
your choice. To maximize detection one should use high concentrations of P450 (see 
Note 2.1) and large assay volumes (see Note 2.2). Initially one should determine the 
complete spectra resulting from substrate binding and determine specific wavelengths to 
monitor to reduce assay times. Within the typical bounds of concentrations obtained in 
deep-well plates, the P450 should be limiting and therefore one does not need to worry 
about relative enzyme concentrations if a binding curve is constructed. 
 
C.1 Materials 
1.   Spectrophotometer/plate reader (Model Spectra max Plus 384, Molecular Devices,  
      Sunnyvale, CA).  Software Softmax Pro 3.1.1. 
2.   96-well microtiter plates: R-96-OAPF-ICO (Rainin, Emeryville, CA) or 384-well   
      microtiter plates (Nalge Nunc International, Rochester, NY). 
3.   Concentrated substrate solution.  
 
C.2 Methods 
1.   Distribute cell lysate into a microtiter plate and read the baseline spectra or baseline  
      individual wavelengths (see Note 2.3).     
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2.   Add substrate solution and measure spectra or individual wavelengths (see Note 2.2  
      and Note 2.3). 
3.   Continue step 2 until enough data is accumulated to produce a binding curve. 
4.   Construct binding curve for comparison of clones. 
 
D. High-throughput screen for aromatic hydroxylation 
The third method describes three different assay systems that detect phenolic compounds 
by producing a colored product that is easily detected in high throughput. These assays 
employ the Gibbs’ reagent, 4-AAP or Fast Violet B (FVB) (Figure 3.2) and are useful for 
detecting the oxidation of aromatic compounds by P450s. The oxidation of aromatic 
compounds is generally important in producing chemical intermediates for the chemical 
and pharmaceutical industries [57,58]. Conventional aromatic oxidation reactions are 
prone to byproduct formation and often require heavy metal catalysts, extremes of 
temperature and pressure, and explosive reagents [59]. In contrast, biocatalysts such as 
P450s perform the same chemistry in water at ambient conditions, usually with higher 
regioselectivity than the analogous chemical process [60-62] and the methods discussed 
here may allow for the optimization of oxygenases to industrially relevant substrates and 
realistic process conditions. The use of these assays with P450s is described here but they 
may be applied to dioxygenases [63,64] and many other enzymes (e.g. oxidative 
dealkylases or dehalogenases). 
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Figure 3.2. Chemistry of assay methods.  (A) Coupling of Gibbs' reagent to a phenolic 
compound [65].  (B) Coupling of 4-aminoantipyrine to a phenolic compound [66].  (C) 
Coupling of Fast Violet B to a phenolic compound [67].  
 
 
The 4-AAP and Gibbs’ assays are very similar in the products they are able to detect 
(Table 3.2), as well as their sensitivity limits and coefficients of variation (see Note 3.1). 
These assays are linearly dependent on concentration for all of the phenols we have 
examined [64] (see Note 3.2) and give clear spectra with distinct λmax in the presence of 
phenolic compounds, especially when compared to the FVB assay (Figure 3.3). In fact, 
FVB is typically less useful in general due to its lower sensitivity and reactivity with cells 
and various media, and the 4-AAP and Gibbs’ assays are preferred.  
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Table 3.2 - The spectroscopic signals resulting from coupling of various phenols to 
Gibbs' reagent, Fast Violet B and 4-aminoantipyrine.   
  Gibbs' assay Fast Violet B assay 4-Aminoantipyrine assay
Compound λmax Max abs. λmax Max abs. λmax Max abs. 
3-hydroxybenzaldehyde 670 0.06 n/a < 0.05 580 0.18 
2-hydroxybenzaldehyde 660 0.09 380 0.09 512 0.13 
2-hydroxybenzamide 660 2.98 n/a < 0.05 512 0.08 
2,3-dihydroxybenzaldehyde 570 0.63 n/a < 0.05 480 0.65 
catechol 460 0.44 n/a < 0.05 500 0.98 
3-methylcatechol 460 0.49 n/a < 0.05 540 0.25 
3-fluorocatechol 450 0.38 n/a < 0.05 535 0.49 
phenol 630 0.10 n/a < 0.05 500 2.57 
o-cresol 610 0.31 n/a < 0.05 505 1.85 
m-cresol 620 0.17 n/a < 0.05 500 1.76 
2-aminophenol 600 0.76 440 0.08 520 1.07 
3-aminophenol 570 1.61 480 0.82 470 2.61 
2-chlorophenol 660 2.77 n/a < 0.05 515 2.77 
3-chlorophenol 670 1.25 n/a < 0.05 545 0.78 
1-naphthol 580 0.31 a n.d. n.d b 505 1.61 
2-naphthol n.d. n.d.b 520 0.47 n.d. n.d c 
2,3-dihydroxynaphthalene 510 0.79 n.d. n.d b 490 0.18 
4-nitrophenol n/a < 0.05 n/a < 0.05 n/a < 0.05 
2-hydroxypyridine n/a < 0.05 n/a < 0.05 n/a < 0.05 
3-hydroxypyridine 600 0.39 n/a < 0.05 n/a < 0.05 
o-coumaric acid 650 0.42 n/a < 0.05 520 2.39 
m-coumaric acid 670 0.24 n/a < 0.05 540 0.87 
p-coumaric acid 560 0.38 n/a < 0.05 470 0.29 
3-hydroxybenzoic acid 640 0.25 n/a < 0.05 505 0.24 
3,4-dihydroxybenzoic acid 460 0.29 n/a < 0.05 495 0.75 
3-hydroxy-4-methylbenzoic acid 610 1.21 n/a < 0.05 465 0.90 
2,3-dihydroxybenzoic acid 440 0.27 n/a < 0.05 500 0.26 
a Product slightly insoluble.  b.Product insoluble.  c.Color change to green that qickly fades to yellow with no λmax. 
n/a - not applicable, no λmax   n.d. - not determined due to insolubility 
 
Compounds were diluted in M9 minimal media to a concentration of 0.25 mM and assayed as 
described.  For the Gibbs' reagent, Fast Violet B and 4-aminoantipyrine assays, 0.1ml of phenol 
solution was assayed in a 96-well microtiter plate.  Thirty minutes, 10 minutes and 10 minutes, 
respectively, were allowed for the reaction to occur before recording the visible spectra using a 
96-well spectrophotometer.   
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Figure 3.3. Spectra of potential assay products. 0.25 mM solutions of o-chlorophenol, o-
coumaric acid and 2-naphthol in M9 media were assayed as described using Gibbs' 
reagent, 4-AAP and FVB, respectively. 
 
 
The 4-AAP and Gibbs’ assays are reported to react well with ortho- and meta-substituted 
phenolic compounds and with para-substituted compounds where the substituent is a 
halide or alkoxy group [68]. For example, if the substituent para to the site of 
hydroxylation is a carbon bond then the product will be less reactive with the 4-AAP and 
Gibbs’ reagents. However, results to the contrary are shown with different regioisomers 
of hydroxynaphthalene in Figure 3.4. Substrates such as 2-naphthol are detectable with 
the 4-AAP assay even though the substituent para to the hydroxyl group is a tertiary 
carbon. These results also indicate that the 4-AAP assay is able to distinguish between 
regioisomers of hydroxynaphthalane by producing different spectra for each product. 
Another example of the value of the 4-AAP assay is its ability to detect 4-
hydroxyatorvastatin, the main human metabolite of the drug atorvastatin (Lipitor). 
Finally, a critical difference between the assays, especially for the work here, is the 4-
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AAP assay does not suffer from background signal due to H2O2 whereas the Gibbs’ and 
FVB reagents do (Figure 3.5). This allows for the use of the ‘peroxide-shunt’ pathway to 
drive P450 catalysis in place of NADPH. 
 
 
 
 
 
 
Figure 3.4. 4-aminoantipyrine assay is able to distinguish between regioisomers of 
hydroxynaphthalene. 
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Figure 3.5. Assay background caused by H2O2 in the 4-AAP and Gibbs’ assays. 
Absorbance readings for 4-AAP (500 nm) and Gibbs’ (650 nm) in 100 mM Epps pH 8.2 
with increasing amount of H2O2. The Gibbs’ assay shows high level of background while 
4-AAP shows almost none. 
 
 
Some issues need to be considered when applying these assays to biotransformations 
using whole cells or cell extracts. When a whole cell system is used, careful consideration 
should be given to the method of supplying substrate to the enzyme. To access the 
enzyme, the substrate must be soluble and must readily permeate the cell membrane. 
Solubility can be increased in most cases by adding a nontoxic organic solvent [69]. 
Polymyxin B increases the permeability of many aromatic and non-aromatic substrates, 
including long chain fatty acids [70,71]. Though TB or LB-media are commonly used for 
whole cell growth, these rich broths contribute a significant amount of background to the 
assays discussed here (especially the Fast Violet B assay). This is easily remedied by 
 77
using a synthetic medium such as M9 minimal medium [72]. Supplying the substrate in 
the vapor phase is sometimes successful when the substrate is volatile and is particularly 
convenient when screening colonies using a solid-phase format [64].  
 
In the assay descriptions below, “sample” refers to the solution containing the phenolic 
product to be determined and may be a cell extract or supernatant depending on which 
type of bioconversion is chosen. The absorbance value yields the total activity of the 
bioconversion. Times for color development are suggested below but this is another 
factor that varies from substrate to substrate and should be determined on an individual 
basis. Because every screening situation is unique, the following protocols should be 
adapted to each system. 
 
D.1. Materials 
1.   0.6% (w/v) 4-aminoantipyrine in H2O. Store at 4°C and prepare fresh daily.  
2.   0.6% (w/v) potassium persulfate in H2O. Store at 4°C and prepare fresh daily. 
3.   0.4% (w/v) 2,6-dichloroquinone-4-chloroimide (Gibbs’ reagent) in ethanol. Store at   
      4°C and prepare fresh every 4 months.  
4.   0.25% (w/v) Fast Violet B in H2O. Prepare fresh every 2-3 days. 
5.   Quench: 100 mM NaOH and 4 M urea (See Note 3.3). 
6.   96-well microtiter plates: R-96-OAPF-ICO (Rainin, Emeryville, CA). 
7.   Spectrophotometer/plate reader (Model Spectra max Plus 384, Molecular Devices,  
      Sunnyvale, CA). Software Softmax Pro 3.1.1. 
8.   Benchtop centrifuge that can accommodate 96-well microtiter plates: Allegra 25R  
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      Centrifuge (Beckman Coulter, Fullerton, CA). 
9.   Pipette robot: Multimek 96 Automated 96-Channel Pipetter (Beckman Instruments,   
      Palo Alto, CA). 
 
D.2. Phenol quantitation with Gibbs’ reagent 
1.   To 100 μL of sample add 20 μL 0.4% (w/v) of Gibbs’ reagent. 
2.   Mix and allow 3-30 minutes for color development (see Note 3.4). 
3.   Record spectrum or wavelength. 
 
D.3. Phenol quantitation with 4-aminoantipyrine  
1.   To 100 μL of sample add 100 μL of quench (see Note 3.5). 
2.   Add 30 μL of 0.6% (w/v) 4-AAP. Mix thoroughly and incubate for 2 minutes. 
3.   Add 30 μL of 0.6% (w/v) potassium persulfate (see Note 3.6).   
4.   Mix and allow 10 minutes for color development (see Note 3.7). 
5.   Record spectrum or wavelength. 
 
D.4. Phenol quantitation with Fast Violet B 
1.   To 100 μL of sample add 10 μL 0.25% of (w/v) Fast Violet B.   
2.   Mix and allow 10 minutes for color development (see Note 3.8 and Note 3.4). 
3.   Record spectrum or wavelength. 
 
D.5. Applying phenol detection with 4-AAP to cytochromes P450 
1.   In a 96-well microtiter plate, following whole cell or cell extract reaction, add an an  
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      equivalent volume of quench (see Notes 3.3, Note 3.5 and Note 3.9). If using a whole   
      cell assay centrifuge at ~3500 g for 10 minutes and transfer the supernatant to a new   
      microtiter plate (see Note 3.10). 
2.   Add 15 μL of 0.6% (w/v) 4-AAP per 100 μL. Mix and incubate for 2 minutes. 
3.   Add 15 μL of 0.6% (w/v) potassium persulfate per original 100 μL (see Note 3.6). 
4.   Record spectrum or wavelength after 10 minutes (see Note 3.4). 
 
E. Notes 
1.1.  The positive pressures applied are not great and this piece of equipment can be     
         improvised. To use a desiccator, vacuum grease is applied liberally around the edge  
         where contact is made with the lid. When a plate is placed inside, the desiccator it is   
         clamped shut with 4 c-clamps evenly distributed around the edges. This easily    
         resists the positive pressure necessary for the assay.  The desiccator is attached to a  
         three-way stopcock with tubing.  The three-way stopcock is connected to a vacuum   
         pump on one end and the carbon monoxide tank on the other.  This allows for  
         switching between the vacuum pump and the carbon monoxide tank.  
1.2.  The high buffer concentration is to buffer against pH changes caused by sodium   
         hydrosulfite, which lowers the pH of the solution. After adding the sodium    
         hydrosulfite, time becomes more critical. 
1.3.  Volumes can be scaled up accordingly but should not exceed 300 μL since the   
        maximum well volume of a 96-well microtiter plate is 320 μL. The assay can also   
        be applied in 384-well plate format, which have a maximal working volume of  
        approximately 110 μL. Enzyme can be diluted if necessary. Using the dilutions   
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        described here, a well containing a total volume of 100 µl with 100 nM P450 has an    
        A450 -A490 of approximately 0.003. Multiple plates can be assayed, but four is the  
        suggested maximum at one time. 
1.4.  Bubbles due to pipetting/mixing can be removed by centrifugation at 3000 g or   
        addition of a small amount of ethanol, using a pipette tip or spray bottle.  
1.5.  Spectra can be recorded every 10 nm from 400 to 500 nm or at smaller intervals.    
        Specific points should be taken at the λmax of your particular cytochrome P450,   
        typically around 450 nm, and 490 nm [51]. Ultimately, the absorption change at 450  
        nm relative to the absorbance change at 490 nm is used to quanitate the amount of  
        enzyme. 
1.6.  Alternatively, CO can be supplied at a slow rate equivalent to the bubbling used in  
        cuvette format. This is approximately one to three bubbles per second from a Pasteur  
        pipette attached to the carbon monoxide tank with tubing. This flow rate will quickly  
        fill a sealed container and provide enough pressure to supply a sufficient amount of   
        carbon monoxide. 
1.7.  The path length will vary based on volume and should be determined using 
        standard cuvette assay. Path lengths have been determined to be approximately 0.37     
        and 0.71 cm for 100 and 200 μL, respectively.  The path length can vary depending    
        on the solution used due to the meniscus that forms.  It is suggested that a control of  
        known enzyme concentration be used in determining exact P450 concentrations.   
2.1.  Concentrations greater than 1 µM should be used. A typical concentration obtained   
        from a 1 ml culture produced in 2 ml deep-well plates is 400 µl of a 1 to 10 µM  
        solution. 
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2.2.  Large total volumes will serve to maximize the path length in the microtiter plates.    
        The maximum volumes allowed in 96-well and 384-well microtiter plates are 320 µl  
        and 120 µl, respectively.  Substrate solution should be added in a small but accurate  
        volume for multichannel pipettes (e.g. 4  µl) although larger volumes may be used   
        without concern of dilution since concentration is inversely proportional to path   
        length. Volumes of 290 µl for 96-well plates and 90 µl for 384-well plates allow for   
        addition of substrate seven to eight times.  
2.3.  The individual wavelengths that should be measured needs to be determined for    
        each case and depends on the substrate being used, the individual P450 and whether   
        there is type I or type II binding spectra. The wavelengths which give the maximum  
        difference as substrate is added should be used. 
3.1.  Coefficients of variation tend to be approximately 8-14% for the Gibbs’ and 4-AAP   
assays. The sensitivity limit for the Gibbs’ reagent and 4-AAP is approximately 10 
μM. Tris has been found to give a higher background level than other buffer 
systems. This should  
        be considered when the amount of product formed is near the detection limit. 
3.2.  Phenol, o-coumaric acid and m-coumaric acid have been checked for a linear  
        dependence of concentration on absorbance with the 4-AAP assay. 3-methylcatechol  
        and 3-fluorocatechol have been tested with the Gibbs' assay. 
3.3.  Since cytochrome P450s typically perform a single hydroxylation, no other   
        preparative steps are necessary as they are with dioxygenases [64]. Reactions should  
        be quenched in a suitable manner which terminates the enzymatic reaction allowing  
        for reproducible time points. The NaOH/urea (quench) solution will provide this in  
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        some systems and is effective with the P450s discussed here.   
3.4.  Optimal development time depends on the phenol assayed and, in some cases,  
        accumulation of background absorbance over time.  When assaying for improved   
        enzyme function, only the wavelength of the product is taken and not the entire  
        spectrum. 
3.5.  A pH between 9 and 10.5 is desired since 4-AAP will react with peroxides at a  
        lower pH and produce a red color [66,73].  This also aids in solubilizing any  
        precipitate from cell extract and/or substrate added.  4-AAP works in up to 75%  
        DMSO in water. 
3.6.  Potassium persulfate serves to oxidize the NH2 group of 4-aminoantipyrine, making  
        it available for electrophilic attack by a phenol.  Other oxidizing agents can be used  
        such as ammonium persulfate and potassium hexacyanoferrate [66].  Potassium    
        persulfate gave the least amount of background in the P450 system. 
3.7.  The reproducibility of the 4-AAP assay is not very sensitive to incubation times    
        beyond 10 minutes.  It is a good idea, however, to keep the incubation time constant  
        from screen to screen in order to minimize variance. Centrifuging between addition  
        of 4-AAP and potassium persulfate can be useful in case there is any residual liquid  
        on the sides of the plate-wells. Ethanol can be used to remove any bubbles formed  
        while pipetting, either from a spray bottle or on the tip of a pipette. 
3.8.   Increasing the pH to basic levels before addition of Fast Violet B can be useful in  
         increasing the maximum absorbance value.  It is not necessary, however.   
3.9.   A pipetting robot can be useful when doing multiple 96-well microtiter plate assays,  
         but is not necessary. 
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3.10. Removal of cell debris is not necessary in the Gibbs’ and 4-AAP assays, however it  
         increases the reproducibility of the screens.  It is necessary for FVB. 
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A. Abstract 
Recombination generates chimeric proteins whose ability to fold and function depends on 
minimizing structural perturbations that result when portions of the sequence are 
inherited from different parents. If the folded structure is retained, the new chimeric 
sequences can display functional properties characteristic of the parents. They can also 
acquire entirely new functions. Seventeen double-crossover chimeras were generated 
from two members of the CYP102 subfamily of the functionally diverse cytochrome 
P450 heme enzymes. These hybrid proteins cover a wide range of structural disruption, 
as defined by the number of residue-residue contacts broken upon recombination and 
computed using the SCHEMA algorithm, based on the protein’s three-dimensional 
structure. Chimeras predicted to have limited structural disruption displayed CO-binding 
spectra characteristic of folded P450s, and many were catalytically active. Even this 
small population of chimeras exhibited significant functional diversity: chimeras 
displayed altered substrate specificity profiles, a wide range in thermostabilities, up to a 
40-fold increase in peroxidase activity, and ability to hydroxylate a substrate towards 
which neither parent heme domain shows detectable activity. These results suggest that 
SCHEMA-guided recombination can be used to generate diverse P450s for exploring 
function evolution within the P450 structural framework. 
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B. Introduction 
The cytochrome P450 superfamily of enzymes exhibits an impressive range of chemical 
activities and biological roles. Nature has utilized these diverse enzymes for everything 
from steroid biosynthesis to interspecies chemical warfare, drug detoxification and 
utilization of new food sources [1-5]. Individual members of the superfamily, however, 
show a much narrower range of catalytic activities (usually catalyzing oxygen insertion 
into C-H bonds) and substrate specificities. The heme prosthetic group recruited by 
cytochrome P450 to effect monooxygenation is also used by these and other proteins for 
oxygen transport, electron transfer, reduction, dealkylation and dehalogenation [6,7]. The 
highly versatile cytochrome P450 family offers unique opportunities to investigate the 
evolution of function within a single structural framework [8].   
 
In this study we begin to explore the generation of P450s in the laboratory by 
recombination of homologous sequences. P450s typically exhibit low sequence identity, 
and annealing-based DNA-shuffling techniques [9-13] are not useful for creating highly 
diverse libraries of P450 chimeras. While several methods for making such shuffled gene 
libraries independent of sequence homology have been described [14-19], these 
approaches generate few crossovers and large numbers of inactive sequences, due to 
insertions, deletions, frameshifts, as well as disruptive crossover events. Functional 
characterization of such libraries is difficult without a selection to remove unfolded or 
nonfunctional sequences.   
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Recently, we reported a computational algorithm, SCHEMA, which can estimate the 
disruption caused by swapping different fragments among structurally-similar proteins 
and identify optimal crossover locations for making libraries by recombination [20].  
Using the 3D structure of one of the parent proteins, the algorithm identifies pairs of 
amino acids that are interacting (e.g., residues within a cutoff distance of 4.5 Å) and 
determines the net number of interactions broken when a chimeric protein inherits 
portions of its sequence from different parents (E). By comparing SCHEMA disruption 
predictions to functional β-lactamases selected from a large library of chimeric 
sequences, we demonstrated that sequences retaining the parental protein fold and 
function tend to have low E values [21]. This criterion can be used to select crossover 
positions for individual chimeras or combinatorial libraries prepared by swapping 
elements from related parent sequences.  
 
Here we explore the effects of recombination in a larger and more complex enzyme, the 
cytochrome P450. Seventeen double-crossover chimeras were made by swapping 
fragments between the heme domains of the soluble, bacterial enzyme A1 and A2, which 
are approximately 460 amino acids in length and share 63% amino acid identity. We have 
determined which sequences encode properly-folded heme domains and related those to 
the disruption calculated by SCHEMA. To probe the functional diversity of this small 
population, we have measured their stabilities and activities in different P450-catalyzed 
reactions. A subset of the heme domain chimeras has been reconstituted into 
holoenzymes by fusion with the CYP102A1 reductase domain and characterized. These 
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data are used in Chapter 4 to guide much larger efforts to explore the functional variation 
that is possible within the P450 scaffold.  
 
C. Results 
C.1 Chimera design 
For this work we constructed chimeras of CYP102A1 [22] and CYP102A2 [23], 
homologs from Bacillus megaterium and Bacillus subtilis, respectively. These soluble 
fusion proteins, consisting of a catalytic heme domain and an FAD- and FMN-containing 
NADPH reductase [24], require dioxygen and a cofactor (NADPH) for monooxygenase 
activity. However, the P450 heme domain can also utilize hydrogen peroxide via the 
‘peroxide shunt’ pathway to catalyze hydroxylation reactions. While this peroxygenase 
activity is low in CYP102A1, it is enhanced by the amino acid substitution F87A [25,26]; 
the equivalent F88A mutation in CYP102A2 has a similar effect. The P450 chimeras 
were constructed from the genes for the heme domains of CYP102A1 with the F87A 
mutation and CYP102A2 with the F88A mutation (abbreviated as A1 and A2). With 
these mutations, we can use the peroxygenase activity of the heme domain to explore 
substrate specificities in the chimeras, without having to supply cofactor or a reductase 
(which may or may not interact properly with a chimeric heme domain). The chimeric 
heme domain can also be fused to one of the parental reductase domains to regenerate a 
chimeric holoenzyme (see below). 
 
Initial attempts to randomly recombine the A1 and A2 sequences were unsuccessful due 
to their 64% nucleotide identity, which places them below the limits for effective 
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recombination using annealing-based methods [9]. Both DNA shuffling with a fixed 
annealing temperature, as originally described [9], and with gradually decreasing 
annealing temperatures [27,28] yielded mostly reconstructed parental sequences rather 
than shuffled genes. In addition, random chimeragenesis on transient templates 
(RACHITT) [10,29], a method meant to increase the frequency of crossovers and 
decrease the sequence identity for a crossover to occur, was used. However, this method 
was also unsuccessful due to the inability to form single-stranded templates of the P450 
genes containing uracil instead of thymine.  
 
The effective levels of mutation (amino acid Hamming distance from the closest parent) 
and SCHEMA disruption (E) were calculated for all possible double-crossover chimeras 
of A1 and A2 with a minimum fragment size of ten amino acids. The distribution in the 
levels of disruption and effective mutation (m) for this population of chimeras can be 
seen in Figure 4.1. Fourteen chimeras were individually designed and constructed to 
encompass a broad range of E (2 to 42) and m (11 to 70) (Table 4.1).  Crossovers were 
placed in regions of low and high sequence identity; in the 10 bp surrounding the 
crossovers, identity ranged from 20-90%. For three of the chimeras we generated both 
‘mirror’ sequences, i.e. chimeras that derive sequences from opposite parents at every 
position. The other eleven sequences consisted of A1 with an internal fragment derived 
from A2 (Figure 4.2). 
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Figure 4.1. Effective mutation (m) and disruption (E) for cytochrome P450 heme-domain 
chimeras.  Disruption values for all double-crossover chimeras with a minimum insert 
size of 10 amino acids between A1 and A2 were determined using the structure for the 
CYP102A1 heme-domain.  Disruption values from the substrate-bound structure were 
used.  For all double-crossover chimeras, the average E is 23.5±12.8, and average 
mutation m is 40.6±22.6. The 17 constructed chimeras were assayed for the ability to fold 
and hydroxylate 12-pNCA, 2-phenoxyethanol, and allyloxybenzene: Squares represent 
chimeras that retain the ability to fold, and X’s indicate those that did not.  Chimeras that 
fold but have little or no detectable peroxygenase activity ( ), chimeras with parent-
like substrate specificity profiles ( ), chimeras with altered profiles ( , ), 
chimeras with altered profiles and (new) activity on allyloxybenzene ( ). 
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Table 4.1. Properties of designed A1-A2 chimeric P450s 
Proteina 
E           
(substrate-
bound)b 
E                 
(substrate-
free)b mc 
Folded  
(λ max)d Tm (ºC) 
Peroxidase 
activitye 
A1  --  --  -- yes (448) 55 2.6±0.1 
A2  --  --  -- yes (449) 44 0.4±0.1 
364-403 2 2 13 yes (449) 51 1±0.2 
165-256 7 7 36 yes (449) 48 16.1±1.4 
165-256M [7] [7] 36 yes (448) 50 3.5±0.4 
285-341 10 9 19 yes (448) 53 2.1±0.1 
191-335 12 12 50 yes (449) 40 N.D. 
169-197 12 10 11 yes (449) 52 100.3±3.1 
169-197M [12] [10] 11 yes (449) 43 0.3±0.1 
65-256 15 13 61 yes (447) 36 N.D. 
118-194 20 19 20 yes (449) 47 34.3±1.2 
70-299 21 19 70 yes (448) 42 0.8±0.3 
46-73 27 30 16 yes (448) 55 6.8±0.5 
277-365 27 28 33 yes (421) 39 N.D. 
43-135 34 38 33 yes (448) 53 6.8±0.4 
186-365 34 35 65 no  -- N.D. 
186-365M [34] [35] 65 no  -- N.D. 
50-140 38 39 32 yes (448) 52 10.4±0.6 
345-448 42 43 34 no  -- N.D. 
a A1 and A2 refer to the isolated heme domains of CYP102A1 (with the F87A substitution) 
and CYP102A2  (with the F88A substitution). Chimera names correspond to the first and last 
residue of A2 inserted into A1 according to the numbering of CYP102A1. 'M' indicates 
mirror chimeras where A1 is inserted into A2.   
b SCHEMA-calculated disruption (see methods) based on substrate-bound (1JPZ) [30] and 
substrate-free structures (2HPD) [31]. Brackets [ ] indicate assumed disruption for mirror 
chimeras (due to lack of crystal structure of CYP102A2). 
c Effective level of mutation (= amino acid Hamming distance to closest parent). 
d Folding as assayed by reduced CO difference spectroscopy. λmax for Soret band is reported. 
e Values reported in nmol product/nmol P450/min. Activities < 0.2 were not detectable 
(N.D.). 
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Figure 4.2. Location of crossovers in primary sequence of parent P450s, A1 and A2, and 
seventeen chimeras.   
 
 
 
E values for the different chimeras were computed using the high-resolution structure for 
CYP102A1 with palmitoglycine bound in the active site [30]. Because previous studies 
have shown that substrate binding causes a large conformational change in CYP102A1 
[32-34], we also calculated E using the substrate-free CYP102A1 structure [31]. As 
shown in Table 4.1, similar E values were obtained for the two calculations. Because 
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both parents contain the same heme cofactor, contacts between the heme and the protein 
cannot be broken upon recombination, at least in this simple model. It is assumed that 
chimeras retain parental heme contacts, and heme is not included in the calculation of E.     
 
 
C.2 Folding of chimeric heme domains 
The chimeras were constructed using SOEing [35], cloned into the IPTG-inducible 
pCWori vector [36], and sequenced to confirm the absence of point mutations. All 
proteins were overexpressed in a catalase-free strain of E. coli [37], which allows the 
peroxygenase activity of the heme domains to be monitored directly in cell extracts [38]. 
We used carbon monoxide difference spectroscopy to assess the level of structural 
disruption in the chimeras: a reduced CO difference spectrum producing a Soret band 
near 450 nm is indicative of heme incorporation and thus a correctly-folded P450 heme 
domain [39]. A Soret band near 420 nm is indicative of a folded protein that binds heme, 
but is catalytically inactive due to a disrupted heme environment [40,41]. Fourteen 
chimeras displayed detectable Soret bands: thirteen appeared at 450 nm and one at 420 
nm (Figure 4.3). Chimeras with low calculated disruption (E) were most likely to retain 
folded structures: all with E < 30 were folded, but less than half with E > 30 yielded 
detectable Soret bands (Table 4.1). 
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Figure 4.3. Reduced CO-difference spectra for A1, A2, and their (heme-domain) 
chimeras. Spectra were taken from 400 to 500 nm. The absorbance range for the first two 
rows is -0.5 to 0.6, the third and fourth rows are magnified 3X with a range of -0.17 to 
0.2, and the last row is magnified 40X over the first row. Most chimeras exhibit a Soret 
band at 450±3 nm, characteristic of a folded P450 with correctly incorporated heme 
cofactor. Chimera 277-365 shows a Soret band at 420 nm, and no Soret band could be 
detected for chimeras 186-365, 186-365M and 345-448.    
 
 
 
C.3 Peroxygenase activities of chimeric heme domains  
We assayed the chimeric P450 heme domains for hydroxylation of p-
nitrophenoxydodecanoic acid (12-pNCA), a fatty acid analog that is hydroxylated by A1 
and A2 to yield 4-nitrophenol [42]. Initial rates were measured using a concentration of 
12-pNCA (250 µM) significantly higher than the KM of CYP102A1 for this substrate (KM 
= 8.1 μM [43]). Activities on 2-phenoxyethanol and allyloxybenzene were also 
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determined, using the 4-AAP assay, which is sensitive to phenols and catechols (see 
Chapter 3). This assay yields a detectable product if hydroxylation occurs at the ortho or 
meta positions of the aromatic ring or when hydroxylation yields the hemiacetal, which 
decomposes to form phenol. At the maximum soluble concentrations of substrate, the 
parent CYP102 heme domains were active only on 2-phenoxyethanol; neither showed 
measurable peroxygenase activity towards allyloxybenzene.  
 
Figure 4.4 compares the activities of the folded chimeric heme domains to those of the 
parent enzymes. Unfolded chimeras showed no activity towards any substrate, while all 
but two of the folded ones retained peroxygenase activity on at least one substrate. The 
P420 chimera (277-365) was inactive towards all substrates tested. Several chimeric 
heme domains were more active than the best parent, A1, on one or more substrate. 
Chimera 169-197 was the most active towards 12-pNCA, 46-73 had the highest activity 
on 2-phenoxyethanol, and 43-135 and 165-256 were the most active on allyloxybenzene. 
The chimeras also showed different specificities, falling roughly into three groups: 1) 
chimeras with little or no detectable activity towards any substrate; 2) parent-like 
chimeras, active on 12-pNCA and 2-phenoxyethanol; and 3) chimeras with altered 
substrate specificities relative to the parents, due to loss of activity towards 12-pNCA 
and/or acquisition of activity on allyloxybenzene. For the three chimeras with this ‘novel’ 
activity, one (165-256) had broadened specificity and was active on all three substrates. 
The remaining two (191-335 and 43-135) showed detectable activity on 2-
phenoxyethanol and allyloxybenzene, but not 12-pNCA. The members of each pair of 
mirror chimeras had equivalent folding properties, but were not functionally equivalent.   
 101
 
 
Figure 4.4. Substrate-activity profiles of A1, A2, and the folded chimeric heme domains. 
Chimeras were assayed for peroxygenase activity on 12-pNCA, 2-phenoxyethanol and 
allyloxybenzene, and hierarchical clustering analysis was used to group chimeras based 
on their functional properties. Three major categories are apparent: those with little or no 
detectable peroxygenase activity, those with parent-like profiles (activity on 12-pNCA 
and 2-phenoxyethanol), and those with altered profiles (below dashed line) relative to the 
parents (resulting from loss of activity on 12-pNCA and/or gain of activity on 
allyloxybenzene). The average amino acid Hamming distance (<m>) for the chimeras 
with parent-like profiles is 22, whereas the <m> of chimeras with altered profiles is 34.  
Initial rates are reported in nmol product/nmol P450/minute. Chimeras with no detectable 
activity are shown with values corresponding to the detection limits, which were 0.1, 0.06 
and 0.08 for 12-pNCA, 2-phenoxyethanol and allyloxybenzene, respectively. Chimeras 
lacking detectable peaks in the CO difference spectra showed no activity on the 
substrates assayed.  
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C.4 Peroxidase activities of chimeric heme domains  
P450s can reduce peroxide to water (and a proton) using a mechanism similar to that of 
peroxidases [44], although the intrinsic rate for P450s is orders of magnitude slower. It 
has been proposed that the earliest P450 function may have been as a peroxidase [2]. To 
investigate how recombination affects P450 peroxidase activity, we used the colorimetric 
substrate 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) to monitor this 
reaction [45]. A1 and A2 both show low, but detectable peroxidase activity (Table 4.1). 
Chimeras 50-140, 118-194, 165-256 and 169-197 have significantly higher peroxidase 
activities; 169-197 is approximately 40-fold more active than the most active parent. 
Mirror chimeras 169-197M and 165-256M do not show similarly enhanced levels of 
peroxidase activity. Three folded chimeras, 191-335, 65-256, and 277-335, showed no 
detectable peroxidase activity.   
 
 
C.5 Thermostabilities of chimeric heme domains 
Thermostability was assayed by monitoring the loss of the Soret band at increasing 
temperatures. Chimera melting temperatures ranged from 36°C to 55°C (Table 4.1), with 
none more stable than A1 (Tm = 55°C). More than half of the folded chimeric heme 
domains were more thermostable than A2 (Tm = 44°C); the rest were less stable. We 
found that chimeras less thermostable than the parents exhibited a wide range of E 
values, 12 to 27, and that stability does not correlate with calculated disruption, at least in 
this small population. However, thermostability may be important for retention of 
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catalytic activity: the two chimeras that lacked peroxygenase activity were also the least 
thermostable. 
 
C.6 Folding and monooxygenase activities of chimera-reductase fusion proteins 
We fused five of the functional chimeras (43-135, 46-73, 118-184, 165-256, and 169-
197) to the N-terminus of the CYP102A1 reductase domain in order to investigate how 
the chimeric heme domains behave in the context of a P450 holoenzyme. CO difference 
spectra of the chimera-reductase fusion proteins (CRFPs) were used to monitor folding, 
and their activities on 12-pNCA, 2-phenoxyethanol and allyloxybenzene were measured 
in the presence of dioxygen and NADPH. All five CRFPs displayed a Soret band 
characteristic of a folded heme domain, and four of the five exhibited detectable activity 
on one or more substrates (Table 4.2). Monooxygenase activities of the fusion proteins 
were comparable to the peroxygenase activities of the respective heme domains for 12-
pNCA and 2-phenoxyethanol.The fusion protein monooxygenases were roughly an order 
of magnitude more active towards allyloxybenzene than were the heme-domain 
peroxygenases.  
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Table 4.2. Monooxygenase activities of holoenzymes CYP102A1 (with F87A) and 
CYP102A2 (F88A) and chimera-reductase fusion proteins (CRFPs) on three substrates. 
 
Proteina  12-pNCAb 2-phenoxyethanolc allyloxybenzenec 
CYP102A1 90.9±10.2 1.8±.3 12.0±0.8 
CYP102A2  4.7±0.7 N.D. N.D. 
43-135-CRFP N.D. 0.6±0.1 5.8±0.5 
46-73-CRFP N.D. 3.9±0.1 54.2±3.7 
118-194-CRFP 87.6±4.1 0.8±0.1 6.6±0.9 
165-256-CRFP N.D. N.D. N.D. 
169-197-CRFP 67.9±6.1 1.2±0.1 10.3±1.4 
a CYP102A1 has the F87A substitution, CYP102A2 has F88A. Chimeric heme domains were fused to 
the N-terminus of the CYP102A1 reductase domain. 
b Reported in nmol product/nmol P450/minute. Activity less than 0.1 was not detectable (N.D.). 
c Reported in nmol product/nmol P450/minute. Activity less than 0.2 was not detectable (N.D.). 
 
 
 
Overall, recombination appears to affect the function of the heme domains and the 
reconstituted holoenzymes in similar ways. For example, the specificities of heme-
domain chimeras 118-194 and 169-197 are similar to A1 and A2 (Figure 4.4); their 
holoenzyme counterparts (118-194-CRFP and 169-197-CRFP) are also similar to the full-
length parent with which they retain the most sequence similarity, CYP102A1 (Table 
4.2). Furthermore, the chimeric heme domains 46-73 and 43-135, which showed altered 
peroxygenase activity profiles relative to the parents, also exhibited different oxygenase 
specificity (no activity toward 12-pNCA) when assembled as the holoenzyme. 165-256-
CRFP, on the other hand, exhibited no detectable oxygenase activity on any of the test 
substrates, unlike 165-256, which as a peroxygenase hydroxylated all three.   
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The lower activity of CYP102A2 (having the F88A substitution) relative to CYP102A1 
(with F87A) is more apparent as a monooxygenase than as a heme-domain peroxygenase. 
CYP102A1 was active on all three substrates tested, whereas the activity of CYP102A2 
was measurable only on 12-pNCA, where it was 50 times less active than CYP102A1. If 
CYP102A2 has a substrate specificity similar to its A1 homolog, then the activities on 
allyloxybenzene and 2-phenoxyethanol would be below the detection limit of the assay. 
Although general features were similar, the CRFPs differed from their respective heme-
domain chimeras in the details of the activities and specificities.   
  
D. Discussion 
D.1 Activities and specificities of recombined P450s 
While a chimeric protein often equals the sum of its parts [46], it is also possible for a 
chimera to exceed its parents and find amino acid combinations that allow new properties 
to emerge [47-53]. Creating these beneficial amino acid combinations from different 
parental sequences that are “pre-screened” by nature is one goal of protein engineering by 
recombination [48]. We find that recombination is an effective way to alter the function 
of bacterial cytochrome P450s since more than half the folded P450 chimeric heme 
domains surpassed the parents in peroxidase or peroxygenase activity. In addition, nearly 
half had altered substrate specificities relative to the parents (Figure 4.4). Recombination 
yielded enzymes with detectable activity on only one or two of the substrates analyzed as 
well as a broadly-specific enzyme that hydroxylates all three. One specific heme-domain 
chimera (46-73) displayed 6-fold higher peroxygenase activity with 2-phenoxyethanol 
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than the parent most active on that substrate. Three chimeric heme domains hydroxylated 
allyloxybenzene, an activity not detectable in either of the parent heme domains.  
 
Figure 4.5 shows how the functional properties of chimeras correlate well with their 
similarity to a parent. A1 is the most thermostable protein in this set of P450s at 55 ºC 
while A2 is significantly lower at 44 ºC. As the sequence from A2 is introduced into A1, 
the thermostability gradually decreases and eventually falls below that of A2 (Figure 
4.5A). This is consistent with the additive nature of mutations with respect to protein 
stability shown in previous studies [54,55]. It is unclear, however, whether those 
chimeras with lower stability stem from this additivity or are due to more complex 
interactions. For example, these less stable sequences could result from a stabilizing 
residue from one parent being changed to a destabilizing residue from another parent. 
This is in contrast to a stabilizing residue being replaced by a less stabilizing one such 
that the thermostability would never fall below that of the least thermostable parent. On 
the other hand, the replacement of an amino acid involved in an important interaction, for 
example, the disruption of a hydrogen bond or hydrophobic interaction, could be more 
destabilizing than the individual contributions combined.   
 
Similar to thermostability, the initial rates measured on 12-pNCA also correlate well with 
similarity to parents. As the sequence changes from the most active to least active parent, 
A1 to A2, the initial rate decreases linearly (Figure 4.5B). However, unlike 
thermostability, the initial rate on 12-pNCA was improved to a level greater than either 
parent, as in the case of chimera 169-197.  
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Figure 4.5. Activity and thermostability correlate linearly with sequence. A) As the 
sequence changes from the most to least thermostable parent (A1 to A2), the Tm linearly 
decreases with an R = 0.784. Unfolded and mirror chimeras not shown. B) As the 
sequence changes from the most to least active parent (A1 to A2) the initial rate on 12-
pNCA decreases linearly with an R = 0.815. Inactive and mirror chimeras not shown. In 
both plots A1 is shown as zero mutations and the Tm or initial rate is show for A2 even 
though it does not lie on the graph with respect to mutation (A2 has 185 sequence 
changes relative to A1). 
 
 
 
Using the heme domain’s peroxygenase activity to monitor changes in substrate 
specificity allows us to explore the evolution of functional properties in this versatile 
enzyme upon recombination. Because the three-dimensional structure of the holoenzyme 
is not available, the SCHEMA algorithm can only be applied to the heme domain. The 
peroxygenase activity therefore provides a convenient way to screen chimeric enzyme 
libraries; it is also interesting in its own right for potential applications of this enzyme in 
chemical synthesis [38]. A chimeric heme domain can also be reconstituted into a 
holoenzyme by addition of the CYP102 reductase domain. Four of the five such CRFPs 
that were constructed in fact functioned as monooxygenases (Table 4.2). Furthermore, the 
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two active CRFPs whose heme domains showed altered substrate specificity relative to 
the parent heme domains were also different from the parent holoenzymes. The activity 
and specificity of a chimeric heme domain can be expected to change, however, when it 
is used in a CRFP as a monooxygenase, just as the parent enzymes differ in their 
peroxygenase and monooxygenase activities. Such differences were also reported in our 
previous study of A1 peroxygenase regioselectivity [26].   
 
One of the functional heme-domain chimeras (165-256) generated an inactive CRFP. 
Upon recombination, the region of sequence that is derived from parent CYP102A2 
introduces a glutamic acid residue in place of a lysine at position 241, located at the 
interface between the heme and reductase domains. We believe this impairs electron 
transfer by disrupting an electrostatic interaction between the reductase and heme 
domains of CYP102A1 [56]. None of the other CRFPs had this mutation. Because a 
chimeric heme domain may not in fact be compatible with a specific parental reductase, it 
is preferable to assay for the presence of function directly in the heme domain chimeras 
in order to assess the effects of recombination.     
 
Our finding that recombination is effective in creating P450 chimeras with altered 
substrate specificities and novel activities is consistent with those reported for  
recombination of homologs in other enzyme families [48-52] and with mammalian P450s 
[53,57]. In most of these studies, closely-related proteins exhibiting distinct substrate 
specificities or activities were recombined. For example, Raillard and coworkers shuffled 
two triazine hydrolases, AtzA and TriA, which catalyze dechlorination and deamination 
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reactions, respectively, to obtain chimeras with enhanced activities and novel substrate 
specificities [50]. Our results demonstrate that recombination of functionally-similar 
enzymes can also yield functionally-diverse chimeras. In a previous study in which 
functionally-similar cephalosporinases were shuffled [48], the high levels of point 
mutation made it impossible to deconvolute the effects of recombination and point 
mutation. Here we show that residues that appear to be functionally neutral in the parent 
proteins are able to confer altered properties when recombined, provided the novel 
sequence folds properly. Although they may well be useful, additional point mutations 
were not required to achieve functional diversity.  
 
D.2 Structural features of chimeric heme domains 
The chimeric heme domains that retain the ability to fold and/or function did not result 
from swapping recognizable structural domains or distinct secondary structural elements. 
Instead, as illustrated in Figure 4.6A, the swapped fragments encompass non-trivial 
structural elements that would be difficult to identify without using an algorithm like 
SCHEMA, which takes into account sequence identity when calculating disruption. 
Using structural compactness alone to identify modules (for example, using the 
centripetal definition of Go [58,59]) does not identify most of our swapped elements as 
exchangeable. A great majority of the crossovers in the folded chimeras occur within 
these compact elements, rather than at their boundaries.  
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Figure 4.6.  Structural models of chimeric cytochrome P450 heme domains.  The 
numbers shown for each chimera represent the residues fromA1 that have been swapped 
for those from A2.  A) Residues from A1 (red) and A2 (cyan) are mapped onto the 
structure of the CYP102A1 heme domain [30].  Arrows indicate the F and G-helices.  B) 
Most of the effective mutations in the chimeras (shown in yellow) are located on the 
surface of the protein. 
 
 
 
 
For proteins that share 63% amino acid sequence identity, most non-shared amino acids 
are on the protein surface. Not surprisingly, therefore, most of the sequence changes in 
the chimeras are found on the exterior of the protein (Figure 4.6B). Such mutations are 
less disruptive, on average, than changes in the core. A1 and A2 differ at six of the 21 
residues postulated to contact a fatty-acid substrate [60]. However, it is unclear to what 
extent, if at all, sequence changes at these sites contribute to altered functional properties, 
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since no single change or combination of them is responsible for a particular activity. 
This suggests that  mutations outside the active site effectively modulate substrate 
specificities and activities, as has been observed in previous random mutagenesis studies 
[61-63]. The ‘novel’ activity on allyloxybenzene and altered substrate-specificity profiles 
cannot be attributed to any specific residue alterations since chimeras exhibiting similar 
changes in activity arose by swapping distinct polypeptides in different places in the 
enzyme (Figure 4.4). Clearly, there are multiple ways to evolve functionally similar 
enzymes through recombination of homologous proteins at structurally-related residues. 
 
We nonetheless point out one structural anecdote. The two P450 heme-domain chimeras 
with the highest peroxidase and peroxygenase rates (169-197) and broadest substrate 
specificity (165-256) have swapped a region of amino acids comprising the F helix. It has 
been shown that the F and G helices (Figure 4.6A) move approximately 6 Å upon 
substrate binding [32-34], and mutations affecting catalytic activity have been observed 
there in other protein engineering studies [63]. The new, favorable combination of the F 
helix from A2 and the G helix from A1 in the heme-domain chimera 169-197 and the 
complete substitution of the F and G helices in A1 with that from A2 in the heme-domain 
chimera 165-256 indicate a key role of this region in determining P450 catalytic 
properties. 
 
D.3 Structure-guided design of chimeric enzyme libraries 
Libraries generated by recombination of homologous proteins are rich in folded proteins 
if the parent proteins are highly similar [51,64] or if appropriate structural information is 
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incorporated in the library design [20,21]. It is not known, however, how functional 
diversity depends on the level of sequence diversity in such libraries, and whether 
recombination of less-similar sequences provides any advantage in the search for 
improved or novel functions. We hope this study begins to address this question. Figure 
4.1 shows how chimera function is related to calculated disruption and effective 
mutations. Among the folded chimeras, those with substrate activity profiles similar to 
the parents typically cluster together with lower average mutation (<m> = 22) than those 
with altered profiles (<m> = 34). Thus chimeras with higher levels of mutation, provided 
they fold, may be more likely to have altered properties, while those with lower levels of 
mutation tend to be more similar to the parents. Theoretical models predict that 
recombination facilitates fitness changes [65,66], but there is still ittle information on 
how recombination and mutation level relates to functional evolution. 
 
The probability of retaining function in the P450 chimeras decreases as calculated 
disruption (E = total number of residue-residue contacts broken upon recombination) 
increases. P450 chimeras with as many as 50, 61, and 70 effective mutations were still 
able to properly incorporate a heme cofactor, particularly with chimeric sequences 
characterized by low calculated disruption (typically E ≤ 30) (Table 4.1). We found very 
similar results in a recent study of more than 16,000 chimeric lactamases [21]. Thus we 
believe that E is a useful measure of the likelihood a chimeric protein will retain its 
structure.  
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Taking together the experimental results and disruption calculations, we have in effect 
‘calibrated’ this cytochrome P450 pair with respect to recombination. For example, we 
can now predict that a large fraction of all possible double-crossover chimeras of A1 and 
A2 will fold properly, because most are characterized by values of E < 30-35 (Figure 
4.1).  Once a particular set of crossover positions has been selected, however, only a 
limited number of chimeric sequences can be made (for two parents, this is 23 = 8 
sequences, including the parental ones). In generating large libraries that incorporate a 
larger number of crossovers, reducing disruption becomes an important design criterion. 
Figure 4.7 shows an in silico analysis of 5,000 different libraries in which 10 crossovers 
were allowed between A1 and A2, with the crossover positions chosen at random. Each 
library contains 211 = 2,048 different chimeric sequences. For each library, we calculated 
i) the fraction that is predicted to fold (using F30 = fraction of sequences with E ≤ 30) and 
ii) the average level of effective mutation in these folded chimeras (<m>30). Using this 
method of random enumeration of libraries, we find that the choice of crossover points 
can dramatically affect these values and, in all likelihood, the distribution and nature of 
functional proteins in the library. A library of A1 and A2 chimeras may contain as little 
as 9% that fold properly; on average 42% will fold. In contrast, by constructing libraries 
in silico and using SCHEMA to guide the choice of crossover points, the percentage 
folded can in principle be as high as 75%, and a very high effective level of mutation can 
be retained (with >50 mutations on average per folded sequence). We propose that this 
latter library will contain more folded chimeras and be richer in novel functional proteins 
than libraries made at random. We expect even greater benefits of using SCHEMA when 
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recombining more parents or parental sequences with less sequence identity, provided 
their structures are highly similar overall.  
 
 
 
Figure 4.7.  Theoretical library analysis.  Five thousand libraries were generated in silico, 
in which 10 randomly-selected crossovers were allowed between A1 and A2.  The 
fraction of each library that is predicted to be folded (F30 , those with E ≤ 30) is plotted 
against the average level of effective mutation for the fraction that should fold (<m>30).  
The average <m>30 and F30 for the population is shown as a square with one standard 
deviation.  The arrow points to a library with a F30 of 75% with <m>30 greater than 50. 
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E. Conclusions 
In nature, cytochromes P450 often protect organisms from toxic compounds [3,5] or help 
them adapt to new food sources [4,5]. Thus a scaffold that allows for rapid functional 
evolution could be beneficial.  Such a scaffold is also desirable for protein engineering. 
Recent engineering efforts have demonstrated that P450s can acquire new or improved 
activities by point mutation [38,43,63]; here we show that recombination of homologous 
sequences should be able to generate significant functional diversity as well. We propose 
that SCHEMA can help identify appropriate crossover locations for large, combinatorial 
libraries [21], which can be generated using targeted recombination methods [35,67]. 
With appropriate high-throughput screening, we may then be able to discover new P450s 
with properties that nature has not yet needed or explored. 
 
 
F. Experimental procedures 
 
F.1 Materials 
Enzymes for DNA manipulations were obtained from New England Biolabs (Beverly, 
MA) and Stratagene (La Jolla, CA).  Synthetic oligonucleotides were obtained from 
Invitrogen (Carlsbad, CA) or the California Institute of Technology oligonucleotide 
facility. DNA purification kits were from Zymo Research (Orange, CA) and Qiagen 
(Valencia, CA). Other reagents and chemicals were from Fisher Scientific (Pittsburgh, 
PA), Becton Dickinson (Franklin Lake, NJ) and Sigma Chemical Co (St. Louis, MO). 
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F.2 Calculations 
The number of contacts broken by recombination (E) was calculated as described using 
coordinates from the substrate-bound (1JPZ) and substrate-free structures of CYP102A1 
(2HPD) [20,30,31]. Hydrogens, backbone nitrogens, backbone oxygens, and heme atoms 
were not included in the calculation. The sequences of A1 and A2 were aligned using 
ClustalW (Appendix A) [68], revealing the existence of a one-amino-acid insertion 
relative to A1, between Q229 and S230. This insertion was ignored in the calculations.  
A1 residues G227 and E228 were also ignored because they are unresolved in the 
substrate-bound structure (1JPZ). For calculation of E and mutation for all double 
crossover chimeras, we applied a minimum insert size of 10 residues.  The error values 
reported for E and mutation represent one standard deviation. 
 
The recombination libraries analyzed contained 10 randomly-chosen crossovers, each 
separated by a minimum of 10 residues. Using the substrate-bound structure of 
CYP102A1 (1JPZ) [30], we calculated the total number of contacts disrupted (E) and 
effective level of mutation (m) for all 211 (2,048) chimeras in 5,000 libraries. We also 
computed the fraction of chimeras in each library with E ≤ 30, denoted F30, and the 
average effective level of mutation <m>30 in this low-disruption fraction.  
 
 
F.3 Construction of chimeras   
Selected chimeras were constructed using SOEing methods, as described previously [35]. 
Heme-domain chimeras contained residues 1-463 from CYP102A1 or the corresponding 
residues in CYP102A2 (1-466). Two primers consisting of a 5’ sequence from one parent 
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(A) and a 3’ sequence from the other (B) that encompass the crossover site were used to 
amplify the sequence to be inserted (B) with 25-30 bp overhangs from the other sequence 
(A). The PCR protocol was to heat the plasmids and primers at 95 ºC followed by 22 
cycles of 95 ºC for 1 minute, 48 ºC for 1 minute, and 72 ºC for 2 minutes with a final 
extension at 72ºC for 10 minutes. These products acted as primers in a further PCR 
reaction along with forward and reverse primers external to the ends of the gene 
containing BamHI and EcoRI restriction sites, respectively, for cloning into the pCWori 
vector. The PCR protocol was 95 ºC for 1 minute, 46 ºC for 1 minute, and 72 ºC for 2 
minutes for 22 cycles with a final extension at 72 ºC for 10 minutes. These two products 
were assembled in a two-step PCR reaction: 95 ºC for 1 minute followed by 14 cycles of 
95 ºC for 1 minute, 46 ºC for 1 minute, and 72 ºC for 2 minutes. External primers were 
added followed by PCR 95ºC for 1 minute followed by 14 cycles of 95 ºC for 1 minute, 
46 ºC for 1 minute, and 72 ºC for 2 minutes with a final extension of 72 ºC for 10 
minutes. All PCR products were gel-purified using the Zymoclean-5 column from Zymo 
Research. High-fidelity Pfu Turbo and Pfu Ultra polymerases (Stratagene) were used for 
PCR. Final products were digested with BamHI and EcoRI and cloned into pCWori.  
Plasmids were transformed into a catalase-deficient strain of E. coli. Chimeras were 
sequenced at Laragen Inc. (Los Angeles, CA) and the California Institute of Technology 
sequencing facility (Pasadena, CA) to confirm the sequences, with the absence of point 
mutations. pCWori expression vectors, encoding heme-domain chimeras fused to the N-
terminus of the CYP102A1 reductase domain (CRFP = chimera reductase fusion 
proteins), were constructed for five of the chimeras (43-135, 46-73, 118-184, 165-256, 
and 169-197) using a method similar to that described above. 
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F.4 Protein expression    
Chimeric heme domains and CRFPs were expressed in catalase-deficient E. coli strain 
SN0037 [37] using the isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible pCWori 
vector [36]. Cultures grown in terrific broth (TB) were shaken at 250 rpm and 30 °C until 
they reached an OD600 of approximately 0.8. They were induced with 0.6 mM IPTG, 
supplemented with 25 µg/ml thiamine and 0.5 mM δ-aminolevulinic acid, and grown for 
20 hours at 180 rpm and 25 °C. This procedure yields approximately 100 mg/L of P450 
protein for A1 and A2. Cultures were pelleted at 5,500 g for 15 min, resuspended in 50 
mM Tris (pH 8.2), and lysed by sonification. Centrifugation was used to clear the 
supernatant, which was used for further assays. 
 
 
F.5 Folding assay   
Carbon monoxide reduced difference spectroscopy was performed as reported [69]. Cell 
extracts were diluted into 800 µL of 100 mM Tris buffer (pH 8.2) in a cuvette at room 
temperature. A few mg of sodium hydrosulfite on the tip of a spatula were added, and a 
blank spectrum was determined from 400 to 500 nm. Carbon monoxide was bubbled in 
for 20 seconds at a rate of approximately one bubble per second. Two minutes were 
allowed to pass before a spectrum was taken. Spectra were determined at multiple times 
to ensure complete carbon monoxide binding and maximum absorbance. There were no 
increases beyond 5 minutes of incubation with carbon monoxide for any of the chimeras. 
P450 enzyme concentrations were quantified for further assays using an extinction 
coefficient of 91 mol-1cm-1 for the absorbance difference between 448 nm and 490 nm. 
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F.6 Peroxygenase activity   
First-order rates of p-nitrophenolate accumulation were determined using 1 µM enzyme, 
20 mM H2O2, 250 µM 12-pNCA and 0.5% dimethyl sulfoxide (DMSO) in 100 mM Tris-
HCl (pH 8.2) at room temperature.  Enzyme, substrate, buffer and DMSO were combined 
in a cuvette and zeroed at 410 nm. Reaction mixtures were allowed to incubate for 4 
minutes and initiated by the addition of H2O2 to a final concentration of 20 mM. Initial 
rates were determined by monitoring the accumulation of p-nitrophenolate at 410 nm, 
and data from the first six seconds were used to determine initial rates. If no activity was 
observed at 20 mM H2O2, a second trial at 100 mM was done. No chimera inactive at 20 
mM H2O2 showed activity at the higher concentration. The extinction coefficient of p-
nitrophenolate is 13,200 M-1cm-1 [42]. All rates reported represent the average of three 
independent experiments with error bars corresponding to one standard deviation.  
 
Catalytic activities on 2-phenoxyethanol and allyloxybenzene were determined using 2 
µM enzyme, 20 mM H202, 1% DMSO, and 1% acetone  in 100 mM N-[2-
hydroxyethyl]piperazine-N’-[3-propanesulfonic acid] (EPPS) (pH 8.2) at room 
temperature. Substrate concentrations for 2-phenoxyethanol (100 mM) and 
allyloxybenzene (50 mM) maintained saturation. Total reaction volumes were 400 µl for 
heme domain chimeras and were initiated by the addition of H2O2 and monitored for up 
to 90 minutes. Aliquots of the reaction were removed at time points within the linear 
region of the time course and mixed with an equal volume of a quench solution 
containing 4 M urea and 100 mM NaOH. 15 µl per 100 µl of 0.6% 4-AAP was added, 
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followed by mixing and addition of 15 µl per 100 µl of 0.6% potassium persulfate. Color 
was allowed to develop for 10 minutes before absorbance was read at 500 nm. The major 
products were determined by GC/MS to be the hemiacetal which decomposes to phenol. 
The extinction coefficient for the 4-AAP/phenol complex was determined to be 4,800 M-
1cm-1. 
 
 
F.7 Monooxygenase activity 
CRFP monooxygenase activities were determined under identical conditions as the 
peroxygenase reactions, except H2O2 was replaced with 500 μM NADPH in all reactions.   
 
 
F.8 Clustering analysis 
Chimeras that retained the ability to fold were analyzed using hierarchical clustering 
analysis as performed by the Spotfire® software package (Spotfire, Somerville, MA). 
Chimeras were clustered based on their substrate-specificity profiles, i.e. whether or not 
they possessed measurable peroxygenase activity towards the substrates 12-pNCA, 2-
phenoxyethanol, and allyloxybenzene. Therefore, activities were normalized to the 
presence of activity (1) or the lack of activity (0). UPGMA (Unweighted Pair Group 
Method using Arithmetic Averages) clustering was performed using Euclidean distance 
as a similarity metric and the average value as an ordering function. 
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F.9 Peroxidase activity   
Peroxidase activities were measured by monitoring the accumulation of the radical cation 
of ABTS at 414 nm [45]. Enzyme (1 µM) was mixed with 10 mM ABTS in 200 mM 
phosphate buffer (pH 5.0) in a cuvette at room temperature. Samples were zeroed and 
reactions were initiated with the addition of H2O2 to a concentration of 20 mM. The 
absorbance at 414 nm was monitored for 5 minutes. Rates were determined from the 
initial slope of the time course (typically the first 30 seconds). An extinction coefficient 
of 36,000 mol-1cm-1 for ABTS was used. 
 
 
F.10 Thermostability 
Cell extracts were heated in a thermocycler for 10 minutes at various temperatures, 
followed by cooling to 4°C. Extracts were centrifuged for 5 minutes at 3500 x g to 
remove any precipitates.  Carbon monoxide reduced difference spectroscopy was used to 
quantitate the amount of P450.  The reduction of the carbon monoxide peak was 
monitored over a range of temperatures. 
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A. Abstract 
Creating artificial protein families affords new opportunities to explore the determinants 
of structure and biological function free from many of the constraints of natural selection. 
We have created an artificial family comprising ~3,000 P450 heme proteins that correctly 
fold and incorporate a heme cofactor by recombining three cytochromes P450 at seven 
crossover locations chosen to minimize structural disruption. Members of this protein 
family differ from any known sequence at an average of 72 and by as many as 109 amino 
acids. Most (>73%) of the properly folded chimeric P450 heme proteins are catalytically 
active peroxygenases; some are more thermostable than the parent proteins. A multiple 
sequence alignment of 955 chimeras, including both folded and not, is a valuable 
resource for sequence-structure-function studies. Logistic regression analysis of the 
multiple sequence alignment identifies key structural contributions to cytochrome P450 
heme incorporation and peroxygenase activity and suggests possible structural 
differences between parents CYP102A1 and CYP102A2. 
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B. Introduction 
Our understanding of how protein sequence relates to structure and function is aided by 
comparisons of sequences related by evolution [1-3]. With only limited numbers of 
highly divergent sequences, however, such analyses are often uninformative. 
Furthermore, because the sequences have been culled by natural selection, relationships 
between sequence and physical or chemical properties not under direct selection are 
difficult or impossible to discern. We would like to create artificial protein families in 
order to probe the range of sequence and functional diversity that is compatible with a 
given structure, free from the constraint of having to function in the narrow context of the 
host organism. These artificial sequences would help us to identify connections to 
functions that may not be important biologically (e.g., high thermostability, new substrate 
specificity, or ability to fold into a particular structure, but not catalyze a particular 
reaction), but are critical for understanding the proteins themselves [4,5]. 
 
The products of millions of years of divergence and natural selection, protein families 
contain members that differ at large numbers of amino acids residues. Creating numerous 
diverse and folded sequences in the laboratory is challenging, due in part to the sparsity 
of proteins in sequence space. Among random sequences, estimates of the frequency of 
functional proteins range from 1 in 1011 [6] to as little as 1 in 1077 [7]. Randomly mutating 
a functional parent sequence improves the odds, but highly mutated sequences are still 
exceedingly unlikely to fold into recognizable proteins [8,9]. The methods by which 
novel proteins have been created, including selection from libraries of random [6] or 
patterned [10] sequences, evolution from existing sequences by iterative mutation or 
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recombination [11], and by structure-guided design [12] as well as computation-intensive 
protein design [13,14], either yield small numbers of characterized sequences or 
numerous sequences with low diversity (few sequence changes). 
 
We are developing site-directed, homologous recombination guided by structure-based 
computation (SCHEMA) [15-17] to create libraries of protein sequences that are 
simultaneously highly mutated and have a high likelihood of folding into the parental 
structure. Mutations made by recombination of functional sequences are much more 
likely to be compatible with the particular protein fold than are random mutations [18]. 
SCHEMA calculations allow us to minimize the number of structural contacts that are 
disrupted when portions of the sequence are inherited from different parents, further 
increasing the probability that the chimeric proteins will fold. The validity of the 
SCHEMA disruption metric has been demonstrated in previous work [15-17]. SCHEMA, 
however, has not yet been used to design a library to maximize the number of sequences 
with low disruption and high mutation. 
 
Here we report SCHEMA-guided recombination of three cytochromes P450 to create 
6,561 chimeras, of which ~3,000 are properly folded P450 proteins. Cytochromes P450 
comprise a superfamily of heme enzymes with myriad biological functions, including key 
roles in drug metabolism, breakdown of xenobiotics, and steroid and secondary 
metabolite biosynthesis [19]. More than 4,500 sequences of this ubiquitous enzyme are 
known [20]. Members of the artificial family of chimeric P450s reported here differ from 
any known protein by up to 109 amino acids, yet most retain significant catalytic activity. 
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Unlike natural protein families, this artificial family also includes sequences that do not 
fold or function. Inclusion of nonfunctional sequences enables us to apply powerful 
logistic regression tools [21] to the multiple sequence alignment (MSA) of the laboratory-
generated proteins and determine which elements contribute to correct heme 
incorporation and retention of catalytic activity in the cytochrome P450 heme domain. 
 
C. Results/Discussion 
C.1 SCHEMA design and construction of a chimeric P450 library 
 
We generated an artificial family of cytochromes P450 by recombining fragments of the 
genes encoding the heme-binding domains of three bacterial P450s, A1, A2, and A3, 
which share ~65% amino acid identity [22,23] (Figure 5.1). The parent proteins are 463–
466 amino acids long and contain the single substitution F87A (A1) or F88A (A2 and 
A3), which increases the peroxygenase activities of these heme domains [24]. 
Calculations of the SCHEMA disruption that results when residue–residue contacts 
present in the parent structure are broken by recombination (see Materials and Methods) 
served to guide the placement of crossovers so as to maximize the number of highly 
mutated, folded proteins in the resulting library. 
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Figure 5.1. Diverse chimeras created by site-directed recombination. (A) Site-directed 
recombination of three bacterial cytochromes P450 showing crossover sites chosen to 
minimize the number of disrupted contacts (number is last residue of the sequence block 
according to CYP102A1 numbering). Blocks are assigned numbers 1 through 8 and three 
fragments are possible at each block. Three example chimeras are shown to illustrate the 
fragment nomenclature, e.g., fragment 1.3 is block 1 inherited from parent A3. (B) 
Sequences of three parents and 97 folded P450 chimeras and number of amino acid 
changes relative to the closest parent (bar on right). 
 
 
To accomplish this, we used the structure of the heme domain from CYP102A1 [25] to 
computationally evaluate 5,000 libraries with seven crossovers, each of which contained 
38 = 6,561 chimeric sequences (including the parents). Crossover sites were chosen 
randomly, with a minimum fragment size of 20 residues. To estimate the fraction of 
folded proteins in each library, we counted the number of structural contacts, E, disrupted 
in each chimeric sequence (see Materials and Methods) [15,17]. Based on data from the 
seventee A1–A2 chimeras individually constructed and studied in Chapter 4, we modeled 
the probability of folding as a step function which decreases from 1 to 0 at a threshold of 
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E = 30. Fraction folded was thus calculated as the number of chimeras in each library 
with E ≤ 30 divided by the total number of chimeras (= 6,561). The average number of 
amino acid substitutions from the closest parent <m> for the folded proteins (those with E 
≤ 30) was also calculated as a measure of the library sequence diversity. The fraction 
folded and <m> for 5,000 randomly generated libraries can be seen in Figure 5.2. 
 
 
Figure 5.2. Choosing a library using random enumaration. Blue circles represent 5,000 
randomly chosen seven-crossover libraries with minimum block sizes of twenty amino 
acids. The average fraction folded and average <m> for the randomly enumerated 
libraries are 22.0 ± 6.7% and 54.6 ± 6.0, respectively. Red circles represent complete 
enumeration of fourteen frequently occurring crossovers appearing in the randomly 
generated libraries with a fraction folded greater than 25%. The average fraction folded 
and average <m> for the completely enumerated libraries are 37.0 ± 3.6% and 59.6 ± 4.8, 
respectively. The arrow identifies the library chosen for construction (see text). 
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From the set of 5,000 randomly generated libraries, we selected only those with a fraction 
folded greater than 25% for further study. Within these, 14 crossover locations appeared 
most frequently (crossovers located after residues Ser65, Leu104, Ile122, Leu148, 
Tyr166, Gln204, Val216, Gly227, Thr268, Gln307, Ala328, His361, Pro376, and 
Gln403). Using these 14 crossover sites, we evaluated all 3,432 possible seven-crossover 
libraries and chose one with a high fraction folded (40%), high diversity (<m> = 68 for 
the chimeras with E ≤ 30, <m> = 76.4 for the library as a whole), and crossovers 
distributed over the primary sequence (average number of residues per block = 59 ± 10). 
The final design has crossovers located after residues Glu64, Ile122, Tyr166, Val216, 
Thr268, Ala328, and Gln404, based on the numbering of the A1 sequence (Figure 5.1A).  
 
Figure 5.2 shows how the libraries consisting of subsets of the 14 frequent crossovers 
(subset libraries) compare to those with crossovers chosen randomly. The average 
fraction folded and average diversity (average <m>) are both significantly higher in the 
subset libraries than in the random libraries, demonstrating the enrichment of high quality 
libraries in the subset libraries (see Figure 5.2 legend).  
 
Following design and construction of this library, Endelman et al. employed dynamic 
programming to quickly compute optimal site-directed libraries, termed RASPP 
(recombination as a shortest-path problem) [26,27]. Instead of fraction folded, RASPP 
uses average E to assess the frequency of viable protein sequences. A comparison of the 
random-enumeration to the RASPP curve shows that random enumeration of this small 
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number of libraries does not discover libraries with comparable <E> at a given value of 
<m> (Figure 5.3). Interestingly, the final library design chosen from the population of 
subset libraries falls along the RASPP curve. Thus by choosing frequently occurring 
crossover sites within a small set of randomly sampled libraries and completely 
enumerating those libraries we were able to achieve similar design results to RASPP.  
However, the computational time required for random enumeration followed by complete 
enumeration of the subset libraries is far greater than with RASPP. 
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Figure 5.3. RASPP curve for seven crossover libraries between A1, A2 and A3. The blue 
circles represent 5,000 randomly generated libraries with a minimum mutational level per 
block of two. The green line represents the RASPP curve generated with the same 
mutational constraints as the random generation with a bin size of two.  The large red 
point represents the <E> and <m> values for the library that was chosen here. 
 
 
The individual structural elements identified by SCHEMA are not obvious based on 
secondary or domain structure (Figure 5.4 and 5.5A). For example, the crossovers 
between blocks 2–3, 4–5, 5–6, and 7–8 lie within the D, G, I and L helices, respectively 
[28]. Individual blocks, however, combine to form larger structural elements that 
coincide with protein domains determined from inspection of the A1 crystal structure 
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[28] and concerted motions evident in molecular dynamics simulations of the same 
protein [29] (Figure 5.5A). Blocks 1 and 7 comprise the independent “β domain,” most of 
which is a five-stranded β-sheet. The two-stranded, anti-parallel β-sheet comes from 
block 7, while the remaining three β-strands are contributed by block 1. The library 
design divided this domain into the fewest possible pieces. The remaining blocks 
comprise the “α domain” [28], which on the basis of concerted protein motions has been 
divided further into α′ (corresponding to blocks 4 and 5) and α″ domains (blocks 6 and 8) 
[29]. These three domains reflect groups of residues that move together not only in 
molecular dynamic simulations but also between different conformations of A1, which 
undergoes a large conformational change upon substrate binding [30]. Considering the 
root-mean-square deviation (RMSD) between the substrate-bound (closed) and substrate-
free (open) forms of A1 (Figure 5.5B) [31], five of seven crossovers are in regions which 
move 1.2 Å or less, significantly less than the average displacement of 2.2 Å, and capture 
the boundaries of the previously defined domains within six residues. 
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Figure 5.4. Structural model of heme-domain backbone structure showing positions of 
each block. Model is based on the crystal structure of CYP102A1 (2HPD) [28]. Blocks 
are color-coded as shown and heme is shown in CPK coloring.  
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Figure 5.5. Comparison of library design to domains, dynamics, and secondary structure 
of CYP102A1. (A) Crossovers in the library designed using the SCHEMA energy 
function capture domain boundaries of CYP102A1 determined from molecular dynamics 
simulations [29]. Crossovers between blocks 2–3, 4–5, 5–6, and 7–8 lie within α-helices. 
(Secondary structure assignment is based on the CYP102A1 crystal structure [25]). (B) 
Plot of the RMSD between the backbone atoms of the substrate-bound (closed) and 
unbound (open) structures of CYP102A1. The RMSD was calculated by comparing 
molecule B of the substrate-free structure [31] and molecule A of the structure bound to 
palmitoleic acid [28] using Swiss PDB Viewer. Vertical lines designate crossover 
locations and blocks are numbered. Crossovers between blocks 1–2, 5–6, 6–7, and 7–8 
occur at positions that move < 1.2 Å between the two structures. Crossover 3–4 is located 
next to a region of high identity and may be shifted towards the N-terminus by up to 14 
residues and still produce the same chimeras. This shift allows it to occur at a position 
which moves < 1.2 Å. 
 
 
 
The three gene fragments encoding each of the eight blocks were combinatorially 
assembled using the sequence-independent site-directed chimeragenesis (SISDC) [32] 
method developed specifically for this application to generate a gene library containing 
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6,561 different sequences (Figure 5.1A). These genes were expressed in E. coli, where 
high-throughput sequencing by DNA probe hybridization and functional assays 
determined the sequences and functions of the proteins they encoded. 
 
C.2 Sequence analysis 
Because the crossover locations are fixed, the complete sequence of a chimera (absent 
any point mutations, insertions, or deletions) can be obtained by determining which 
parent sequence is present at each block by DNA probe hybridization [33]. Out of 1,512 
randomly selected colonies analyzed this way, 754 complete sequences were obtained. Of 
these, 628 were unique. The distribution of fragments in this sample revealed two main 
biases from the ideal incorporation of 33% of each parent at each block (Figure 5.6): at 
block 1, parent A1 is present in 10% of the chimeras, while parent A2 is present at block 
4 in only 0.5%. 
 
 
 
Figure 5.6. Fragment distribution at each block based on probe hybridization of genes 
from 754 unselected clones. 
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We completely sequenced 39 chimeras in order to assess the frequency of point 
mutations and of insertions, deletions, and remaining tag sequences (indels). Tag 
sequences were inserted at each crossover location for library construction by SISDC, 
and any remaining tag sequences result in a large insertion. In seven randomly chosen 
chimeras we found only one synonymous point mutation and no indels. We also 
sequenced 32 randomly chosen chimeras for which folding status had been determined. 
Twenty of these encoded folded P450s, while 12 encoded proteins that were not P450s. 
In the 20 folded P450 sequences, there were zero remaining tag indels and two point 
mutations. In the 12 not-folded sequences, one point mutation and one remaining tag 
sequence were found. From the overall point mutation frequency of 0.007% (in 51,568 
nucleotides), we estimate that fewer than 10% of the chimeras in the library contain a 
point mutation. No indels or tag sequences were found in any of the folded P450 
sequences, and fewer than 9% of the not folded chimeras contain indels or tags. 
Comparing the results from DNA sequencing and probe hybridization analysis, we found 
that probe hybridization identified the correct fragment at all eight blocks in 31 of 32 
sequences. Thus the sequencing information from probe hybridization reflects the true 
sequences of the chimeras with errors in less than 10% of the chimeras, the majority of 
which are due to single point mutations. 
 
C.3 Assignment of folding status 
Using high-throughput CO difference spectroscopy (see Chapter 3), we assayed clones 
from the chimeric P450 library for the characteristic Soret peak at 450 nm. The presence 
of this peak indicates correct heme binding and thus a properly folded P450 heme 
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protein. Of the 628 unique full-length sequences, 293 (47%) encoded folded P450s. 
Additional sequencing of folded P450s yielded an expanded dataset containing 955 
unique sequences (including the three parents), of which 620 correctly incorporate heme 
and 335 do not (Appenix B). Thirty-eight of these 335 not-folded sequences gave a peak 
at 420 nm, characteristic of improperly incorporated heme and a nonfunctional enzyme 
[34,35]. The remaining not-folded sequences lack a compatible heme-binding site and 
likely do not fold into a well-defined structure. 
 
The folded sequences are highly mosaic and differ from their parents by 72.5 amino acids 
on average, with as many as 109 amino acid substitutions from the nearest parent 
sequence (Figure 5.1B and Appendix B). The average number of disruptions (<E>) is 
lower in chimeras that bind heme (29.5) versus those that do not (34.8). The average 
number of mutations in the heme-binding chimeras is also lower, 72.9 versus 77.5. The 
compositions of chimeras can be easily visualized using ternary diagrams (Figure 5.7). 
For example, the sequence biases against single A1 and A2 fragments in the library 
construction generates fewer chimeras whose compositions are very close to A1 or A2 
(Figure 5.7A). It is clear from this plot, however, that the overall compositions of folded 
and not-folded chimeras are not markedly different and are well distributed over the 
accessible composition space. 
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Figure 5.7. Ternary diagrams showing the distribution of chimera amino acid 
compositions. (A) Compositions of 955 folded (closed circles) and not-folded (open 
circles) chimeric sequences. Each data point represents the relative amino acid identity 
between a chimera and each parental sequence not including positions conserved between 
all three parents. This distance was calculated by determining the number of amino acids 
a chimera shares with each parent and dividing by their sum. The three relative identities 
add up to one. Since each parent shares some sequence identity with the other two, they 
do not lie at the corners of the diagram. (B) Compositions of 441 chimeras tested for 
activity on 12-pNCA: active chimeras (closed circles) and not active (open circles). 
Chimeras composed mostly of A3 and chimeras near the center tend to be inactive on 12-
pNCA. 
 
 
 
C.4 Catalytic activities of folded P450 chimeras 
We estimated the fraction of chimeras that are functional by assaying 320 folded P450 
chimeras for peroxygenase activity on 2-phenoxyethanol, a substrate accepted by all three 
parents. Reaction on this substrate yields phenol (Figure 5.8), which is detectable in high 
throughput(see Chapter 3). The three parent P450s naturally occur as fusion proteins to 
an FAD- and FMN-containing NADP reductase [22]. These monooxygenases use 
NADPH and molecular oxygen to hydroxylate fatty acids [23]. The parent heme 
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domains, by virtue of the single amino acid substitutions F87A in A1 and F88A in A2 
and A3, also function as peroxygenases, catalyzing oxygen insertion in the presence of 
hydrogen peroxide [24]. Chimeras that produced at least 25% of the total product formed 
in the assay by the most active parent (A1) were considered active. Of the 320 folded 
chimeras assayed, 72% were found to be active on 2-phenoxyethanol. 
 
 
 
Figure 5.8. Substrates and major products of P450 peroxygenase reactions with 2-
phenoxyethanol and 12-pNCA. In both cases, hydroxylation yields a hemiacetal which 
decomposes to phenolic products detectable in high-throughput assays. 
 
 
 
We also assayed all the 955 chimeras for which the sequences and folding status were 
determined for activity on the fatty acid analog p-nitrophenoxydodecanoic acid (12-
pNCA, Figure 5.8). The parent A1 and A2 heme domains are active on 12-pNCA, while 
A3 is not. Chimeras with 25% of the total product formed by A1 during the assay were 
considered active. None of the chimeras that did not fold properly showed activity. We 
then determined activity status for folded P450s whose concentration was at least 500 
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nM, in order to remove false negatives based on low expression or other experimental 
errors. Of the folded chimeras, 441 met this constraint, of which 134 (30%) were active 
on 12-pNCA (Appendix B). The average number of disruptions is lower for chimeras 
active on 12-pNCA versus those that are not (<E> = 26.3 versus 31.4). Mutations are 
similarly lower in active chimeras (<m> = 70.9 versus 76.9). The average number of 
crossovers in the active chimeras was 4.6 compared to 4.4 for those that were not active. 
 
A ternary diagram showing the 441 chimeras tested for activity on 12-pNCA (Figure 
5.8B) demonstrates that the sampled sequences are distributed similarly to the larger 
dataset (Figure 5.7A). Parent A3 is inactive on 12-pNCA, and there are only a few 
chimeras with a high fraction of sequence from A3 that exhibit this activity. Additionally, 
there is a lower density of active chimeras near the center, where the chimeric sequences 
have the greatest divergence from the parents. 
 
Fewer chimeras showed activity on 12-pNCA than on 2-phenoxyethanol, which we 
attribute to the fact that one parent, A3, is not active towards 12-pNCA, while all three 
parents are active on 2-phenoxyethanol. Overall, 73% of the folded chimeras assayed 
exhibited peroxygenase activity on at least one of these two substrates. Thus, at least 35% 
of the 6,561 sequences in the library are folded and functional, corresponding to 2,300 
new P450 enzymes, not including any that are active on substrates not tested. This 
functional fraction is roughly three times higher than reported in a study in which more 
closely related cytochromes P450 (>71% amino acid identity) were recombined using a 
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DNA shuffling methodology that leads to crossovers at regions of high sequence identity 
[36]. 
 
C.5 Thermostabilities of folded P450 chimeras 
To examine how recombination affects protein stability, we measured the melting 
temperatures of the parent P450s and 14 chimeras (all of which denature irreversibly at 
high temperature) by monitoring the disappearance of the P450 Soret peak with 
increasing temperature. A range of Tm’s (42 °C–62 °C) was observed in this small sample 
(Table 5.1). The most stable chimera differs from its closest parent by 84 amino acid 
substitutions, yet its melting temperature is 7 °C higher than the most stable parent. It is 
also higher than that of a variant of the A1 heme domain previously stabilized by 
sequential random mutagenesis and screening [37]. If a chimera is able to bind heme, 
then on average its stability appears not to be compromised relative to the parent proteins. 
The ability of the blocks to assemble into more thermostable proteins when removed 
from their natural context supports the modular nature of these elements and likely 
reflects some intrinsic stability of the individual blocks, due to the large number of 
structural contacts preserved by the library design. 
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Table 5.1. Thermostabilities of parent and chimeric heme domains. 
Sequence* Tm (°C) † 
A1 55 
A2 44 
A3 49 
23113312 43 
23133121 45 
32312231 51 
22312333 62 
32312332 52 
32312333 56 
21333223 54 
12112333 49 
12313331 49 
11213231 53 
22313232 52 
21113212 49 
22213222 48 
32213333 47 
* Sequence listed as parent sequence (A1 = 1, A2 =2, A3 = 3) at each block 
† Tm’s are the average of three measurements. Standard deviations is less than 
1°C. 
 
 
 
C.6 Logistic regression analysis of the multiple sequence alignments 
Small sets of chimeric P450s have been constructed previously for investigations of 
sequence-structure-function relationships [38,39]. The MSA of natural protein families 
are also widely used for this purpose. Comprised of sequences largely uncoupled from 
natural selection, including sequences that encode nonnatural functions (such as not 
folding or not functioning), the artificial protein family described here offers a unique 
opportunity to elucidate key sequence and structural contributions to P450 folding and 
function. By analyzing the MSAs of the chimeric P450s we can identify how different 
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blocks and their parental identities influence folding and heme binding or catalytic 
activity. Because this dataset also includes sequences that encode not-folded and not-
functional proteins, we can use logistic regression analysis (LRA), an analog of linear 
regression suitable for the type of binary data presented here, to analyze the MSAs. 
Other, more commonly used methods such as contingency table [40,41] and statistical 
coupling [1,42] are unable to utilize the additional information provided by the sequences 
that do not fold or function. 
 
Underlying our LRA of the folded/not-folded dataset is the idea that individual fragments 
and interactions between fragment pairs contribute to whether a chimera will fold and 
bind heme. LRA fits an energy model containing intra- and inter-fragment terms; the 
magnitude of each term reflects how strongly that variable affects the likelihood of 
folding, with negative values increasing the likelihood and positive values decreasing it 
[21]. If energy is below a threshold, a chimera is assumed to be folded; otherwise it is 
not. In order to avoid overfitting the data, p-value testing is used to determine which 
fragments make a significant contribution to predicting chimera folding status. 
 
We applied LRA to the MSA of the entire set of 955 chimeric P450s in Appendix B to 
determine which blocks contribute to folding and correct heme binding. The resulting 
energy model includes blocks and block pairs that are significant with the likelihood ratio 
test and cross-validation (see Materials and Methods). This analysis revealed that blocks 
1, 5, and 7 by themselves and the interaction between blocks 1 and 7 (abbreviated 1–7) 
contribute significantly to whether a chimeric P450 folds and binds heme (Figure 5.9). 
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All other blocks and block pairs are apparently to a large extent interchangeable with 
respect to whether a chimera folds properly. 
 
 
Figure 5.9. Logistic regression analysis of multiple sequence alignments identified 
blocks and block pairs that contribute to whether a chimera folds and binds heme and 
whether it exhibits activity on 12-pNCA. (A) Intra-fragment terms in the energy model 
from LRA of folded/not-folded sequences indicate that blocks 1, 5, and 7 make 
significant contributions to folding and incorporation of heme. Negative energies increase 
the likelihood of folding and correctly binding heme while positive ones decrease it. (B) 
The single significant inter-fragment interaction from LRA of folded/not-folded 
sequences comes from pair 1–7 and includes the nine energy terms for pair 1–7, which 
can be divided into three groups. The on-diagonal elements (filled black) are the most 
stabilizing. The three terms filled gray have roughly average energy. The three white 
elements are destabilizing relative to the others. (C) Significant intra-fragment terms from 
LRA of the MSA of active/not-active sequences indicate that blocks 2 and 4 have 
significant effects on peroxygenase activity. (D) The single significant inter-fragment 
interaction between blocks 1 and 8, showing the nine terms, divided into similar groups 
as in part B.  
 
 
 
As shown in Figure 5.9A, the intra-fragment terms for fragments 1.2 and 7.3 have lower 
energy relative to the other parents, which means the sequence changes in these 
fragments are more favorable for heme binding. Blocks 1 and 7 are in fact expected to be 
important, because they contain the most residues, the greatest number of intra-fragment 
contacts (Figure 5.10), and block 1 has the highest average number of sequence changes, 
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whereas block 7 has the third most (Figure 5.10). In contrast, block 5 has the third fewest 
intra-fragment contacts and the second fewest average number of sequence changes 
(Figure 5.10). At this block, fragment 5.1 is the least favored of all the fragments for 
folding and heme binding (Figure 5.9A). Parent A1 contains a deletion relative to A2 and 
A3 in block 5, which may contribute to this behavior. We suspect that some of the 
importance of block 5 is due to the dynamic nature of cytochromes P450, similar to what 
has been observed in multiple sequence analyses of other protein families [2]. The F, G, 
and H helices (in blocks 4 and 5) undergo displacements of more than 5 Å between the 
substrate-bound and substrate-free forms of A1 [31], and block 5 moves an average of 3.6 
Å (Figure 5.11A). This portion of the enzyme acts as a “hinge” by which the F and G 
helices close down upon the substrate. Because none of the residues in block 5 that 
contact the heme differ among the three parents, the importance must stem from how 
variable amino acids in block 5 affect dynamics or interact with conserved residues. 
 
 
Figure 5.10. Black bars, intra-fragment contacts within each block, as defined by the 
SCHEMA distance of 4.5 Å [17]. Gray bars, the average number of sequence changes 
between each parent. 
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Figure 5.11. Structural elements that contribute significantly to proper folding and 
incorporation of heme and model of substrate binding in CYP102A1 and CYP102A2. (A) 
Movement of block 5 between open (red) and closed (green) structural forms based on 
alignment of heme cofactor. The average displacement over the whole block is 3.6 Å. (B) 
Residues that could contribute to positively and negatively interacting fragments at 
blocks 1 and 7. Residue 56 (shown as arginine) is an arginine, glutamate, and glutamine; 
and residue 344 (shown as glutamate) is a glutamate, lysine, and glutamate in A1, A2, 
and A3, respectively. The fragment pairs that result in unfavorable charge–charge 
interactions for these closely spaced side chains are unfavorable overall for folding and 
heme incorporation. (C) In CYP102A1 the carboxylate group of the fatty acid substrate 
(in green) interacts with arginine 47 from block 1 (dashed line). Residue 435, from block 
8, and residue 24 may form a salt bridge. Portions of blocks 1 and 8 are shown in purple 
and grey, respectively. (D) Proposed model for CYP102A2 showing an alternative 
binding configuration for the fatty acid substrate. Residue 437 (in block 8) is a glutamine 
in A2. Thus in A2, lysine 25 is free to interact with the substrate carboxylate group 
(dashed line). Structure shown is 1FAG [28]. Amino acid residues are in black and heme 
is grey. 
 
 
 
Block pair 1–7 was the only pair revealed by LRA as significant for folding and 
incorporation of heme. Blocks 1 and 7 interact extensively to form the β-domain (Figure 
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5.11B) and experience the largest average number of broken contacts when the blocks are 
inherited from different parents. As expected, chimeras that inherit blocks 1 and 7 from 
the same parent are more likely to fold and bind heme (Figure 5.9B). This result supports 
the core hypothesis of SCHEMA and other penalizing energy functions [43] which assign 
the best possible score to these wild-type interactions. 
 
Inspection of the sequences of the parents in these two blocks revealed an electrostatic 
interaction that could contribute to the pattern of energies in Figure 5.9B. Residues 56 
(block 1) and 344 (block 7) are 2.8 Å apart in the A1 crystal structure (Figure 5.11B). At 
position 56, parent A1 contains a positively charged arginine, A2 has a negatively 
charged glutamate, and A3 has a neutral glutamine. Residue 344 is a glutamate in A1 and 
A3, but lysine in A2. Thus the interaction 1.1–7.2 pairs arginine and lysine, while 1.2–7.3 
pairs glutamate and glutamate, both of which are repulsive. 
 
We repeated the logistic regression analysis to determine which blocks affect activity on 
12-pNCA, independent of heme binding, by applying LRA to the subset of 441 folded 
chimeras for which presence or absence of activity on 12-pNCA had been determined 
(Appendix A). This analysis revealed that blocks 2 and 4 by themselves and block pair 1–
8 contribute to whether a folded chimera is catalytically active on this substrate. At 
blocks 2 and 4, the fragments derived from parent A3 are detrimental to activity (Figure 
5.9C). These sequence elements likely account for A3’s lack of activity on this substrate, 
since sequence from this parent at other blocks has little affect on 12-pNCA activity in 
the chimeras. The importance of block pair 1–8 may reflect a difference between A1 and 
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A2 with respect to substrate binding: when A1 or A2 is present at either block 1 or 8, 
activity is strongly dependent on whether the other block comes from the same parent 
(Figure 5.9D). This indicates that there are one or more interactions between blocks 1 and 
8 that must be preserved in order for the enzyme to be active on 12-pNCA. 
 
C.7 Residues contributing to peroxygenase activity on 12-pNCA 
We sought to determine what interactions(s) might be responsible for the importance of 
the 1–8 pair, using the sequence differences in parents A1 and A2 for guidance. One 
obvious difference occurs at the position corresponding to Arg47 in fragment 1.1, which 
is located at the opening of the active site and is thought to interact with the carboxylate 
group of fatty acid substrates [31]. Substitutions of this residue in the A1 holoenzyme 
significantly reduce catalytic activity [44,45]. In A2, the equivalent residue is Gly48, a 
residue that favors the binding of polycyclic aromatic hydrocarbons when present in the 
A1 holoenzyme [46]. We tested the importance of R47 to peroxygenase activity by 
swapping the residues at position 47/48 in A1 and A2, i.e., making the single mutation 
R47G in A1 and G48R in A2. The R47G mutation in A1 reduced the initial rate nearly 25 
fold (from 65.9 ± 8.5 to 2.7 ± 0.5 nmol product/nmol P450/min), making it comparable to 
the activity of A2. On the other hand, the G48R mutation in A2 had no effect on rate. 
This suggested to us that G48 in A2 does not interact with the substrate carboxylate 
group, as the equivalent residue appears to do in A1. 
 
We postulated that the different mode of substrate binding could be facilitated by a 
positively charged residue elsewhere in the A2 sequence. Only a small portion of block 8, 
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consisting of halves of two β-strands (residues 434 to 439), is located near the active site 
(Figure 5.11C). Examination of the parental sequence alignment in this region (Appendix 
A), however, revealed no lysines or arginines unique to fragment 8.2. Because fragments 
8.1 and 8.3 are equally incompatible with 1.2 according to the LRA, we looked for a 
residue between 434 and 439 that was shared by A1 and A3 but not A2. Residue 435 in 
A1 (437 in A2 and A3), which is a glutamate in A1 and A3 and a glutamine in A2, met 
these criteria. 
 
We then swapped these residues by making the E435Q mutation in A1 and the Q437E 
mutation in A2. The E435Q mutation in A1 reduced catalytic rate by 8 fold, whereas the 
Q437E mutation completely abolished the activity of A2 (Table 5.2). Having shown this 
residue to be important to activity in both parents, we next chose eight inactive chimeras 
containing unfavorable 1–8 block combinations to determine whether swapping these 
positions could “rescue” the activity. We introduced the Q437E mutation into four 
chimeras with fragments 1.1 and 8.2 and the E435Q mutation into four with fragments 
1.2 and 8.1 (Table 5.2). This single substitution was able to confer activity in two of the 
eight chimeras. 
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Table 5.2. Peroxygenase activities of site-directed mutants of parents CYP102A1 and 
CYP102A2 and selected chimeric heme domains on 12-pNCA. 
Sequence Wild type1 
Glu435Gln or 
Gln437Glu2 
CYP102A1 65.9 ± 8.5 8.9 ± 1.7 
CYP102A2 2.3 ± 0.5 n.d. 
11332212 n.d. n.d. 
11331312 n.d. 0.8 ± 0.3 
12232232 n.d. n.d. 
13233212 n.d. n.d. 
21113211 n.d. n.d. 
23213211 n.d. n.d. 
22131221 n.d. n.d. 
22233211 n.d. 0.9 ± 0.1 
1All rates are reported in nmol product/nmol P450/minute. 
Activities < 0.1 were not detectable (n.d.). Wild type 
indicates heme-domain sequence with F87A (A1) or F88A 
(A2) mutation. 
2The Glu435Gln mutation was made when block 8 
contained fragment 8.1.  The Gln437Glu mutation was 
made in fragment 8.2. 
 
 
Thus the LRA analysis in combination with mutation studies uncovered a residue 
(Glu435/Gln437) previously unknown to be important for catalytic activity and suggests 
a different substrate binding mode in CYP102A2. One structural explanation for these 
results is illustrated in Figure 5.11C and 5.11D. Since A2 lacks a positive charge at 
position 48 and has no unique positively charged residues in the small portion of block 8 
near the active site (or block 8 altogether), we hypothesized that another sequence change 
may have caused a positively charged residue to be made available elsewhere. Glu435 in 
A1 appears to participate in a salt bridge with Lys24, which is roughly 4 Å away in the 
crystal structure. The equivalent residue 25 is a lysine in A2 and a glutamine in A3. The 
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lack of a salt bridge partner near Lys25 in A2 could free Lys25 to interact with the 
carboxylate tail of the fatty acid (Figure 5.11D). In support of this, a single substitution of 
Gln437 to Glu rescued the activity of a chimera containing A2 sequence at block 8, but 
A1 sequence at block 1. Conversely, switching Glu435 to Gln in a chimera containing A1 
sequence at block 8 but A2 sequence at block 1 was also able to rescue the activity. Of 
course, this single switch was unable to rescue activity in six more folded, but inactive 
chimeras, which indicates that additional interactions are also important (such as the 
contributions from residues in blocks 2 and 4). 
 
C.8 SCHEMA-guided recombination creates a library rich in properly folded, highly 
mutated sequences 
The approach used here to identify optimal recombination sites differs from the 
SCHEMA profile described previously [15]. Evaluating libraries with randomly sampled 
crossovers, as was done here, and a recently developed global optimization of 
recombination sites [26] are both preferred over the SCHEMA profile, which neglects 
important structural interactions between amino acids distant in the primary sequence. 
Based on this design, three cytochromes P450 were divided into “building blocks” and 
combinatorially reassembled to yield a library in which 47% of the members fold and 
correctly bind heme. This folded fraction is slightly larger than the prediction of 40% 
from the design. The full library therefore contains an estimated 3,000 unique chimeric 
P450s, many of which are highly mutated compared to the parent P450s.  
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It is interesting to estimate the extent to which SCHEMA recombination has enriched the 
library relative to a library having the same distribution of mutation levels, but made 
using random mutagenesis. The fraction of folded proteins in a random library can be 
estimated using the protein’s “neutrality,” or probability that a random amino acid 
substitution will not disrupt folding. Neutrality ν has been calculated for other proteins 
and ranges from 0.38 to 0.56 [8]. Using 0.6 as a conservative estimate for P450 
neutrality, the fraction of folded P450s having a mutation distribution equaling that of the 
chimeras (ffr) is given by  
 
∑ = ×= 10911 m mmr NNff ν ,        (3) 
 
were ν = 0.60, N = total number of mutants (628, equal to the unique set of randomly 
sampled chimeras), m = number of amino acid changes, and Nm = number of mutants 
with a given value of m. This yields a fraction folded ffr = 6.3 × 10−5. The fraction of 
folded chimeras in the library is 0.47, giving an enrichment of 0.47/ffr = 7.5 × 103. Thus, 
by this conservative estimate, SCHEMA-guided recombination has increased the 
frequency of folded chimeras by nearly four orders of magnitude. 
 
D. Conclusions 
Protein families generated in the laboratory can be used to identify regions of the 
sequence and structure that are important for folding and function. This approach may be 
especially valuable for proteins with few naturally occurring family members. Datasets 
such as this one, containing hundreds of proteins for which functional information can be 
 157
determined in high-throughput assays, will be invaluable for developing and validating 
structure prediction tools and for protein sequence-structure-function analysis. Finally, 
rich in sequence diversity as well as the ability to fold properly, these proteins may be 
sources of novel functions for laboratory protein evolution. 
 
 
E. Materials and Methods 
 
E.1 Calculation of SCHEMA disruption 
The parent heme-domain sequences of A1, A2, and A3 were aligned using ClustalW [47] 
(Appendix A). The number of broken contacts in a chimera E [15,17] is 
ij ij
i j i
E C
>
=∑ ∑ Δ ,        (4) 
where the Cij are elements of the contact matrix which depend solely on the protein 
structure. Specifically, Cij = 1 if residues i and j are within 4.5 Å in the structure of A1 
bound to N-palmitoylglycine (1JPZ) [25]; otherwise Cij = 0. The SCHEMA delta 
function Δij uses only the parental sequence alignment: Δij = 0 if the amino acids found in 
the chimera at positions i and j are also found together in any single parent at the same 
positions. Otherwise, the i–j contact is considered broken, and Δij = 1. 
 
E.2 Library construction 
The heme domains of A1 and A2 are described in Chapter 4. The heme domain (first 
1,401 nucleotides) of the A3 gene (a gift from Claes von Wachenfeldt, Lund University) 
was subcloned into the BamHI/EcoRI sites of the pCWori expression vector [48], and the 
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mutation corresponding to F88A was introduced. The chimeric library was constructed 
following the sequence-independent site-directed chimeragenesis (SISDC) method [32], 
using the type IIb restriction endonuclease BsaXI. This required removal of a BsaXI site 
in parent A1 using a synonymous mutation at Gly368 (GGA to GGT). N- (blocks 1-4) 
and C-terminal (blocks 5-8) half-length parental genes were constructed separately with a 
tag sequence containing a BsaXI recognition site at each of the three crossover locations 
(Table 5.3). The half-length genes were cloned into the pCR®-Blunt II-TOPO plasmid 
(Invitrogen) and their DNA sequences were confirmed by sequencing (Laragen, Los 
Angeles, CA). Digestion of the half-length parental genes with BsaXI to remove the tag 
sequences yielded DNA fragments with unique 3 bp overhangs at each crossover site. 
After column purification to remove the small (30 bp) tags, the fragments from three 
parents were mixed in equimolar amounts and ligated to make two half-length chimeric 
libraries. Digestion with NheI (restriction site designed into tag sequence) and BsaXI after 
ligation removed genes with residual tags from the final library. Each half-length library 
was PCR amplified, cloned back into the TOPO vector and transformed into Escherichia 
coli TOP10 cells (Invitrogen).  
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Table 5.3. Primers used for site-directed recombination of cytochromes P450 heme 
domains of A1, A2 and A3. 
 
Tag Site Tag Sequence (5’ to 3’)  Primer (5’ to 3’) 
N N-term - A123-Nf GGAGGTACCAGATCTATCGATGCTTAGGAGGTCATATG 
Tag 1 64 gaaTGAAGTACTACCTGT
CCTCCGCTAGCTgaa 
A1-64f 
 
A1-64r 
 
A2-64f 
 
A2-64r 
 
A3-64f 
 
A3-64r 
GTACTACCTGTCCTCCGCTAGCTgaaTCACGCTTTGATAA
AAACTTAAGT 
AGCGGAGGACAGGTAGTACTTCAttcATCGCATGCTTCTT
TAATTAGAC 
GTACTACCTGTCCTCCGCTAGCTgaaGAACGGTTTGATAA
AAGCATTG 
AGCGGAGGACAGGTAGTACTTCAttcATCACAAACCTCTT
TCACCA 
GTACTACCTGTCCTCCGCTAGCTgaaAAACGCTTTGACAA
GAACCT 
AGCGGAGGACAGGTAGTACTTCAttcATCACACACTTCA
GCCAC 
Tag 2 122 atcTAAAGGCCTACATAC
TCTCCGCTAGCAatc 
 
A1-122f
 
A1-122r
 
A2-122f
 
A2-122r
 
A3-122f
 
A3-122r
GGCCTACATACTCTCCGCTAGCAatcGCCGTGCAGCTTG
TTC 
AGCGGAGAGTATGTAGGCCTTTAgatATCGACCATCATC
GCATGAT 
GGCCTACATACTCTCCGCTAGCAatcGCTGTTCAGCTCAT
TCAAAAATG 
AGCGGAGAGTATGTAGGCCTTTAgatATCGACCATTTTCT
CATGATAGTC 
GGCCTACATACTCTCCGCTAGCAatcGCAACCCAGCTGA
TTC 
AGCGGAGAGTATGTAGGCCTTTAgatATCCAGCATCATA
GAATGATAGC 
Tag 3 166 tacTGATCGCGAACAATT
ACTCCGCTAGCTtac 
 
A1-166f
 
A1-166r
 
A2-166f
 
A2-166r
 
A3-166f
 
A3-166r 
CGCGAACAATTACTCCGCTAGCTtacCGAGATCAGCCTC
ATCC 
AGCGGAGTAATTGTTCGCGATCAgtaAAAGCTGTTAAAG
CGATAGTTAAA 
CGCGAACAATTACTCCGCTAGCTtacAGAGAAACGCCCC
ACC 
AGCGGAGTAATTGTTCGCGATCAgtaGTAACTGTTAAAG
CGGTAGTTAAA 
CGCGAACAATTACTCCGCTAGCTtacCGTGATTCACAGC
ATCC 
AGCGGAGTAATTGTTCGCGATCAgtaAAAGCTGTTGAAT
CGATAGTTAAA 
 216/217 - 
 
A1-216f
A1-216r
A2-216f
A2-216r
A3-216f
A3-216r 
CGAGGTACCgtcgacAAAATTATTGCAGATCGCAAAGC 
CCGCTCGAGgtcgacTAGGTCGTTCATCACCTTG 
CGAGGTACCgtcgacAGCATTATTGCAGAG 
CCGCTCGAGgtcgacTAACGAAAACATCGTTTG 
CGAGGTACCgtcgacAGAATGATAGCGGAGCGAAAG 
CCGCTCGAGgtcgacCAGGGAGTTCATGACTTC 
Tag 4 268 acaTGAACGCGTACTTAT
TCTCCGCTAGCTaca 
 
A1-268f
 
A1-268r
 
A2-268f
 
A2-268r
 
CGCGTACTTATTCTCCGCTAGCTacaACAAGTGGTCTTTT
ATCATTTGC 
AGCGGAGAATAAGTACGCGTTCAtgtTTCGTGTCCCGCA
ATTAAG 
CGCGTACTTATTCTCCGCTAGCTacaACGAGCGGCCTGC
TTT 
AGCGGAGAATAAGTACGCGTTCAtgtTTCATGGCCGGCA
ATC 
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A3-268f
 
A3-268r
CGCGTACTTATTCTCCGCTAGCTacaACAAGCGGGTTGC
TATC 
AGCGGAGAATAAGTACGCGTTCAtgtCTCATGTCCAGCA
ATTAAAAATG 
Tag 5 328 gctTAAGTATACACCATC
CCTCCGCTAGCAgct 
 
A1-328f
 
A1-328r
 
A2-328f
 
A2-328r
 
A3-328f
 
A3-328r
 
TATACACCATCCCTCCGCTAGCAgctCCTGCGTTTTCCCT
ATATG 
AGCGGAGGGATGGTGTATACTTAagcAGTTGGCCATAAG
CGC 
TATACACCATCCCTCCGCTAGCAgctCCGGCTTTCAGCC
TTTATC 
AGCGGAGGGATGGTGTATACTTAagcTGTCGGCCATAAG
CGC 
TATACACCATCCCTCCGCTAGCAgctCCGGCTTTTTCTCT
ATATGC 
AGCGGAGGGATGGTGTATACTTAagcTGTTGGATACAGT
CTGAGG 
Tag 6 404 cagTGATTCGAAACCATT
ACTCCGCTAGCTcag 
 
A1-404f
 
A1-404r
 
A2-404f
 
A2-404r
 
A3-404f
 
A3-404r
  
TCGAAACCATTACTCCGCTAGCTcagTTCGCTCTTCATGA
AGC 
AGCGGAGTAATGGTTTCGAATCActgCTGACCGATACAC
GCAC 
TCGAAACCATTACTCCGCTAGCTcagTTTGCCCTTCATGA
AGC 
AGCGGAGTAATGGTTTCGAATCActgCATGCCGATACAG
GCC 
TCGAAACCATTACTCCGCTAGCTcagTTTGCTCTTCAAGA
AGCG 
AGCGGAGTAATGGTTTCGAATCActgCATGCCAATACAA
GCGC 
C C-term - A1-Cr 
A2-Cr 
A3-Cr 
CAACAATTGTTAAGTGCTAGGTGAAGGAATACC  
CAACAATTGTTATTCAGCTGCCTGGACGTC 
CAACAATTGTTATGCCTGTTCTTTTCTCTGTAC 
Bold letters: BsaXI recognition site; underline: NheI recognition site; Lower-case letters: 
consensus sequence (sticky ends by BsaXI digestion); Italic letters: complementary to 
parental gene sequence; Shadowed letters: BglII or MfeI recognition site of N-terminal or 
C-terminal primer, respectively. 
 
The N- and C-terminal half-libraries were digested with BglII/SalI, and SalI/MfeI, 
respectively, and cloned into the BamHI/EcoRI sites of the pCWori vector. The SalI 
recognition site corresponds to crossover site 216-217 and was introduced into all three 
P450 genes synonymously. The N- and C- terminal libraries were ligated at this site to 
yield the full-length library, which was transformed into the catalase-deficient E. coli 
strain SN0037 [49]. 
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E.3 Probe hybridization analysis 
Probe hybridization was performed as described [33,50]. Twenty-four unique 
oligonucleotide probes were designed to specifically recognize each parent fragment with 
a Tm ~63°C (Table 5.4). Probes were labeled using the terminal transferase reaction with 
either fluorescein (Amersham) or digoxigenin (Roche) following the manufacturer’s 
protocol. Anti-fluorescein (Amersham) or anti-digoxigenin (Roche) antibodies 
conjugated to alkaline phosphatase were used for chemiluminescent detection according 
to the manufacturer’s protocol and recorded with a Gel-Doc system from BIORAD or 
BIOMAX films from Kodak. 
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Table 5.4. Sequences of probes for hybridization analysis. 
Block Parent Sequence (5’ to 3’) 
1 A1 GAC AAT TAA AGA AAT GCC TCA GCC AAA AAC GTT TGG  
 A2 GAA GGA AAC AAG CCC GAT TCC TCA GCC  
 A3 GAA ACA GGC AAG CGC AAT ACC TCA GCC  
2 A1 GCG CAT AAT ATC TTA CTT CCA AGC TTC AGT CAG C  
 A2 GCG CAC AAC ATT CTG ATG CCG ACG TTC  
 A3 CC CAC CGC ATT TTG CTG CCG AGT TTT AG  
3 A1 GAG CGT CTA AAT GCA GAT GAG CAT ATT GAA GTA CCG 
 A2 GCA AGG CTC AAC CCG AAT GAA GCA GTC 
 A3 G AGC CGG TTA AAC CCC AAT GAA GAA ATT GAT GTA G 
4 A1 CCA GAC GAC CCA GCT TAT GAT GAA AAC AAG C  
 A2 GTT CAA GAT AAG CTT ATG GTC AGA ACA AAG CGG C  
 A3 CTG CAA GAT AAA ATG ATG GTG AAA ACG AAG CTG CAG  
5 A1 GCA AGC GGT GAA CAA AGC GAT GAT TTA TTA ACG C 
 A2 GCG AAT GGA GAC CAG GAT GAA AAA GAT TTG CTC 
 A3 GCG AAT CCG GAT GAA AAC ATT AAG GAT CTC TTG TC 
6 A1 GCA GCA CGA GTT CTA GTA GAT CCT GTT CC  
 A2 GTC GAT CGG GTG CTG ACG GAT GCA G  
 A3 GCG GAT CGC GTG TTA ACG GAT GAC AC  
7 A1 CCA AGT GCG ATT CCG CAG CAT GCG  
 A2 CAG GAC CAA GTG CCT CAT CAT GCG TAC  
 A3 CCT TCA AGT ATC CCT CAC CAT GCG TAT AAG C  
8 A1 ATC GAA AAA AAT TCC GCT TGG CGG TAT TCC TTC AC 
 A2 GCC GTC ATC AGG AAG CCA TTC ATG CAG A  
 A3 CGC GAA AAA CAG CGG CAA TCA ATG TAC AGA G  
 
 
 
E.4 High-throughput carbon monoxide binding assay 
Clones grown in 96-well plates were replicated into 500 µl of Luria-Bertani (LB) 
medium with 100 µg/ml ampicillin in 2 ml deep-well plates (Falcon, manufacturer 
location) and grown in a humidified shaker (Kuhner ISF-1-W, manufacturer location) for 
20 h at 210 rpm, 30 °C and 80% relative humidity. Samples (150 µl) of these saturated 
cultures were transferred to 850 µl of terrific broth (TB) medium supplemented with 117 
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µg/ml ampicillin, 30 µg/ml thiamine, 0.6 mM δ-aminolevulinic acid, and 0.7 mM IPTG. 
These were grown for 24 h at 210 rpm, 25 °C and 80% relative humidity and harvested 
by centrifugation at 4 °C, 4,900 × g. Cell pellets were stored frozen at −20 °C until they 
were resuspended in 300 µl of lysis buffer (100 mM Tris [pH 8.2] with 0.5 mg/ml 
lysozyme and 2 units/ml DNAse) using a pipetting robot (Beckman Multimek 96, 
manufacturer location). Plates were incubated at room temperature for 1 h, followed by 
centrifugation at 4,900 × g for 10 min at 4 °C to clear the lysate.  
 
CO binding assays were carried out as described in Chapter 2 with minor modification. 
Lysate (160 µl) was added to wells of a 96-well plate followed by addition of 40 µl of 
freshly-prepared 0.1 M sodium hydrosulfite (in 1.3 M phosphate buffer, pH 8.0). Using a 
Spectra Max Plus 384 plate reader (Molecular Devices), blank spectra were taken every 
10 nm from 400 to 500 nm, as were readings for 450 and 490 nm. Plates were put in a 
vacuum oven and the atmosphere was removed (to ~350 mbar) and replaced with CO. 
Plates were allowed to incubate for 5 to 10 minutes, at which point the spectra and 
absorbencies at 450 and 490 nm were read. Assays were performed in duplicate. 
 
Chimeras were assigned a folding status (folded P450 = 1, not folded = 0) based on the 
following.  To be folded, the spectrum must have a distinct Soret peak within an 
absorbance range of -0.01 to 0.01 at 450 nm. In addition, the minimum CO difference 
value (A450 – A490) must be ≥ 0.0015. The background, as assayed using cells with a null 
vector (pCWori with no insert), was 4.9 x 10-4 ± 4.2 x 10-4, which set 1.5 x 10-3 as the 
minimum CO difference value giving greater than 95% confidence (greater than two 
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standard deviations).   If the sequence was not assigned folded status, it was deemed ‘not 
folded’ = 0. 
 
E.5 Functional assays 
Chimeras were assayed for peroxygenase activity on 12-pNCA in 96-well plate format as 
described [51]. Reactions were carried out in a volume of 200 µl with 250 µM 12-pNCA 
and 20 mM H2O2 in 100 mM Tris (pH 8.2) at room temperature and monitored at 410 nm 
for 30 min for accumulation of 4-nitrophenol. Chimeras in wells with total product 
formation greater than 25% of the average of four control wells with the A1 heme 
domain after 30 min were considered active (corresponding to > 5 µM product).  
 
Activity on 2-phenoxyethanol was assayed in 96-well plates using the 4-aminoantipyrine 
assay (4-AAP), which detects phenol-like compounds (see Chapter 3). Reactions were 
carried out in 120 µl with 1% DMSO, 1% acetone, 100 mM 2-phenoxyethanol and 20 
mM H2O2 in 100 mM EPPS (pH 8.2). Reactions were mixed and left at room temperature 
without shaking for 2 h then quenched with 120 µl of 0.1 M NaOH and 4 M urea. Thirty-
six µl of 0.6% 4-AAP was added, the 96-well plate reader was zeroed at 500 nm, and 36 
µl of 0.6% potassium persulfate was added. After 20 min the A500 was read. Chimeras in 
wells with an A500 greater than 25% of the average of four control wells with the A1 
heme domain were considered active, corresponding to > 20 µM product. 
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E.6 Thermostability 
Thermostabilities (as described by Tm, the temperature at which half of the protein is 
unfolded) were measured using CO difference spectroscopy to monitor the disappearance 
of the Soret band with increasing temperature as described as described in Chapter 3 . 
 
E.7 Logistic regression analysis 
The significance of each block (intra-fragment) and block pair (inter-fragment) was 
calculated relative to a reference model with all eight blocks using the likelihood ratio 
test [21]. In the case of heme binding, this identified six potentially significant variables 
which were collected into a second-round reference model and reevaluated using the 
likelihood ratio test (Table 5.5). Blocks 1, 5, 7, and block pair 1–7 remained highly 
significant in the second round, whereas pairs 1–5 and 5–8 dropped in significance to p > 
10−3, a threshold established previously [21]. Cross-validation tests (data not shown) 
provide further evidence that only the variables 1, 5, 7, and 1–7 are significant. The same 
analysis was done for activity on 12-pNCA and determined blocks 2, 4 and 1–8 are 
significant. 
 
Table 5.5. Significance of the top six variables identified by logistic regression analysis 
of cytochrome P450 chimeras. 
 
Variable p-value1 
1 1 x 10-12 
5 3 x 10-8 
7 2 x 10-17 
1-7 3 x 10-12 
1-5 0.01 
5-8 0.02 
1p-values were calculated by removing each variable from the model and applying the likelihood ratio test 
(see Methods). 
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E.8 Construction and analysis of site-directed mutants 
Single mutations were made in the A1 and A2 genes and in the genes of the eight 
chimeras seen in Table 5.2. The R47G and G48R mutations were made using the codon 
from the alternate parent, Arg (CGT) and Gly (GGC), respectively. The E435Q and 
Q437E mutations were made in the same fashion with the codons Glu (GAA) and Gln 
(CAA) being swapped. Mutants were constructed using PCR overlap extension 
mutagenesis [52], cloned into the BamHI/EcoRI site of pCWori and transformed into 
catalase-deficient E. coli. P450 chimeras and parents were cultured in 200 ml of TB 
medium and the initial rates on 12-pNCA were measured with 1 µM enzyme, 250 µM 
12-pNCA, 1% DMSO, 20 mM H2O2 in 100 mM EPPS (pH 8.2), as described Chapter 4. 
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Chapter 6 
 
Functional analysis of an artificial family of P450s 
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A. Abstract 
 
The limited number of protein folds found in Nature requires that one fold serve many 
functional roles for its host. In fact, certain protein folds appear to be favored as they 
dominate known protein structure space. These protein superfamilies have diversified 
over millions of years to yield numerous diverse sequences capable of variety of 
functions. We have created an artificial protein family containing thousands of new, 
diverse P450s. Here, we analyze the functional diversity present in this family on a 
variety of substrates. We show that chimeras are able to exceed the parental 
peroxygenase activities as well as acquire new ones on a set of eight substrates. K-means 
clustering analysis of a set of 37 P450s shoed they cluster into five groups based on their 
activity profiles. Additionally, a large data set of 330 chimeras is assembled for further 
analysis. 
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B. Introduction 
 
The amino acid sequence of a protein determines its structure, but that structure does not 
restrict its biological function. This is evident in Nature were similar protein structures 
perform a variety of biological functions. In fact, the number of protein folds is thought 
to be limited to only a few thousand [1,2] demonstrating that protein structure changes 
slowly over evolutionary time while amino acid sequences changs more quickly. The 
utilization of a similar protein structure for multiple functions is well demonstrated by the 
(βα)8 (or TIM) barrel fold which has been recruited to fulfill numerous biological roles 
such as glycosidases, synthetases as well as binding a wide range of substrate [3,4]. The 
ubiquitous thioredoxins also share a common protein structure and use sulfur redox 
chemistry to carry out transferase, peroxidase and isomerase reactions to name a few[5]. 
Numerous examples of these protein superfamilies exist [6].   
  
Cytochromes P450 comprise a superfamily of heme enzymes with myriad biological 
functions, including key roles in drug metabolism, breakdown of xenobiotics, and steroid 
and secondary metabolite biosynthesis [7]. P450s are postulated to have first functioned 
in the detoxification of oxygen or peroxide [8,9]. From this ancestral P450, evolution has 
created  the plethora of sequences that exist today. Cytochromes P450 tend to share high 
levels of structural similarity despite their low levels of sequence identity [10-12]. This 
high level of sequence diversity allows for the various functions present in this enzyme 
scaffold. 
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In the previous chapter, we described the creation of an artificial family of cytochromes 
P450 by recombining three bacterial P450s, A1, A2 and A3 using structure-guided 
recombination guided by SCHEMA. SCHEMA is an energy function that an allows us to 
minimize the number of structural contacts that are disrupted when portions of the 
sequence are inherited from different parents, further increasing the probability that the 
chimeric proteins will fold. This library contained roughly 3,000 new P450 sequences 
which had 72 amino sequence changes relative to the closest natural P450 on average. 
Analysis of these new sequences identified key structural contributions to correct heme 
binding and peroxygenase activity. Here we begin to analyze the functional diversity 
present within these artificially created P450s.  
 
C. Results 
 
C.1 Characterization of functional diversity 
Using the artificial family of cytochromes P450 described in Chapter 5, we randomly 
selected 640 chimeras that were able to correctly bind heme as characterized by a Soret 
band at approximately 450 nm using high-throughput CO difference spectroscopy (see 
Chapter 3). This set of chimeras was assayed in high-throughput on a total of 47 different 
substrates (Appendix C and 12-pNCA) that range in size from single aromatic rings to 
larger substrates with multiple rings and numerous side groups. Of these 47, chimeras 
showed detectable activity using the 4-AAP assay on 18 substrates. A final set of eight 
substrates was selected based on chemical diversity and having activity levels high 
enough for repeatabilty in high throughput. For example, 11-phenoxyundecanoic acid 
was not used since its structure is very similar to 12-pNCA. Molecules such as 
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zoxazolamine, chlorzoxazone, tolbutamide and allyloxybenzene were not used do to poor 
reproducability from low activity or high background signals in high throughput. The 
final set of eight substrates is shown in Figure 7.1. 
 
Figure 6.1 Set of eight substrates for characterization of chimeric P450s. Abbreviations 
are shown in parentheses. 
 
 
 
We first determined the activity profile for each of the three parent P450s on these eight 
substrates (Figure 6.2). Two µM P450 was combined with substrate (Table 6.1) and 20 
mM H2O2 and allowed to react for 2 hours. After 2 hours the reactions were quenched 
and the hydroxylated aromatic products were detected using the 4-AAP assay (Chapter 
3). Activity on 12-pNCA was assayed by monitoring the accumulation of 4-nitrophenol 
at 410 nm due to hydroxylation forming a hemiacetal [13]. The parents showed 
detectable activity on six of the eight substrates. As expected from work in previous 
chapters, A1 was most or equally active on the six substrates compared to the other two 
parents. A1 and A2 were active on the same six substrates while A3 was only active on 
four. None of the parents showed activity on diphenyl ether or 3-phenoxytoluene. 
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Table 6.1 Substrate concentrations used in bioconversions. 
Substrate Concentration (mM) 
12-pNCA 0.25 
2-phenoxyethanol 100 
ethoxybenzene 50 
ethylphenoxyacetate 10 
ethyl-4-phenylbutyrate 5 
propranolol 4 
diphenyl ether 10 
3-phenoxytoluene 10 
 
 
 
Figure 6.2 Peroxygenase activity of parental P450s A1, A2 and A3 on eight substrates 
using the 4-AAP assay and 12-pNCA. Activity was measured as the absorbance at 500 
nm minus the background absorbance when the reaction was pre-quenched. One standard 
deviation for any of the measurements was less than 30%. 
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This analysis was then extended to thirty-four chimeric P450s from the set of 640 
mentioned above. These folded P450 chimeras were assayed in the same way as the 
parents A1, A2 and A3. We found numerous chimeras with activity on the substrates not 
accepted by the parents (Figure 6.3). We also identified chimeras with greater activity 
than any of the parents on all of the substrates on which the parents had activity. 
Chimeras were able to exeed total activity of the most active parent, A1, on all eight 
substrates. Chimera 112122112 (see naming convention from Chapter 5) is more active 
than A1 on both 12-pNCA and propranolol. Chimera 21313311 is more active on 2-
phenoxyethanol, ethyl-4-phenylbutyrate, ethoxybenzene and ethylphenoxyacetate. 
Chimeras also acquire activiy on diphenyl ether and 3-phenoxytoluene, substrates for 
which the parents showed no activity. Chmiera 32313233 is the most active chimera on 
diphenyl ether while 21313311 is most active on 3-phenoxytoluene. Chimera 32313231 
is an example of a chimera that acquired activity on diphenyl ether and 3-phenoxytoluene 
without a large increase on all other substrates such as 2-phenoxyethanol. Chimeras 
23312123 and 23132111 (not shown) are folded P450s that show no catalytic activity on 
any of the substrates tested. 
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Figure 6.3 Select chimeras showing altered activity profiles and enhanced activities.  
 
 
 
C.2 K-means clustering 
K-means clustering can be used to determine how the expression of genes or enzymes 
with different activity profiles group together [14,15]. The activities of the 34 chimeras 
and three parent P450s were normalized to the maximum value for each substrate to 
avoid overweighting more active substrates. We used Cluster 3.0 [16] to perform K-
means clustering on chimeras based on their activity profiles. The total number of groups 
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was increased until groups began containing only one member, which occurred with six 
groups. Silhouette values can be calculated to determine optimal group numbers based on 
their distance from other groups but that was not done here. We selected the five activity 
groups shown in Figure 6.4. Group A is characterized by high activity on 12-pNCA and 
propranolol. Group B is active on 2-phenoxyethanol, ethylphenoxyacetate, diphenyl ether 
and 3-phenoxytoluene. Group C is active on 2-phenoxyethanol and ethyl-4-
phenylbutyrate. Group D has generally low activity with some members being active on 
2-phenoxyethanol, ethylphenoxyacetate and propranolol. These groups demonstrate some 
of the functional diversity present in this artificial protein family of cytochromes P450. 
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Figure 6.4 K-means clustering of the acitivy profiles 37 P450 peroxygenase on eight substrates 
cluster them into five groups. Relative activity represents the activity on each substrate 
normalized to the highest activity of all the P450s tested using the 4-AAP assay. The chimeras are 
assigned to each group as follows: A) A1, 11212112; B) 21113212, 12113221, 11113311, 
32313231, 22213132, 32111333, 32312333, 32312231; C) 12212212, 21113211, 22233211, 
21313112, 21313111; D) A1, A2, 22113232, 23312123, 23132233, 22312132, 22132231, 
11332212, 23213311, 23132111, 21132112 22113111, 23312112; E) 21113312, 32313233, 
21313311. 
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C.3 High-throughput activity measurements 
To assemble a larger data set of hundreds of chimera activity profiles we measured the 
activity of 640 folded chimeras in high-throughput. The sequences of many of these are 
known from DNA probe hybridization described in Chapter 5 [17]. Measurements on 
each substrate were done at least in triplicate, and if a chimera had less than 500 nM P450 
in a given assay it was removed to eliminate false negatives due to low expression or 
experimental errors. If this resulted in fewer than two measurements for a chimera on a 
substrate, this chimera was discarded. After removing chimeras with too little data or 
without sequences, 330 unique chimeric P450 sequences remained with data on all eight 
substrates. For each of these chimeras there are activity measurements and CO difference 
measurement which reflect the enzyme concentration. Control wells containing the 
parents A1, A2 and A3 as well as a null vector (pCWori with truncated CYP102A1) were 
included on each microtiter plate. The null vector wells serve to determine the 
background absorbance level. 
 
To demonstrate the validity of the high-throughput data, activity values were determined 
in two ways. In method A, we normalized the raw activity absorbance to the average of 
control wells containing A1 (Equation 5): 
><
><−=
1102
)(
ACYP
nullchimera
ABS
ABSABSAactivity        (5), 
were ABS = activity absorbance, null = null vector, and EXPR = CO difference value 
(Abs450 – Abs490). The final activity value was the average of two greatest values. The 
mean percent standard deviation was calculated for each substrate by taking the average 
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of the standard deviation for the pairs of measurements (Table 6.2). In method B, the 
average background measurement (from the null vector) was subtracted from the activity 
value for absorbance and normalized to the average of control wells containing A1 as 
well as the CO difference value for that chimera:  
))(( 1102
)( ><
><−=
ACYPchimera
nullchimera
ABSEXPR
ABSABSBactivity       (6). 
This effectively removes the background absorbance and controls for expression. 
However, it also leads to a much higher mean standard deviation across each substrate set 
(Table 6.2). This is due to the chimeras with absorbencies near the background level 
giving artificially high standard deviations. To remedy this, those with activities less than 
10% of the most active chimera were removed and the mean percent standard deviation 
was recalculated (Table 6.2).  This reduced the mean standard deviation to a level similar 
to that of Method A and eliminates chimeras with low activities. 
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Table 6.2 Mean percent standard deviations for each substrate across data set of 330 
active chimeras.  
  Mean percent standard deviation (%) 
Substrate Method Aa Method Bb Method B with removalc 
12-pNCA 31.1 105.1 22.0 
2-phenoxyethanol 25.4 27.8 22.4 
ethoxybenzene 23.9 48.0 22.2 
ethylphenoxyacetate 20.0 158.6 33.8 
propranolol 40.3 117.5 42.9 
diphenyl ether 26.8 162.2 27.6 
3-phenoxytoluene 18.5 208.6 40.0 
ethyl-4-phenylbutyrate 13.9 170.1 37.6 
aMethod A uses the raw activity value and normalizes it the average A1 activity value. See Results.  
bThe average background measurement (from the null vector) was subtracted from the activity value for absorbance 
and normalized to the average of control wells containing A1 as well as the CO difference value for that chimera. 
See Results. 
cData from method be with values less than 10% of most active chimera removed. See Results. 
  
 
 
 
D. Discussion 
 
Many natural enzymes are able to perform a variety of functions using the same protein 
fold. Here we show that by diversifying protein sequence using site-directed 
recombination and retaining the ability to fold into a cytochrome P450, we can diversify 
the activity of hundreds of new sequences on a set of eight substrates (Figure 6.1). Some 
chimeras are more active than any of the parent sequences, A1, A2 and A3, and others 
are even able to accept diphenyl ether and 3-phenoxytoluene, substrates that the parents 
do not accept. Additionally, K-means clustering analysis shows that chimeras may be 
clustered into five groups based on their activity profiles. This initial analysis shows that 
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functional diversity exists in our artificial family of cytochromes P450 generated using 
site-directed protein recombination in the absence of external mutations. 
 
This functional information can also be used to derive information about the parental 
enzymes. This is similar to ‘enzyme fingerprinting’ where understanding the different 
substrates an enzyme accepts can assist in developing surrogate substrates, examining 
enzyme specificity and understanding enzyme mechanisms [18-21]. The larger data set 
discussed here will be very useful to these ends. The data set appears to be accurate due 
to its acceptable level of mean percent standard deviation and may be further improved 
by removal of chimeras with high variance or through the use of additional processing 
methods. Analysis of these data may reveal a number of things. First, they can be 
analyzed to pinpoint which sequence blocks contribute to specific activities. This would 
best be done using linear regression analysis similar to that done previously [22]. Data on 
a large number of these chimeras can be used to learn which regions of the sequence 
contribute to altered activity profiles similar to how logistic regression was used to learn 
about what contributed to the overall structure in Chapter 4. This can be achieved using 
hierarchical or k-means clustering or linear regression [15,23-25]. Methods such as 
principal component analysis can be used to extract how different substrates may covary 
together and serve as surrogates for one another.  
 
The new and diverse functions present in this library are not limited to the substrates 
tested here. For example, in the next chapter we discuss how they are able to accept the 
substrates of human P450s and produce authentic human metabolites. As new substrates 
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for which a cytochrome P450 is needed, an artificial family such as this can be used in 
conjunction with natural enzymes to search for the desired function. This methodology 
may lead to these enzymes use in drug discovery or chemical synthesis [26]. 
 
E. Materials and Methods 
 
E.1 Materials 
All chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, MO) or MP 
Biomedicals, Inc. (Solon, OH). Solvents were from EM Sciences (Gibbstown, NJ).  
 
E.2 Testing of individual chimeras 
Cleared cell lysates of individual chimeras were prepared as in Chapter 3. Enzyme 
concentrations were determined using CO binding difference spectroscopy with an 
extinction coefficient of 91 mM-1 cm-1 [27]. 4-AAP reactions were carried out in 120 µl 
with 2 µM P450, 1% dimethyl sulfoxide, 1% acetone and substrate concentrations 
according to Table 7.1 in 100 mM EPPS (pH 8.2). Reactions were initiated by the 
addition of H2O2 to a final concentration of 20 mM. After two hours at room temperature, 
reactions were quenched by addition of 120 µl of 4 M urea and 100 mM NaOH. 
Additionally, identical reactions were carried out in which the reaction was quenched 
prior to the addition of H2O2 in order to establish the background level in the presence of 
no reaction. To these quenched reactions, 36 µl of 0.6 % 4-AAP was added and the 
spectrophotometer was zeroed. Thirty-six µl of 0.6% potassium persulfate was added and 
the A500 was read after ten minutes. Each measurement was done in triplicate and the 
total activity was determined by subtracting the pre-quenched point from the two hour 
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point. Assays on 12-pNCA were done with 1 µM P450 with 2% DMSO in 100 mM EPPS 
(pH 8.2). Before addition of H2O2 the spectrophotometer was zeroed at 410 nm.  H2O2 
was then added to a final concentration of 20 mM and after 30 minutes the A410 was read. 
 
 
E.3 High-throughput functional assays 
Chimeras were cultured and prepared in 96-well plate format as described in Chapter 5. 
12-pNCA assays were conducted as previously. For the other substrates, 80 µl of cell 
lysate was added to a 96-well plate and brought to a final volume of 120 µl containing 
substrate (Table 7.1) with 1% dimethyl sulfoxide (DMSO) and 1% acetone. Reactions 
were initiated with addition of H2O2 to a final concentration and after two hours they 
were quenched with 120 µl quench (0.1 M NaOH and 4 M urea). To these quenched 
reactions, 36 µl of 0.6 % 4-AAP was added and the spectrophotometer was zeroed at 500 
nm. Thirty-six µl of 0.6% potassium persulfate was added and the absorbance at 500 nm 
was read after ten minutes. The concentration of P450 was also monitored in each assay 
using high-throughput CO-difference spectroscopy (see Chapter 3). 
 
E.4 K-means clustering analysis 
K-means clustering was done using Cluster 3.0 [16]. Activity on each substrate for the set 
of 34 chimeras and three parents was normalized to the highest activity. We used 20,000 
runs to determine optimal groups. 
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Chapter 7 
 
     Chimeric P450s produce authentic human 
metabolites                                                     
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A. Abstract 
One of the main functions of P450s in humans is the processing and breakdown of drug 
compounds and other xenobiotics. The products of these reactions can have various 
biological properties including being more active drugs, toxic compounds or prepared for 
degradation. Here we show that chimeric bacterial P450s are capable of accepting human 
drug compounds as substrates and are able to produce authentic human metabolites of 
propranolol, chlorzoxazone, zoxazolamine. Chimeric P450s also accepted two additional 
substrates from human P450s, the drug tolbutamide and the carcinogen 4-aminobiphenyl. 
The product of the tolbutamide reaction was not any of the known human metabolites and 
the product of the 4-aminobiphenyl reaction was the same as that produced by horse 
radish peroxides (HRP). This demonstrates the utility of chimeric P450s created by site-
directed recombination in the hydroxylation of valuable drug-like compounds.  
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B. Introduction 
Cytochromes P450 from humans drove early research in the field due to their importance 
in drug metabolism and steroid biosynthesis [1]. Not long after these initial studies, it was 
discovered that P450s were plentiful in lower organisms as well and these P450s had very 
similar mechanistic properties to their human counterparts. These P450s have since 
proven extremely valuable as model systems for understanding the details of the enzymes 
structure and mechanism [2]. Bacterial P450s, for example, are easier to work with in that 
they are soluble, highly-active on their natural substrates and easily expressed at high 
levels. In contrast, human P450s are generally membrane associated, less stable and 
suffer from low activity. One property that is missing, however, is similar substrate 
specificities whereby bacterial P450s could accept the substrates of the human enzymes. 
The ability of a bacterial variant to produce the same chemicals as a human P450 has 
great value in drug discovery and testing [3].  
 
Members of the artificial family of cytochromes P450 discussed in previous chapters 
were tested for their activity on five substrates of human P450s, four of which are drug 
molecules. We show that bacterial P450 chimeras are able to produce many of the same 
products as the human enzymes and in some cases not by any of the parental enzymes, 
A1, A2 and A3. Additionally, P450 chimeras are potentially able to produce novel 
metabolites not produced by the human P450s as well as form a conjugate product using 
a peroxidase mechanism like that in horse radish peroxidase (HRP). 
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C. Results 
C.1 4-AAP analysis of drug-like compounds 
The chimeras individually assayed in Chapter 6 were also assayed on chlorzoxazone, 
tolbutamide, zoxazolamine, propranolol and 4-aminobiphenyl. The 4-AAP assay was 
used since it should detect any products in which the aromatic rings of these substrates 
were hydroxylated. Chlorzoxazone, zoxazolamine, 4-aminobiphenyl, propranolol and 
tolbutamide are substrates of the mammalian P450s CYP2E1, CYP1A2, CYP2D6 and 
CYP2C9 respectively [4]. The main human metabolite of chlorzoxazone made by 
CYP2E1 has been shown to be 6-hydroxychlorzoxazone [5] and the metabolites of 
tolbutamide made by CYP2C9 have been shown to be 4-hydroxytolbutamide and 
carboxytolbutamide [6]. Zoxazolamine is converted to 6-hydroxyzoxazolamine [4] and 4-
aminobiphenyl is converted to n-hydroxyaminobiphenl by CYP1A2 [7]. Propranolol is 
converted to 4’-hydroxypropranolol (4’OHP), 5’-hydroxypropranolol (5’OHP) and 
desisopropylpropranolol by CYP2D6 (DIP) [8]. 
 
The four chimeric P450s which showed the highest levels of activity on these substrates 
in the 4-AAP assay were used for further study. These reactions were driven by 20 mM 
H2O2 using the peroxygenase mechanism [9]. The activities of these four chimeras and 
the three parental enzymes measured with the 4-AAP assay can be seen in Figure 7.1. 
Most notably, the parental P450s A1 and A2 show low activity on propranolol and 
chlorzoxazone and no detectable activity on tolbutamide or zoxazolamine. Parent A3 
only shows activity on propranolol. Interestingly, the chimeras do not just gain activity 
on all substrates but appear to prefer specific substrates. For example, chimera 22213132 
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has high activity on chlorzoxazone but low activity on the other three substrates. In 
contrast, chimera 11212112 has no detectable activity on chlorzoxazone but high activity 
on propranolol.  
 
 
Figure 7.1 Total activity of P450 chimeras and parental enzymes A1, A2 and A3 on 
drug-like compounds (P450 chimera sequence represented in block-fragment format, see 
Chapter 5). Activity is measured as the absorbance at 500 nm minus the absorbance of 
control wells. Error bars are one standard deviation. 
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C.2 HPLC analysis of reactions with drug compounds 
The most active chimera on each substrate was used for HPLC analysis along with the 
three parental enzymes, A1, A2 and A3. P450s were combined with substrate and 20 mM 
H2O2 and allowed to react for two hours. Control reactions were done in which substrate 
was omitted and in which peroxide was omitted. The reaction lacking substrate tests for 
any side products being created by reaction of P450 with molecules present besides the 
specific substrate. The reaction without peroxide tests for product formation not 
originating from non-peroxygenase reactions. After sample preparation (see Methods), 
the reactions were analyzed on HPLC.  
 
Chimera 22213132 was used to examine the chlorzoxazone reaction. Figure 7.2 shows 
this chimera produced 6-hydroxychlorzoxazone as identified by retention time and 
matching absorbance spectra (see Appendix D for spectra of all substrates and products). 
Comparing peak areas normalized to the internal standard, zoxazolamine, we found that 
chimera 22213132 produced ten times as much 6-hydroxychlorzoxazone as the most 
active parent, A2. This is similar to the fifteen times more product produced in the 4-
AAP assay. 
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Figure 7.2 HPLC chromatogram of chlorzoxazone and the metabolite 6-
hydroxychlrozazone produced by chimera 22213132. The retention times for 
chlorzoxazone and 6-hydroxychlorzoxazone were 8.0 and 4.3 min, respectively. 
 
 
Chimera 11212112 was used for analysis of propranolol product formation. We found 
that it produced the three major metabolites 4’OHP, 5’OHP and DIP (Figure 7.3).  
Chimera 32313233 was used to analyze the products formed from zoxazolamine and 
Figure 7.4 shows that 6-hydroxyzoxazolamine was produced. The products of the 
reaction of 21313311 with tolbutamide were also analyzed. Standards for the two known 
metabolites 4-hydroxytolbutamide and carboxytolbutamide had retention times of 3.3 and 
3.9 minutes (Figure 7.5). These peaks were not present in either control reaction and did 
not match the retention time or absorbance spectra for carboxytolbutamide or 4-
hydroxytolbutamide. Therefore the specific product of the tolbutamide reaction is neither 
of these metabolites and remains unknown. 
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Figure 7.3 HPLC chromataogram of propranolol and its metabolites 5’OHP, 4’OHP, DIP 
and the side product 1-naphthol produced by chimera 11212112. The retention times for 
5’OHP, 4’OHP,  DIP, propranolol  and 1-naphthol were 5.2 min, 5.7 min, 7.4 min, 12.9 
min, 18.5 min, respectively. 
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Figure 7.4 HPLC chromatogram of zoxazolamine and the metabolite 6-
hydroxyzoxazolamine by chimera 32313233. The retention times for zoxazolamine and 
6-hydroxyzoxazolamine were 7.1 and 3.9 minutes, respectively.  
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Figure 7.5 HPLC chromatogram of tolbutamide and two unidentified products produced 
by chimera 21313311. The retention times for the two unidentified products were 3.3 and 
3.9 minutes. The retention time for tolbutamide was 11.7 min. 
 
 
 
C.3 Reactions and analysis of 4-aminobiphenyl 
Reactions containing chimeric P450s, H2O2 and 4-aminobiphenyl produced a reddish 
color and showed an increase in absorbance at 360 nm prior to addition of 4-AAP. 
Addition of 4-AAP did not increase absorbance near 500 nm suggesting there was no 
phenolic compound. Since 4-AAP was not required for the appearance of the reddish 
color, we suspected that a peroxidase reaction may be responsible for the color change 
via a conjugation reaction. HRP has been shown to react with 4-aminobiphenyl in the 
presence of H2O2 [10]. In this reaction, 4-aminobiphenyl serves as a reducing cosubstrate 
for HRP followed by conjugation of two 4-aminobiphenyl molecules forming 4,4’-
azobis(biphenyl) [10]. Since cytochrome P450s also perform peroxidase chemistry we 
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tested to see if this was the reaction that occurred with the chimeric P450 21313311. The 
HRP reactions and P450 reactions were run side by side and analyzed using HPLC 
(Figure 7.6). They both turned a reddish color, showed an absorbance increase near 360 
nm and the HPLC chromatogram had the same product peak with matching absorbance 
spectra at the same retention time. This supports that the product of the P450 chimera 
reaction with 4-aminobiphenyl was 4,4’-azobis(biphenyl). 
 
 
 
Figure 7.6 HPLC chromataogram of 4-aminobiphenyl and the conjugation product 4,4’-
azobis(biphenyl) produced by 21313311. The retention times for 4-aminobiphenyl and 
4,4’-azobis(biphenyl) were 28.5 and 54.8 min, respectively.  
 
 
D. Discussion 
The production of the drug metabolites produced by human P450s is of great interest 
since these chemicals may cause negative affects in a patient or have enhanced properties 
beyond that of the original drug. In fact, the FDA now requires study of all relevant drug 
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metabolites making their production critical to the drug approval process. The use of 
bacterial P450s able to accept drug-like compounds could be of great use in production of 
these metabolites. Here we show that bacterial P450s and their chimeric variants are able 
to produce authentic human metabolites as well as other chemical products. Figure 7.7 
summarizes the findings showing the products of zoxazolamine, propranolol and 
chlorzoxazone were the authentic human metabolites. Chlorzoxazone and zoxazolamine 
are centrally acting muscle relaxants [11] while propranolol is a beta-adrenergic blocker 
[12].  4-aminobiphenyl is a carcinogen found in tobacco smoke and serves as a 
carcinogen in human cancer [13]. The P450 chimeras did not appear to produce the 
human metabolite n-hydroxyaminobiphenl [7]. Instead, a peroxidase mechanism was 
utilized to conjugate two molecules of 4-aminobiphenyl to produce 4,4’-azobis(biphenyl) 
(Figure 7.7). Peroxidase chemistry in P450 chimeras was also observed in Chapter 4 on 
the substrate ABTS. 
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Figure 7.7 Products identified by HPLC that are produced by chimeric P450s. 
 
 
The product of tolbutamide, an antidiabetic [14], was undetermined since it was not 
either of the known human metabolites. This was not entirely unexpected however since 
the 4-AAP assay detects aromatic ring hydroxylation and neither carboxytolbutamide nor 
4-hydroxytolbutamide are hydroxylated on the aromatic ring. It is therefore likely that the 
product formed by the chimeric P450s is hydroxylated on the single aromatic ring in the 
substrate (Figure 7.8). Production of novel metabolites not made by the human enzymes 
such as this has potential for creating new drug molecules with enhanced efficacy from 
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existing chemical scaffolds. For example, new protein kinase inhibitors based on the 
indigoid scaffold [15] or novel metabolites of warfarin and an angiotensin II antagonist 
[16,17] have been generated. Finally, since the products formed by the chimeric P450s 
were not always the human metabolites it seems that merely acquire the ability to bind 
the substrate is enough for a specific activity. The orientation of the molecule in the 
active site is important for selectivity. The acceptance of drug-like compounds by 
engineered P450s opens up the potential for the production of known human metabolites 
as well as novel metabolites with possibly enhanced properties. 
 
 
Figure 7.8 Potential hydroxylation sites for the products of tolbutamide produced by 
chimeric P450s. 
 
 
E. Materials and Methods 
E.1 Materials 
All chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, MO), MP 
Biomedicals, Inc. (Solon, OH) or BD Biosciences (San Jose, CA). Solvents were from 
EM Sciences (Gibbstown, NJ).  HRP was from Amersham Biosciences (Piscataway, NJ). 
 
E.2 Protein expression and preparation 
All P450 BM3 heme domains were cloned, transformed and expressed in the catalase-
deficient strain of E. coli SN0037 [18] using the IPTG-inducible pCWori vector [19]. For 
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protein expression, 50 mL of Terrific Broth (TB) supplemented with 100 µg/mL 
ampicillin and 25 µg/mL thiamine were inoculated with 500 µL of an overnight culture 
and incubated for 5 hours at 30 oC with shaking. P450 expression was induced by adding 
0.5 mM IPTG and the heme precursor δ-ALA to a final concentration of 1 mM. The 
cultures were grown for another 18 hours and the cells were pelleted and stored at -20 oC. 
Cell pellets were resuspended in 100 mM Epps pH 8.2, sonicated for 3 x 45 seconds and 
centrifuged at 10,000 g for 30 min. The supernatant was passed through a PD10 size 
exclusion column and P450 concentration was measured by CO difference spectroscopy 
[20]. 
 
E.3 Testing of individual chimeras 
Cleared cell lysates of individual chimeras were prepared as in Chapter 4. Enzyme 
concentrations were determined using CO binding difference spectroscopy with an 
extinction coefficient of 91 mM-1 cm-1 [21]. 4-AAP reactions were carried out in 120 µl 
with 2 µM P450, 1% dimethyl sulfoxide, 1% acetone in 100 mM EPPS (pH 8.2). 
Substrate concentrations were 5 mM for chlorzoxazone, zoxazolamine, 4-aminobiphenyl 
and propranolol and 10 mM for tolbutamide. Reactions were initiated by the addition of 
H2O2 to a final concentration of 20 mM. After two hours at room temperature, reactions 
were quenched by addition of 120 µl of 4 M urea and 100 mM NaOH. Additionally, 
identical reactions were carried out in which the reaction was quenched prior to the 
addition of H2O2 in order to establish the background level. To these quenched reactions, 
36 µl of 0.6 % 4-AAP was added and the spectrophotometer was zeroed at 500 nm. 
Thirty-six µl of 0.6% potassium persulfate was added and the A500 was read after ten 
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minutes. Each measurement was done in triplicate and the total activity was determined 
by subtracting the pre-quenched point from the two hour point.  4-aminobiphenyl 
conditions were carried out in an identical fashion except no 4-AAP or potassium 
persulfate was added. Instead, the reactions were quenched and allowed to incubate for 
30 minutes in order to partially dissolve precipitates. The A500 was then read. 
  
E.4 Bioconversions for HPLC analysis and sample preparation  
Bioconversions for HPLC analysis of chimeric P450s were prepared as above except 
were done in 600 µl volumes and with 5 μM P450. Propranolol analysis was similar to 
that described previously [22]. Perchloric acid (7%) was added to the reaction mixture at 
a volume of 10 µL/100 µL of reaction, followed by addition of 2.5 mg/100 µL ascorbic 
acid. The reaction mixture was vortexed and centrifuged. The chlorzoxazone and 
zoxazolamine bioconversions were adjusted to pH 7 using H3PO4  and extracted three 
times with equivolumes of CH2Cl2. After removal of solvent and resuspension in 300 μl 
of 65% solvent A (1% triethylamine (v/v) and 0.8% acetic acid (v/v) in H2O) and 35% 
solvent B (acetonitrile), an internal standard was added to a final concentration of 100 
µM. Zoxazolamine was used as an internal standard for chlorzoxazone and vice versa for 
zoxazolamine reactions. 4-aminobiphenyl reactions were run directly on the HPLC. 
Tolbutamide bioconversions were acidified with 60 μl 7% perchloric acid and 15 mg 
ascorbic acid followed by vortexing and centrifugation. 
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E.5 HRP reaction with 4-aminobiphenyl 
Reactions contained five units of HRP, 5 mM aminobiphenyl in 100 mM EPPS (pH 8.2) 
and were initiated by the addition of H2O2 to a final concentration of 1 mM. The 
reactions were allowed to proceed for 30 minutes at which point they were run directly 
on HPLC for analysis.   
 
E.6 HPLC analysis  
All bioconversions were analyzed on an Alliance HPLC system (Waters, Milford, MA) 
equipped with a photodiode array detector. Metabolites were identified by retention times 
and absorption spectra (see Appendix D for substrate and product spectra).  Propranolol, 
chlorzoxazone, zoxazolamine and 4-aminobiphenyl were separated on a Microsorb-MV 
phenyl column (250 x 4.6 mm, particle diameter 5 µm, Varian, Palo Alto, CA) with 
varying HPLC conditions using solvent A (1% triethylamine (v/v) and 0.8% acetic acid 
in HB2BO) and solvent B (acetonitrile). Fifty µl of the propranolol preparation was analyzed 
using the following elution protocol: 0-10 min., A:B 75:25; 10-20 min., linear gradient to 
A:B 25:75; 20-22 min., A:B 75:25; 22-27 min., linear gradient to A:B 75:25. Retention 
times for 5’-hydroxypropranolol, 4’-hydroxypropranolol, desisopropylpropranolol, 
propranolol  and 1-naphthol were 5.2 min, 5.7 min, 7.4 min, 12.9 min, 18.5 min, 
respectively. Twenty µl of the chlorzoxazone and zoxazolamine extracts were run 
isocratically for 10 minutes with solvent A:B 65:35 at 1 ml/min. Retention times for 
chlorzoxazone and 6-hydroxychlorzoxazone were 8.0 and 4.3 min, respectively. 
Retention times for zoxazolamine and 6-hydroxyzoxazolamine were 7.1 and 3.9 min, 
respectively. Twenty μl of the 4-aminobiphenyl bioconversions were run directly on 
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HPLC and eluted with the following conditions: 0-10 min, A:B 75:25; 10-50 min, linear 
gradient to A:B 25:75; 50-70 min, A:B 25:75; 70-80 min, linear gradient to A:B 75:25. 
The retention times for 4-aminobiphenyl and 4,4’-azobis(biphenyl) were 28.5 and 54.8 
min, respectively. Twenty μl  of the tolbutamide extracts were run on a Phenomenex C8 
(2) column (150 x 4.6mm, particle diameter 5 µm, Phenomenex, Torrance, CA) using 
45% acetonitrile and 55% 0.325% H3PO4 at 1.8 ml/min for 15 minutes. The retention 
times for tolbutamide, carboxytolbutamide and 4-hydroxytolbutamide were 11.7, 3.8 and 
2.4 min.  
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Chapter 8 
 
Preparation of human metabolites of propranolol using 
laboratory-evolved bacterial cytochromes P450                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material from this chapter appears in Otey CR, Bandara G, Lalonde J, Takahashi K, 
Arnold FH (2006) Preparation of human metabolites of propranolol using 
laboratory-evolved bacterial cytochromes P450. Biotechnol. Bioeng. 93: 494-499, and 
is reprinted with permission from John Wiley & Sons, Inc. Additional thanks to Professor 
Wendel Nelson for generously providing the 4’ and 5’-hydroxy propranolol standards 
and James Ross for laboratory assistance. This work was supported by National Institutes 
of Health Grant R01 GM068664-01.  
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A. Abstract 
Testing the toxicities and biological activities of the human metabolites of drugs is 
important for the development of safe and effective pharmaceuticals. Producing these 
metabolites using human cytochrome P450s is difficult, however, because the human 
enzymes are poorly stable and slow. We have used directed evolution to generate variants 
of P450 BM3 from Bacillus megaterium that function via the ‘peroxide shunt’ pathway, 
using hydrogen peroxide in place of the reductase domain, oxygen and NADPH. Here, 
we report further evolution of the P450 BM3 heme domain to optimize production of the 
authentic human metabolites of propranolol by this approach. This biocatalytic system 
offers a versatile, cost-effective, and scaleable route to the synthesis of drug metabolites. 
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B. Introduction 
The cytochromes P450 comprise a ubiquitous superfamily of heme-containing enzymes 
which perform a variety of oxidative reactions on a wide range of substrates [1,2]. In 
humans, P450s are responsible for the disposition of many xenobiotics, including 
pharmaceuticals [3]. During initial clearance, most drugs are metabolized in the liver by 
P450s [4,5].  Some of the metabolites are biologically active themselves, and 
understanding their effects is crucial in evaluating a drug’s efficacy, toxicity and 
pharmacokinetics [6]. Identification of so-called “active metabolites,” as in the case of 
terfenadine [7], early on in the drug development process could result in the early 
identification of safer, more well tolerated therapies. Such studies, however, can require 
large quantities of the pure metabolites, and these may be difficult to synthesize. An 
alternative to chemical synthesis is to use P450s to generate the metabolites of drugs or 
drug candidates. Hepatic microsomes are a source of human P450s, but their limited 
availability and highly variable expression levels make their use in preparative-scale 
metabolite synthesis impractical. Some human enzymes can also be obtained by 
expression in recombinant hosts. As membrane-bound, multi-protein systems, however, 
they commonly misfold and aggregate or are not expressed in active form. Metabolite 
preparation has been demonstrated using human P450s expressed in E. coli and in insect 
cells [8-10], but these systems are costly and have low productivities due to limited 
stabilities and slow reaction rates (usually <5 min-1 [11]). 
 
The bacterial cytochrome P450 BM3, a fatty acid hydroxylase from Bacillus megaterium, 
is expressed at high levels in E. coli and exhibits very fast reaction rates (thousands per 
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minute) on favored substrates [12]. This enzyme has been engineered to accept a variety 
of new substrates, on which its variants catalyze regio- and enantio-selective oxidations 
[13-19]. In previous work, we used directed evolution, with iterations of random 
mutagenesis and high-throughput screening, to generate variants of the CYP102A1 heme 
domain  which efficiently hydroxylate fatty acids using hydrogen peroxide in place of the 
reductase domain, oxygen and the costly NADPH cofactor (P450 ‘peroxygenases’)  [20]. 
Here, we demonstrate that an engineered P450 CYP102A1 heme domain peroxygenase 
can be used to produce the authentic human metabolites of propranolol, a multi-function 
beta-adrenergic blocker used to treat hypertension, arrhythmia, angina, migraine 
headaches, overactive thyroids and anxiety [21]. Furthermore, this activity can be 
improved by directed evolution to produce more of the biologically active metabolites. 
 
C. Results 
C.1 Bioconversion of propranolol by P450 A1-9C1 
In previous work, we created variants of A1 with high peroxygenase activity and 
thermostability by directed evolution, using multiple rounds of mutagenesis and 
screening [20]. In each round, a mutant library created by error-prone PCR random 
mutagenesis was screened for H2O2-driven hydroxylation of 12-p-
nitrophenoxycarboxylic acid (12-pNCA) [22]. The most active mutants were recombined 
to obtain the parents for subsequent rounds of evolution.  A1 variant 21B3 obtained in 
this way was further evolved during four rounds of error-prone PCR and screening to 
generate variant 9C1, which has 13 amino acid substitutions relative to the original 
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sequence, wild-type P450 CYP102A1 with the F87A mutation (Table 8.1) and catalyzes 
~1000 turnovers on 12-pNCA.  
 
 
            Table 8.1. Amino acid substitutions in cytochrome P450 A1 variants. 
Position 
(A1-9C1a) 
 
DE10 
 
D6H10 
 
2C11 
K24b   R 
R47b,c   H 
A74c V  V 
L75c  H  
V78c  E  
A82c 
A87c 
L P L 
G  G 
                      a The 9C1 parent has the following amino acid substitutions compared to wild-type CYP102A1:  
              F87A, I58V, H100R, I102T, F107L, A135S, M145A, N239H, S274T, L324I, I366V, K434E,    
              E442K, V446I.  
                      b Identified by random mutagenesis 
                      c Targeted active-site residues 
 
 
In humans, CYP2D6 and CYP1A2 are the main P450s responsible for the metabolism of 
propranolol [23], forming the three major products shown in Figure 8.1. The ring-
hydroxylated products, 4’OHP and 5’OHP, are of particular importance due to their 
pharmacological activities [24,25]. Upon testing different peroxygenase variants of A1 
from our previous work, we found that variant 9C1 produces a very similar product 
profile in a bioconversion carried out using E. coli cell extracts overexpressing the P450 
heme domain. A representative chromatogram showing the products from a propranolol 
bioconversion by A1-H 9C1 is shown in Figure 8.2. 
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Figure 8.1. Major metabolites of propranolol formed by human cytochromes P450. 
 
 
 
 
 
Figure 8.2.  HPLC chromatogram showing the relevant human metabolites of 
propranolol produced in a bioconversion of (5 mM) propranolol with A1-9C1.  Products 
from left to right are 5’-hydroxypropranolol (5.2 min.), 4’-hydroxypropranolol (5.7 min.), 
desisopropylpropranolol (7.4 min.).  Propranolol (12.9 min.) and 1-naphthol (18.5 min.) 
are not shown.   
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Since A1-9C1 was evolved for activity on the fatty acid analog, 12-pNCA [20], we did 
not expect it to function optimally on the chemically different propranolol. Initial 
reactions containing 5 µM P450 and 5 mM propranolol driven by a single addition of 
H2O2 to a final concentration of 1 mM converted 8% of the substrate to products. To test 
whether H2O2 or P450 was limiting in this reaction we followed the amount of P450 
present and product produced every 30 minutes for 6.5 hours (Figure 8.3). H2O2 was 
added either once or multiple times and in the presence or absence of the substrate 
propranolol. We found that roughly 75% of the initial P450 was still present after 3 hours 
when H2O2 was added only once. Production could be more than doubled to 18% 
conversion by multiple additions of 1 mM H2O2 every 30 minutes which equates to ~180 
turnovers per P450 active site. Under these conditions, the reaction was complete in 180 
minutes, at which point no more product was made, and no P450 remained (as 
determined by carbon monoxide difference spectroscopy). Interestingly, in the absence of 
the substrate propranolol, P450 degraded much more rapidly suggesting that the substrate 
is protecting the enzyme. The precise mechanism is unknown but it likely serves to 
reduce the frequency of interactions between the heme and oxygen radicals resulting 
from H2O2 which can cause heme alkylation [26-28] or oxidize or form radicals at 
individual amino acids [29-34], both of which inactivate the enzyme. 
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Figure 8.3. Productivity and lifetime of A1-9C1 under varying reaction conditions. 
Product formation was monitored by HPLC and remaining P450 by CO difference 
spectroscopy.  H2O2 was added either once (single) or multiple times to a concentration 
of 1 mM. The concentrations of P450 and propranolol were 5 µM and 5 mM, 
respectively. 
 
 
 
C.2 Directed evolution to enhance activity of A1-9C1 on propranolol 
To test whether the bacterial P450 heme domains can be engineered to increase 
production of the hydroxylated products 4’OHP and 5’OHP and total activity towards 
drug compounds such as propranolol, we carried out additional directed evolution, this 
time with mutations targeted specifically to the active site. Using A1-9C1 as the parent, a 
library was created by directing mutations to seven active-site residues (A74, L75, V78, 
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F81, A82, F87 and T88) which are within 5 Å of the substrate, based on the crystal 
structure of P450 BM3 bound to N-palmitoylglycine [35]. The mutagenic 
oligonucleotides were doped such that two of the seven residues were mutated in each 
sequence, on average. This gene library was transformed into catalase-deficient E. coli 
[36] to allow screening for activity in the presence of hydrogen peroxide. Propranolol 
hydroxylation activity was monitored using the 4-AAP assay (see Chapter 3), which 
detects the products of aromatic hydroxylation, 4’OHP, 5’OHP, and 1-naphthol. It does 
not detect the dealkylation product DIP.  
 
Mutants DE10 and D6H10 were selected on the basis of increased formation of 
detectable products compared to parent A1-9C1. Sequencing showed that each mutant 
contained three amino acid substitutions relative to A1-9C1 (Table 8.1). HPLC analysis 
of the reaction mixture showed that DE10 and D6H10 convert 13% and 9% of the 
propranolol, respectively, to products. Although DE10 and D6H10 lead to less 
conversion than 9C1, they produce more of the metabolites detected by the 4-AAP assay. 
As shown in Figure 8.4, DE10 produces twice as much 4’OHP, while D6H10 produces 
50% more 5’OHP. These variants make 33% less DIP.  
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Figure 8.4. Propranolol metabolites produced by A1-9C1 and variants obtained by 
further directed evolution. Results are from bioconversions containing 5 µM P450 and 5 
mM propranolol, driven by H2O2. Error bars represent one standard deviation from three 
experiments. 
 
 
 
 
We next generated a second mutant library using error-prone PCR to introduce random 
mutations throughout the DE10 gene and screened the resulting clones for enhanced 
product formation. From this library we isolated 2C11. This mutant generates a product 
profile similar to DE10 but converts more (20%) of the propranolol to the hydroxylated 
products (Figure 8.4). Relative to A1-9C1, it produces 50% more 5’OHP, 200% more 
4’OHP, 100% more 1-naphthol and 40% of the DIP. The four products 4’OHP, 5’OHP, 
and 1-naphthol and DIP account for ~75-80% of the propranolol converted. Other, minor 
products were also visible in the HPLC traces, but their identities are unknown. Mutant 
2C11 contains an additional two amino acid substitutions compared to DE10 (Table 8.1). 
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D. Discussion  
We have demonstrated that a bacterial P450 heme domain can be used to prepare the 
authentic human metabolites of propranolol in a reaction driven by hydrogen peroxide. 
Furthermore, the activity can be enhanced and product selectivity can be optimized by 
directed evolution. In the first round of evolution, mutations were targeted to active-site 
residues believed to contact the substrate during catalysis. In wild-type P450 CYP102A1, 
phenylalanine 87 sequesters the ω-end of the fatty acid, which is hydroxylated at adjacent 
positions [37]. Substitution of this residue for alanine increases the activity of wild-type 
BM3 on polycyclic aromatics [38] and affects the regioselectivity of fatty acid 
hydroxylation [39]. It is also known that the residue size at position 87 plays a critical 
role in H2O2 dependent substrate hydroxylation: replacement of phenylalanine 87 with 
smaller residues such as alanine or glycine increases peroxygenase activity [39,40]. It is 
thought that the additional space provided by these mutations allows more water 
molecules to remain at the active site pocket after substrate binding, promoting H2O2 
access. We therefore introduced the F87A mutation into the wild-type parent CYP102A1 
during the initial directed evolution efforts to find an efficient peroxygenase. This F87A 
mutation in the parent 9C1 used for the present study was exchanged for the even 
smaller, glycine residue after the first round of evolution. 
 
Mutations in the active site have been shown to alter the stereo- and regioselectivity of 
P450 BM3 [13,14,17,19]. Saturation mutagenesis of active-site residues and screening 
has generated a range of CYP102A1 variants with novel activities, ranging from ethane 
hydroxylation [41] to enantioselective epoxidation of terminal alkenes [15] and 
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enantioselective hydroxylation of protected carboxylic acids [18], demonstrating the ease 
with which this enzyme’s substrate specificity and product selectivity can be modified. 
The active-site mutations described here produce similar results, altering the 
regioselectivity of A1 in the peroxygenase reaction on propranolol. Activity is shifted 
activity away from the dealkylation reaction and towards aromatic hydroxylation (Figure 
8.4). 
 
The specific effects of each mutation are difficult to rationalize since the substrate likely 
binds in more than one conformation, as indicated by its multiple products. The 
mutations in the active site, however, influence the binding geometries available to the 
substrate and thereby alter the regioselectivity of oxidation. In variants DE10 and 2C11, 
active-site residues A82 and A74 are both changed to larger hydrophobic amino acids, 
leucine and valine, respectively, which presumably reduce the volume of the active site. 
A82L has previously been shown to alter the regioselectivity of substrate hydroxylation 
[17]. In contrast, A87G increases the volume of the active site directly above the heme. In 
2C11, substitutions R47H and K24R introduced during random mutagenesis increase 
total activity while retaining a product profile similar to DE10 (Figure 8.4). K24R, which 
is not an active-site residue, is conservative and may be neutral. R47H, in contrast, is 
located at the mouth of the active site. Mutation of this residue to leucine has been shown 
to increase activity towards polycyclic aromatic hydrocarbons [42]. D6H10 has three 
mutations which lower total activity relative to parent A1-9C1 but increase production of 
5’OHP. In this variant, the valine at position 78 is mutated to glutamic acid, introducing a 
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charged residue into the hydrophobic active site and likely resulting in weaker binding of 
the substrate. 
 
In human liver microsomes, ring hydroxylation of propranolol is mediated by CYP2D6, 
whereas desisopropylation is mediated mainly by CYP1A2 and to a lesser extent by 
CYP2D6 [23]. Of these metabolites, the ring-hydroxylated products are of particular 
importance. 4’OHP has been demonstrated to be equipotent to propranolol as a β-receptor 
antagonist [24] and is believed to contribute to the bioactivity of propranolol in humans 
[43]. Other monohydroxylated products have also been shown to produce β-blockade and 
direct vasodilation in dogs [25]. Chemical synthesis for each individual metabolite 
involves multiple steps that require organic solvents and expensive chemical catalysts 
such as palladium [25,44]. The variants of bacterial P450 A1 described here produce all 
the major products of human propranolol metabolism, but, importantly, the evolved 
mutants make more of the key ring-hydroxylated products 4’OHP and 5’OHP. The 
variants here are also more productive than the human P450s. CYP2D6 has rates of < 5 
per min and capable of less than 10 turnovers per P450 [45], much lower than the mutant 
2C11 which catalyzes 180 total turnovers.  
 
The heme domain of CYP102A1 is expressed at high levels (~100 mg/L) in a typical 
shake culture, and this can be further increased in a high density fermentation. Using 
crude cell lysate containing evolved heme domains capable of 180 turnovers when 
provided with H2O2, one could generate >70 mg of products with the enzyme from one 
liter of batch culture. This is similar to the quantities produced in S. frugiperda and E. 
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coli cells using human P450s [9,10], but the preparation is simpler and far less costly. In 
addition, the productivity can likely be increased by further optimizing the reaction 
conditions or protein expression. By simply serially adding H2O2 in small amounts rather 
than a large, single addition to high concentration, we were able to double the 
productivity (Figure 8.3). Recently it has been shown that the addition of other proteins, 
such as bovine serum albumin [46], increases the productivity of CYP102A1 and other 
parameters such as enzyme: substrate ratio, pH, buffer, ionic strength, temperature, etc. 
could be modified to further increase productivity.  
 
An advantage of using the CYP102A1 heme domain, which utilizes H2O2 to drive these 
reactions, is its self-sufficiency. Catalysis does not depend on the addition or regeneration 
of NADPH, the cofactor required for most P450 reactions. Using the peroxygenase 
activity significantly decreases the cost and complexity of the preparation of these 
metabolites. With further optimization of the catalyst and reaction conditions, we 
anticipate that this system can be used to generate larger quantities of valuable drug 
metabolites. Additionally, laboratory-evolved P450s may be used for combinatorial 
biocatalysis of drug scaffolds to further diversify and increase the efficacy of these 
molecules. Using bacterial P450s to create the authentic human metabolites of drugs 
provides an easily scaleable and improvable system for the biosynthesis of these valuable 
compounds. 
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E. Methods 
E.1. Materials 
All chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, MO).  Solvents were 
from EM Sciences (Gibbstown, NJ). Enzymes for DNA manipulation were from New 
England Biolabs (Beverly, MA). DNA purification kits were from Zymo Research 
(Orange, CA) and Qiagen (Valencia, CA). T4 DNA ligase was from Invitrogen 
(Carlsbad, CA). Propranolol standards 4’-hydroxypropranolol (4’OHP) and 5’-
hydroxypropranolol (5’OHP) were generously provided by Professor Wendel Nelson of 
the University of Washington, Seattle. (S)-N-desisopropylpropranolol was purchased 
from ABX Advanced Biochemical Compounds (Radeberg, Germany). 
 
E.2. Protein expression 
All P450 BM3 heme domains were cloned, transformed and expressed in the catalase-
deficient strain of E. coli SN0037 [36] using the IPTG-inducible pCWori vector [47]. For 
protein expression, 50 mL of Terrific Broth (TB) supplemented with 100 µg/mL 
ampicillin and 25 µg/mL thiamine were inoculated with 500 µL of an overnight culture 
and incubated for 5 hours at 30 oC with shaking. P450 expression was induced by adding 
0.5 mM IPTG and the heme precursor δ-ALA to a final concentration of 1 mM. The 
cultures were grown for another 18 hours and the cells were pelleted and stored at -20 oC. 
 
E.3. Bioconversion of propranolol 
Cell pellets were resuspended in 100 mM EPPS pH 8.2, sonicated for 3 x 45 seconds and 
centrifuged at 10,000 g for 30 min. The supernatant was passed through a PD10 size 
 223
exclusion column and P450 concentration was measured by CO difference spectroscopy 
[48]. 
  
Bioconversions were done in 400 µL of 100 mM Epps pH 8.2 containing 5 µM P450 and 
5 mM propranolol. Reactions were initiated by adding H2O2 to a final concentration of 1 
mM, and the equivalent amount every 30 minutes thereafter. After 180 minutes at room 
temperature, the reaction products were analyzed using the 4-AAP assay and HPLC. 
Control reactions performed without the addition of enzyme or peroxide produced no 
detectable products. 
 
E.4. HPLC analysis  
Product analysis was similar to that described previously [49]. Perchloric acid (7%) was 
added to the reaction mixture at a volume of 10 µL/100 µL reaction, followed by addition 
of 2.5 mg/100 µL ascorbic acid. Samples were vortexed, centrifuged, and 50 µL of the 
supernatant were analyzed using an Alliance HPLC system (Waters, Milford, MA) 
equipped with a photodiode array detector.  Separation was achieved on a Microsorb-MV 
phenyl column (250 x 4.6 mm, particle diameter 5 µm, Varian, Palo Alto, CA). 
Conditions with solvent A (1% triethylamine (v/v) and 0.8% acetic acid in HB2BO) and 
solvent B (acetonitrile) used to elute propranolol and products were: 0-10 min., A:B 
75:25; 10-20 min., linear gradient to A:B 25:75; 20-22 min., A:B 75:25; 22-27 min., 
linear gradient to A:B 75:25. Metabolites were identified by retention times and 
absorption spectra and were quantified by comparison to peak areas of known amounts of 
synthetic standards.  
 224
E.5. Saturation mutagenesis 
Using A1-9C1 as the parent sequence, a mutant library was generated in which active site 
residues A74, L75, V78, P81, A82, F87 and T88 were randomly mutated. The primers 
were designed so that each clone would contain, on average, two amino acid substitutions 
[50]. The sequence of the forward primer was 5’-
CTCGCTTTGATAAAAACTTAAGTCAARSRSXXAAATTTRXWCGTGATXXXRS
WGGAGACGGGTTGRSSWSWAGCTGGACG-3’, in which R=85%G, 5% of C, A and 
T; S=85%C, 5% of G, C and T; W=85% A, 5% of G, C and T; X=85% T, 5% of G, C 
and A.  The bold letter shows the doped nucleotides, and italic sequence is a BfrI 
restriction site.  The reverse primer sequence was 5’-
CGTACTATGGTTTGCTTTGACGC-3’. Silent mutation A321G was introduced to the 
parent 9C1 gene to disrupt a BrfI restriction site for subsequent cloning purposes. 
Polymerase chain reaction was performed with Pfu Turbo DNA polymerase using these 
primers and the mutated A1-9C1 gene (with A321G) as the template. PCR conditions 
were 94 oC (1 min.), {94 oC (30 s) -> 63 oC (30 s) -> 72 oC (2 min.)} x 30 cycles, 72 oC 
(10 min.). Following agarose gel electrophoresis, the band corresponding to the P450 
gene was excised from the gel and purified. The purified DNA fragment was treated with 
EcoRI and BfrI and ligated into the pCWori plasmid. The ligated DNA was transformed 
into catalase-deficient E. coli, and the resulting clones were screened as described below. 
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E.6. Random mutagenesis  
Error-prone PCR was performed on the BM3-H DE10 gene with the GeneMorph PCR 
Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturers’ protocol, with 
5-50 ng of target DNA. The reaction mixture was treated with DpnI for template 
degradation followed by agarose gel purification. The purified DNA fragment was 
digested with EcoRI and BamHI, gel purified, and ligated into the pCWori vector. The 
ligation product was used to transform the catalase-deficient E. coli strain, and the 
transformants were plated on LB agar medium supplemented with 100 µg/mL of 
ampicillin. 
 
E.7. Screening for increased activity on propranolol  
Single colonies were picked and inoculated into 500 µL of Luria-Bertani (LB) medium 
supplemented with 100 µg/mL ampicillin, in 96 well deep-well plates. The plates were 
incubated overnight at 30 PoC with shaking and 80% humidity. 150 µL of the pre-cultures 
were inoculated into 850 µL of TB supplemented with 100 µg/mL ampicillin, 25 µg/mL 
thiamine, 0.5 mM IPTG and 1 mM δ-ALA, and grown under the same conditions for 
another 20 hours. The plates were then centrifuged to pellet the cells, supernatants 
discarded, and frozen overnight at -20 oC. Cells were resuspended in 300 µL of 100 mM 
Epps pH 8.2 containing 0.5 mg/mL lysozyme and 2 units/mL DNaseI. After 60 minutes 
at 37 oC, the lysates were centrifuged, and the supernatant was used for the activity assay. 
To 80 µL of the cleared supernatant, 30 µL of Epps pH 8.2 containing propranolol was 
added followed by 10 µL of 12 mM H2OB2. Final concentrations in the reaction mixture 
were 1 mM propranolol, 1% DMSO, 1% acetone and 1 mM H2BO2. After 90 minutes at 
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room temperature, the 4-AAP assay was used to quantify the products of propranolol 
bioconversions. 
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Appendix A 
Nucleotide and amino acid sequences 
 
 
This appendix contains a ClustalW alignment of the heme domains of CYP102A1, 
CYP102A2 and CYP102A3 amino acid sequences with the F87A mutation (in 
CYP102A1) and F88A mutation (in CYP102A2 and CYP102A3). Following these are 
the different amino acid and nucleotide sequences of the genes and proteins used in this 
thesis. The accession numbers for the genes and gene products discussed are CYP102A1 
(J04832 and CAB12544) and CYP102A3 (U93874) 
(http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi). 
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Table A.1. ClustalW amino acid sequence alignment of the heme domain of CYP102A1 
(residues 1-463), CYP102A2 and CYP102A3 (residues 1-466).  Numbering is according 
to the CYP102A1 sequence. 
 
           1                                                         60 
CYP102A1  .TIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKE  
CYP102A2  KETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKE  
CYP102A3  KQASAIPQPKTYGPLKNLPHLEKEQLSQSLWRIADELGPIFRFDFPGVSSVFVSGHNLVAE  
 
          61                                                        121 
CYP102A1  ACDESRFDKNLSQALKFVRDFAGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVD 
CYP102A2  VCDEERFDKSIEGALEKVRAFSGDGLATSWTHEPNWRKAHNILMPTFSQRAMKDYHEKMVD 
CYP102A3  VCDEKRFDKNLGKGLQKVREFGGDGLATSWTHEPNWQKAHRILLPSFSQKAMKGYHSMMLD 
 
          122                                                       183 
CYP102A1  IAVQLVQKWERLNADEHIEVPEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALD 
CYP102A2  IAVQLIQKWARLNPNEAVDVPGDMTRLTLDTIGLCGFNYRFNSYYRETPHPFINSMVRALD 
CYP102A3  IATQLIQKWSRLNPNEEIDVADDMTRLTLDTIGLCGFNYRFNSFYRDSQHPFITSMLRALK 
 
          184                                                       245 
CYP102A1  EAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKASGEQ.SDDLLTHMLNGKD 
CYP102A2  EAMHQMQRLDVQDKLMVRTKRQFRYDIQTMFSLVDSIIAERRANGDQDEKDLLARMLNVED 
CYP102A3  EAMNQSKRLGLQDKMMVKTKLQFQKDIEVMNSLVDRMIAERKANPDENIKDLLSLMLYAKD 
 
          246                                                       307 
CYP102A1  PETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVP  
CYP102A2  PETGEKLDDENIRFQIITFLIAGHETTSGLLSFATYFLLKHPDKLKKAYEEVDRVLTDAAP  
CYP102A3  PVTGETLDDENIRYQIITFLIAGHETTSGLLSFAIYCLLTHPEKLKKAQEEADRVLTDDTP 
 
 
          308                                                       369 
CYP102A1  SYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDK 
CYP102A2  TYKQVLELTYIRMILNESLRLWPTAPAFSLYPKEDTVIGGKFPITTNDRISVLIPQLHRDR 
CYP102A3  EYKQIQQLKYIRMVLNETLRLYPTAPAFSLYAKEDTVLGGEYPISKGQPVTVLIPKLHRDQ 
 
          370                                                       431 
CYP102A1  TIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFED  
CYP102A2  DAWGKDAEEFRPERFEHQDQVPHHAYKPFGNGQRACIGMQFALHEATLVLGMILKYFTLID  
CYP102A3  NAWGPDAEDFRPERFEDPSSIPHHAYKPFGNGQRACIGMQFALQEATMVLGLVLKHFELIN  
 
          432                                463 
CYP102A1  HTNYELDIKETLTLKPEGFVVKAKSKKIPLGGIPSPST. 
CYP102A2  HENYELDIKQTLTLKPGDFHISVQSRHQEAIHADVQAAE  
CYP102A3  HTGYELKIKEALTIKPDDFKITVKPRKTAAINVQRKEQA 
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Figure A.1. Plasmid map of pCWori [1] with A) P450 heme domain or B) P450 
holoenzyme (heme domain plus reductase domain).  Expression is under the control of a 
double tac promoter (Ptac)[2] and has a β-lactamase as an ampicillin resistance marker 
(AmpR).  The lacIq gene (lac Iq) which expresses the Lac I repressor and origin of 
replication (Ori).  BamHI and EcoRI are typical cloning sites. 
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Nucleotide sequences 
 
CYP102A1 Heme Domain – F87A – library 
        1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA TTTACCGTTA  
       61 TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG CGGATGAATT AGGAGAAATC  
      121 TTTAAATTCG AGGCGCCTGG TCGTGTAACG CGCTACTTAT CAAGTCAGCG TCTAATTAAA  
      181 GAAGCATGCG ATGAATCACG CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT  
      241 GATTTTGCAG GAGACGGGTT GGCCACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG  
      301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA TGCGATGATG  
      361 GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC TAAATGCAGA TGAGCATATT  
      421 GAAGTACCGG AAGACATGAC ACGTTTAACG CTTGATACGA TTGGTCTTTG CGGCTTTAAC  
      481 TATCGCTTTA ACAGCTTTTA CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT  
      541 GCACTGGATG AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT  
      601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT CGACAAAATT  
      661 ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT TATTAACGCA CATGCTAAAC  
      721 GGAAAAGATC CAGAAACGGG TGAGCCGCTT GATGACGAGA ACATTCGCTA TCAAATTATT  
      781 ACATTCTTAA TTGCGGGACA CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC  
      841 TTAGTGAAAA ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA  
      901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT GGTCTTAAAC  
      961 GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC TATATGCAAA AGAAGATACG  
     1021 GTGCTTGGAG GAGAATATCC TTTAGAAAAA GGCGACGAAC TAATGGTTCT GATTCCTCAG  
     1081 CTTCACCGTG ATAAAACAAT TTGGGGTGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT  
     1141 GAAAATCCAA GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG  
     1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT GATGCTAAAA  
     1261 CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTGGATA TTAAAGAAAC TTTAACGTTA  
     1321 AAACCTGAAG GCTTTGTGGT AAAAGCAAAA TCGAAAAAAA TTCCGCTTGG CGGTATTCCT  
     1381 TCACCTAGCA CT 
 
CYP102A2 Heme Domain – F88A – library 
        1 ATGAAGGAAA CAAGCCCGAT TCCTCAGCCG AAGACGTTTG GGCCGCTCGG CAATTTGCCT  
       61 TTAATTGATA AAGACAAACC GACGCTTTCG CTGATCAAAC TGGCGGAAGA ACAGGGCCCG  
      121 ATTTTTCAAA TCCATACACC CGCGGGCACG ACCATTGTAG TGTCCGGCCA TGAATTGGTG  
      181 AAAGAGGTTT GTGATGAAGA ACGGTTTGAT AAAAGCATTG AAGGCGCCTT GGAAAAGGTT  
      241 CGCGCATTTT CCGGTGACGG ATTGGCCACT AGTTGGACGC ATGAGCCTAA CTGGAGAAAA  
      301 GCGCACAACA TTCTGATGCC GACGTTCAGC CAGCGGGCCA TGAAGGACTA TCATGAGAAA  
      361 ATGGTCGATA TCGCTGTTCA GCTCATTCAA AAATGGGCAA GGCTCAACCC GAATGAAGCA  
      421 GTCGATGTCC CGGGAGATAT GACCCGGCTG ACGCTCGACA CCATTGGGCT ATGCGGGTTT  
      481 AACTACCGCT TTAACAGTTA CTACAGAGAA ACGCCCCACC CGTTTATCAA CAGCATGGTG  
      541 CGGGCGCTTG ATGAAGCGAT GCATCAAATG CAGCGGCTTG ATGTTCAAGA TAAGCTTATG  
      601 GTCAGAACAA AGCGGCAATT CCGCTATGAT ATTCAAACGA TGTTTTCGTT AGTCGACAGC  
      661 ATTATTGCAG AGCGCAGGGC GAATGGAGAC CAGGATGAAA AAGATTTGCT CGCCCGCATG  
      721 CTGAATGTGG AAGATCCGGA AACTGGTGAA AAGCTCGACG ACGAAAATAT CCGCTTTCAG  
      781 ATCATCACGT TTTTGATTGC CGGCCATGAA ACAACGAGCG GCCTGCTTTC CTTTGCGACT  
      841 TACTTTTTAT TGAAGCATCC TGACAAACTG AAAAAGGCGT ATGAAGAGGT CGATCGGGTG  
      901 CTGACGGATG CAGCGCCGAC CTATAAACAA GTGCTGGAGC TTACATACAT ACGGATGATT  
      961 TTAAATGAAT CACTGCGCTT ATGGCCGACA GCTCCGGCTT TCAGCCTTTA TCCAAAAGAA  
     1021 GACACAGTCA TTGGCGGAAA ATTTCCGATC ACGACGAATG ACAGAATTTC TGTGCTGATT  
     1081 CCGCAGCTTC ATCGTGATCG AGACGCTTGG GGAAAGGACG CAGAAGAGTT CCGGCCGGAA  
     1141 CGGTTTGAGC ATCAGGACCA AGTGCCTCAT CATGCGTACA AACCATTCGG AAATGGACAA  
     1201 CGGGCCTGTA TCGGCATGCA GTTTGCCCTT CATGAAGCCA CACTTGTGTT AGGCATGATT  
     1261 CTAAAATATT TCACATTGAT TGATCATGAG AATTATGAGC TTGATATCAA ACAAACCTTA  
     1321 ACACTTAAGC CGGGCGATTT TCACATCAGT GTTCAAAGCC GTCATCAGGA AGCCATTCAT  
     1381 GCAGACGTCC AGGCAGCTGA A 
 
CYP102A3 Heme Domain – F88A - library 
         1 ATGAAACAGG CAAGCGCAAT ACCTCAGCCC AAAACATACG GACCTTTAAA AAATCTTCCG  
       61 CATCTGGAAA AAGAACAGCT TTCTCAATCC TTATGGCGGA TAGCTGATGA ATTGGGACCG  
      121 ATTTTCCGTT TTGATTTTCC GGGAGTATCC AGTGTTTTTG TGTCCGGCCA CAATCTTGTG  
      181 GCTGAAGTGT GTGATGAAAA ACGCTTTGAC AAGAACCTTG GCAAAGGCTT GCAAAAGGTG  
      241 CGTGAGTTCG GGGGAGATGG CTTAGCCACT AGTTGGACGC ACGAACCGAA CTGGCAAAAA  
      301 GCCCACCGCA TTTTGCTGCC GAGTTTTAGT CAAAAAGCGA TGAAAGGCTA TCATTCTATG  
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      361 ATGCTGGATA TCGCAACCCA GCTGATTCAA AAGTGGAGCC GGTTAAACCC CAATGAAGAA  
      421 ATTGATGTAG CGGACGATAT GACACGTCTG ACGCTTGATA CGATTGGGTT ATGCGGGTTT  
      481 AACTATCGAT TCAACAGCTT TTACCGTGAT TCACAGCATC CGTTTATCAC CAGTATGCTC  
      541 CGTGCCTTAA AAGAGGCGAT GAATCAATCG AAAAGACTGG GCCTGCAAGA TAAAATGATG  
      601 GTGAAAACGA AGCTGCAGTT CCAAAAGGAT ATAGAAGTCA TGAACTCCCT GGTCGACAGA  
      661 ATGATAGCGG AGCGAAAGGC GAATCCGGAT GAAAACATTA AGGATCTCTT GTCTCTCATG  
      721 CTTTATGCCA AAGATCCAGT AACGGGTGAA ACGCTGGATG ACGAAAACAT TCGATACCAA  
      781 ATCATCACAT TTTTAATTGC TGGACATGAG ACAACAAGCG GGTTGCTATC CTTTGCGATT  
      841 TATTGTCTGC TTACACATCC GGAAAAACTG AAAAAAGCTC AGGAGGAAGC GGATCGCGTG  
      901 TTAACGGATG ACACGCCTGA ATATAAACAA ATCCAGCAGC TCAAATACAT TCGGATGGTT  
      961 TTAAATGAAA CCCTCAGACT GTATCCAACA GCTCCGGCTT TTTCTCTATA TGCGAAGGAG  
     1021 GATACTGTTC TTGGCGGGGA ATATCCGATC AGCAAAGGGC AGCCAGTCAC TGTTTTAATT  
     1081 CCAAAACTGC ACCGGGATCA AAACGCTTGG GGACCGGATG CGGAAGATTT CCGTCCGGAA  
     1141 CGGTTTGAAG ATCCTTCAAG TATCCCTCAC CATGCGTATA AGCCGTTTGG AAACGGACAG  
     1201 CGCGCTTGTA TTGGCATGCA GTTTGCTCTT CAAGAAGCGA CAATGGTTCT CGGTCTTGTA  
     1261 TTAAAGCATT TTGAATTGAT AAACCATACT GGCTACGAAC TAAAAATCAA AGAAGCATTA  
     1321 ACGATCAAGC CGGATGATTT TAAAATTACT GTGAAACCGC GAAAAACAGC GGCAATCAAT  
     1381 GTACAGAGAA AAGAACAGGC A 
 
CYP102A1 Holoenzyme 
        1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA TTTACCGTTA  
       61 TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG CGGATGAATT AGGAGAAATC  
      121 TTTAAATTCG AGGCGCCTGG TCGTGTAACG CGCTACTTAT CAAGTCAGCG TCTAATTAAA  
      181 GAAGCATGCG ATGAATCACG CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT  
      241 GATTTTGCAG GAGACGGGTT ATTTACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG  
      301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA TGCGATGATG  
      361 GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC TAAATGCAGA TGAGCATATT  
      421 GAAGTACCGG AAGACATGAC ACGTTTAACG CTTGATACAA TTGGTCTTTG CGGCTTTAAC  
      481 TATCGCTTTA ACAGCTTTTA CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT  
      541 GCACTGGATG AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT  
      601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT AGATAAAATT  
      661 ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT TATTAACGCA TATGCTAAAC  
      721 GGAAAAGATC CAGAAACGGG TGAGCCGCTT GATGACGAGA ACATTCGCTA TCAAATTATT  
      781 ACATTCTTAA TTGCGGGACA CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC  
      841 TTAGTGAAAA ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA  
      901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT GGTCTTAAAC  
      961 GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC TATATGCAAA AGAAGATACG  
     1021 GTGCTTGGAG GAGAATATCC TTTAGAAAAA GGCGACGAAC TAATGGTTCT GATTCCTCAG  
     1081 CTTCACCGTG ATAAAACAAT TTGGGGAGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT  
     1141 GAAAATCCAA GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG  
     1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT GATGCTAAAA  
     1261 CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTCGATA TTAAAGAAAC TTTAACGTTA  
     1321 AAACCTGAAG GCTTTGTGGT AAAAGCAAAA TCGAAAAAAA TTCCGCTTGG CGGTATTCCT  
     1381 TCACCTAGCA CTGAACAGTC TGCTAAAAAA GTACGCAAAA AGGCAGAAAA CGCTCATAAT  
     1441 ACGCCGCTGC TTGTGCTATA CGGTTCAAAT ATGGGAACAG CTGAAGGAAC GGCGCGTGAT  
     1501 TTAGCAGATA TTGCAATGAG CAAAGGATTT GCACCGCAGG TCGCAACGCT TGATTCACAC  
     1561 GCCGGAAATC TTCCGCGCGA AGGAGCTGTA TTAATTGTAA CGGCGTCTTA TAACGGTCAT  
     1621 CCGCCTGATA ACGCAAAGCA ATTTGTCGAC TGGTTAGACC AAGCGTCTGC TGATGAAGTA  
     1681 AAAGGCGTTC GCTACTCCGT ATTTGGATGC GGCGATAAAA ACTGGGCTAC TACGTATCAA  
     1741 AAAGTGCCTG CTTTTATCGA TGAAACGCTT GCCGCTAAAG GGGCAGAAAA CATCGCTGAC  
     1801 CGCGGTGAAG CAGATGCAAG CGACGACTTT GAAGGCACAT ATGAAGAATG GCGTGAACAT  
     1861 ATGTGGAGTG ACGTAGCAGC CTACTTTAAC CTCGACATTG AAAACAGTGA AGATAATAAA  
     1921 TCTACTCTTT CACTTCAATT TGTCGACAGC GCCGCGGATA TGCCGCTTGC GAAAATGCAC  
     1981 GGTGCGTTTT CAACGAACGT CGTAGCAAGC AAAGAACTTC AACAGCCAGG CAGTGCACGA  
     2041 AGCACGCGAC ATCTTGAAAT TGAACTTCCA AAAGAAGCTT CTTATCAAGA AGGAGATCAT  
     2101 TTAGGTGTTA TTCCTCGCAA CTATGAAGGA ATAGTAAACC GTGTAACAGC AAGGTTCGGC  
     2161 CTAGATGCAT CACAGCAAAT CCGTCTGGAA GCAGAAGAAG AAAAATTAGC TCATTTGCCA  
     2221 CTCGCTAAAA CAGTATCCGT AGAAGAGCTT CTGCAATACG TGGAGCTTCA AGATCCTGTT  
     2281 ACGCGCACGC AGCTTCGCGC AATGGCTGCT AAAACGGTCT GCCCGCCGCA TAAAGTAGAG  
     2341 CTTGAAGCCT TGCTTGAAAA GCAAGCCTAC AAAGAACAAG TGCTGGCAAA ACGTTTAACA  
     2401 ATGCTTGAAC TGCTTGAAAA ATACCCGGCG TGTGAAATGA AATTCAGCGA ATTTATCGCC  
     2461 CTTCTGCCAA GCATACGCCC GCGCTATTAC TCGATTTCTT CATCACCTCG TGTCGATGAA  
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     2521 AAACAAGCAA GCATCACGGT CAGCGTTGTC TCAGGAGAAG CGTGGAGCGG ATATGGAGAA  
     2581 TATAAAGGAA TTGCGTCGAA CTATCTTGCC GAGCTGCAAG AAGGAGATAC GATTACGTGC  
     2641 TTTATTTCCA CACCGCAGTC AGAATTTACG CTGCCAAAAG ACCCTGAAAC GCCGCTTATC  
     2701 ATGGTCGGAC CGGGAACAGG CGTCGCGCCG TTTAGAGGCT TTGTGCAGGC GCGCAAACAG  
     2761 CTAAAAGAAC AAGGACAGTC ACTTGGAGAA GCACATTTAT ACTTCGGCTG CCGTTCACCT  
     2821 CATGAAGACT ATCTGTATCA AGAAGAGCTT GAAAACGCCC AAAGCGAAGG CATCATTACG  
     2881 CTTCATACCG CTTTTTCTCG CATGCCAAAT CAGCCGAAAA CATACGTTCA GCACGTAATG  
     2941 GAACAAGACG GCAAGAAATT GATTGAACTT CTTGATCAAG GAGCGCACTT CTATATTTGC  
     3001 GGAGACGGAA GCCAAATGGC ACCTGCCGTT GAAGCAACGC TTATGAAAAG CTATGCTGAC  
     3061 GTTCACCAAG TGAGTGAAGC AGACGCTCGC TTATGGCTGC AGCAGCTAGA AGAAAAAGGC  
     3121 CGATACGCAA AAGACGTGTG GGCTGGGCAT CATCATCATC ATCAT 
 
CYP102A2 Holoenzyme 
        1 ATGAAGGAAA CAAGCCCGAT TCCTCAGCCG AAGACGTTTG GGCCGCTCGG CAATTTGCCT  
       61 TTAATTGATA AAGACAAACC GACGCTTTCG CTGATCAAAC TGGCGGAAGA ACAGGGCCCG  
      121 ATTTTTCAAA TCCATACACC CGCGGGCACG ACCATTGTAG TGTCCGGCCA TGAATTGGTG  
      181 AAAGAGGTTT GTGATGAAGA ACGGTTTGAT AAAAGCATTG AAGGCGCCTT GGAAAAGGTT  
      241 CGCGCATTTT CCGGTGACGG ATTGTTTACG AGCTGGACGC ATGAGCCTAA CTGGAGAAAA  
      301 GCGCACAACA TTCTGATGCC GACGTTCAGC CAGCGGGCCA TGAAGGACTA TCATGAGAAA  
      361 ATGGTCGATA TCGCTGTTCA GCTCATTCAA AAATGGGCAA GGCTCAACCC GAATGAAGCA  
      421 GTCGATGTCC CGGGAGATAT GACCCGGCTG ACGCTCGACA CCATTGGGCT ATGCGGGTTT  
      481 AACTACCGCT TTAACAGTTA CTACAGAGAA ACGCCCCACC CGTTTATCAA CAGCATGGTG  
      541 CGGGCGCTTG ATGAAGCGAT GCATCAAATG CAGCGGCTTG ATGTTCAAGA TAAGCTTATG  
      601 GTCAGAACAA AGCGGCAATT CCGCTATGAT ATTCAAACGA TGTTTTCGTT AGTCGACAGC  
      661 ATTATTGCAG AGCGCAGGGC GAATGGAGAC CAGGATGAAA AAGATTTGCT CGCCCGCATG  
      721 CTGAATGTGG AAGATCCGGA AACTGGTGAA AAGCTCGACG ACGAAAATAT CCGCTTTCAG  
      781 ATCATCACGT TTTTGATTGC CGGCCATGAA ACAACGAGCG GCCTGCTTTC CTTTGCGACT  
      841 TACTTTTTAT TGAAGCATCC TGACAAACTG AAAAAGGCGT ATGAAGAGGT CGATCGGGTG  
      901 CTGACGGATG CAGCGCCGAC CTATAAACAA GTGCTGGAGC TTACATACAT ACGGATGATT  
      961 TTAAATGAAT CACTGCGCTT ATGGCCGACA GCTCCGGCTT TCAGCCTTTA TCCAAAAGAA  
     1021 GACACAGTCA TTGGCGGAAA ATTTCCGATC ACGACGAATG ACAGAATTTC TGTGCTGATT  
     1081 CCGCAGCTTC ATCGTGATCG AGACGCTTGG GGAAAGGACG CAGAAGAGTT CCGGCCGGAA  
     1141 CGGTTTGAGC ATCAGGACCA AGTGCCTCAT CATGCGTACA AACCATTCGG AAATGGACAA  
     1201 CGGGCCTGTA TCGGCATGCA GTTTGCCCTT CATGAAGCCA CACTTGTGTT AGGCATGATT  
     1261 CTAAAATATT TCACATTGAT TGATCATGAG AATTATGAGC TTGATATCAA ACAAACCTTA  
     1321 ACACTTAAGC CGGGCGATTT TCACATCAGT GTTCAAAGCC GTCATCAGGA AGCCATTCAT  
     1381 GCAGACGTCC AGGCAGCTGA AAAAGCCGCG CCTGATGAGC AAAAGGAGAA AACGGAAGCA  
     1441 AAGGGTGCAT CGGTCATCGG TCTTAACAAC CGCCCGCTTC TCGTGCTGTA CGGCTCAGAT  
     1501 ACCGGCACCG CAGAAGGCGT CGCCCGGGAG CTTGCTGATA CTGCCAGTCT TCACGGCGTA  
     1561 AGGACAAAGA CAGCACCTCT GAACGACCGG ATTGGAAAGC TGCCGAAAGA GGGAGCGGTT  
     1621 GTCATTGTGA CCTCGTCTTA TAATGGAAAG CCGCCAAGCA ATGCCGGACA ATTCGTGCAG  
     1681 TGGCTTCAAG AAATCAAACC GGGTGAGCTT GAGGGCGTCC ATTACGCGGT ATTTGGCTGC  
     1741 GGCGACCACA ACTGGGCGAG CACGTATCAA TACGTGCCGA GATTCATTGA TGAGCAGCTT  
     1801 GCGGAGAAAG GCGCGACTCG GTTTTCTGCG CGCGGGGAAG GGGATGTGAG CGGTGATTTT  
     1861 GAAGGGCAGC TTGACGAGTG GAAAAAAAGC ATGTGGGCGG ATGCCATCAA AGCATTCGGA  
     1921 CTTGAGCTTA ATGAAAACGC TGATAAGGAA CGAAGCACGC TGAGCCTTCA GTTTGTCAGA  
     1981 GGGCTGGGCG AGTCTCCGCT CGCTAGATCG TACGAAGCCT CTCACGCATC CATTGCCGAA  
     2041 AATCGTGAAC TCCAGTCCGC AGACAGCGAT CGAAGCACTC GCCATATCGA AATTGCATTG  
     2101 CCGCCGGATG TTGAATATCA AGAGGGCGAC CATCTTGGCG TATTGCCAAA AAACAGCCAA  
     2161 ACCAATGTCA GCCGGATTCT TCACAGATTC GGTCTGAAGG GAACCGACCA AGTGACATTG  
     2221 TCGGCAAGCG GCCGCAGTGC GGGGCATCTG CCATTGGGCC GTCCTGTCAG CCTGCATGAT  
     2281 CTTCTCAGCT ACAGCGTCGA GGTGCAGGAA GCAGCCACAA GAGCGCAAAT ACGTGAACTG  
     2341 GCGTCATTTA CAGTGTGTCC GCCGCATAGG CGCGAATTAG AAGAACTGTC AGCAGAGGGT  
     2401 GTTTATCAGG AGCAAATATT GAAAAAACGA ATTTCCATGC TGGATCTGCT TGAAAAGTAT  
     2461 GAAGCGTGTG ACATGCCGTT TGAACGATTT TTAGAGCTTT TACGGCCGTT AAAACCGAGA  
     2521 TACTATTCGA TTTCAAGCTC TCCAAGAGTG AATCCGCGGC AAGCATCGAT CACAGTCGGT  
     2581 GTCGTGCGCG GCCCGGCGTG GAGCGGCCGT GGCGAATACA GGGGTGTGGC ATCAAATGAT  
     2641 TTAGCTGAGC GTCAAGCCGG TGATGATGTC GTGATGTTTA TCCGCACACC GGAATCCCGG  
     2701 TTTCAGCTTC CGAAAGACCC TGAAACGCCA ATTATTATGG TCGGGCCAGG CACGGGAGTC  
     2761 GCGCCATTTC GCGGTTTCCT TCAAGCCCGC GATGTTTTAA AGCGGGAGGG CAAAACGCTC  
     2821 GGTGAGGCTC ATCTCTATTT TGGATGCAGG AACGATCGGG ATTTTATTTA CCGAGATGAG  
     2881 CTTGAGCGGT TTGAAAAAGA CGGAATCGTC ACTGTCCACA CAGCCTTTTC CCGAAAAGAG  
 238
     2941 GGCATGCCGA AAACATATGT CCAGCATCTC ATGGCTGACC AAGCAGATAC ATTAATATCA  
     3001 ATCCTTGACC GCGGTGGCAG GCTTTATGTA TGCGGTGATG GCAGCAAAAT GGCCCCGGAT  
     3061 GTGGAGGCGG CACTTCAAAA AGCGTATCAG GCTGTCCATG GAACCGGGGA ACAAGAAGCG  
     3121 CAAAACTGGC TGAGACATCT GCAGGATACC GGTATGTACG CTAAGGATGT CTGGGCAGGG  
     3181 ATA 
 
CYP102A3 Holoenzyme 
        1 ATGAAACAGG CAAGCGCAAT ACCTCAGCCC AAAACATACG GACCTTTAAA AAATCTTCCG  
       61 CATCTGGAAA AAGAACAGCT TTCTCAATCC TTATGGCGGA TAGCTGATGA ATTGGGACCG  
      121 ATTTTCCGTT TTGATTTTCC GGGAGTATCC AGTGTTTTTG TGTCCGGCCA CAATCTTGTG  
      181 GCTGAAGTGT GTGATGAAAA ACGCTTTGAC AAGAACCTTG GCAAAGGCTT GCAAAAGGTG  
      241 CGTGAGTTCG GGGGAGATGG CTTATTTACA AGCTGGACGC ACGAACCGAA CTGGCAAAAA  
      301 GCCCACCGCA TTTTGCTGCC GAGTTTTAGT CAAAAAGCGA TGAAAGGCTA TCATTCTATG  
      361 ATGCTGGATA TCGCAACCCA GCTGATTCAA AAGTGGAGCC GGTTAAACCC CAATGAAGAA  
      421 ATTGATGTAG CGGACGATAT GACACGTCTG ACGCTTGATA CGATTGGGTT ATGCGGGTTT  
      481 AACTATCGAT TCAACAGCTT TTACCGTGAT TCACAGCATC CGTTTATCAC CAGTATGCTC  
      541 CGTGCCTTAA AAGAGGCGAT GAATCAATCG AAAAGACTGG GCCTGCAAGA TAAAATGATG  
      601 GTGAAAACGA AGCTGCAGTT CCAAAAGGAT ATAGAAGTCA TGAACTCCCT GGTTGATAGA  
      661 ATGATAGCGG AGCGAAAGGC GAATCCGGAT GAAAACATTA AGGATCTCTT GTCTCTCATG  
      721 CTTTATGCCA AAGATCCAGT AACGGGTGAA ACGCTGGATG ACGAAAACAT TCGATACCAA  
      781 ATCATCACAT TTTTAATTGC TGGACATGAG ACAACAAGCG GGTTGCTATC CTTTGCGATT  
      841 TATTGTCTGC TTACACATCC GGAAAAACTG AAAAAAGCTC AGGAGGAAGC GGATCGCGTG  
      901 TTAACGGATG ACACGCCTGA ATATAAACAA ATCCAGCAGC TCAAATACAT TCGGATGGTT  
      961 TTAAATGAAA CCCTCAGACT GTATCCAACA GCTCCGGCTT TTTCTCTATA TGCGAAGGAG  
     1021 GATACTGTTT TAGGCGGGGA ATATCCGATC AGCAAAGGGC AGCCAGTCAC TGTTTTAATT  
     1081 CCAAAACTGC ACCGGGATCA AAACGCTTGG GGACCGGATG CGGAAGATTT CCGTCCGGAA  
     1141 CGGTTTGAAG ATCCTTCAAG TATCCCTCAC CATGCGTATA AGCCGTTTGG AAACGGACAG  
     1201 CGCGCTTGTA TTGGCATGCA GTTTGCTCTT CAAGAAGCGA CAATGGTTCT CGGTCTTGTA  
     1261 TTAAAGCATT TTGAATTGAT AAACCATACT GGCTACGAAC TAAAAATCAA AGAAGCATTA  
     1321 ACGATCAAGC CGGATGATTT TAAAATTACT GTGAAACCGC GAAAAACAGC GGCAATCAAT  
     1381 GTACAGAGAA AAGAACAGGC AGACATCAAA GCAGAAACAA AGCCAAAAGA AACCAAACCT  
     1441 AAACACGGCA CACCTTTACT TGTTCTTTTT GGTTCAAATC TTGGGACAGC TGAGGGAATA  
     1501 GCCGGTGAAC TGGCTGCTCA AGGCCGCCAG ATGGGCTTTA CAGCTGAAAC GGCTCCGCTT  
     1561 GATGATTATA TCGGCAAGCT CCCTGAAGAA GGGGCAGTCG TCATTGTAAC GGCTTCTTAT  
     1621 AATGGGGCGC CGCCTGATAA TGCTGCCGGA TTTGTAGAGT GGCTGAAAGA GCTTGAGGAA  
     1681 GGCCAATTGA AAGGTGTTTC CTATGCGGTA TTCGGCTGCG GAAACCGGAG CTGGGCCAGC  
     1741 ACGTATCAGC GGATTCCCCG CCTGATTGAT GACATGATGA AAGCAAAGGG GGCATCGCGT  
     1801 TTAACAGCGA TTGGGGAAGG TGACGCCGCC GATGATTTTG AAAGCCACCG CGAGTCTTGG  
     1861 GAAAACCGCT TCTGGAAGGA AACGATGGAC GCATTTGATA TTAACGAAAT AGCCCAGAAA  
     1921 GAAGACAGGC CTTCATTATC GATTACTTTT CTCAGTGAAG CGACGGAAAC GCCGGTTGCT  
     1981 AAAGCATATG GCGCGTTTGA AGGGATTGTG TTAGAGAATC GAGAACTCCA GACAGCTGCC  
     2041 AGCACGCGTT CAACCCGCCA TATTGAATTG GAAATTCCGG CTGGTAAAAC ATATAAAGAA  
     2101 GGCGATCATA TCGGAATCCT GCCAAAGAAC AGCAGGGAGC TTGTTCAGCG GGTTCTCAGC  
     2161 CGATTCGGTT TGCAGTCCAA TCATGTGATA AAAGTAAGCG GAAGCGCTCA TATGGCTCAT  
     2221 CTGCCGATGG ATCGGCCAAT CAAAGTAGTG GATTTATTGT CGTCCTATGT AGAGCTGCAG  
     2281 GAACCGGCAT CAAGGCTTCA GCTTCGGGAG CTGGCCTCTT ATACAGTTTG TCCGCCGCAT  
     2341 CAAAAAGAGC TGGAACAGCT CGTTTCAGAT GATGGCATTT ACAAAGAGCA GGTACTTGCA  
     2401 AAACGTCTTA CCATGCTTGA TTTTTTAGAG GATTATCCTG CTTGCGAAAT GCCGTTTGAA  
     2461 CGGTTTTTAG CACTTTTGCC ATCACTAAAA CCGAGATACT ATTCCATTTC AAGCTCACCG  
     2521 AAAGTTCATG CAAATATCGT GAGCATGACG GTAGGAGTTG TGAAAGCCTC AGCATGGAGC  
     2581 GGCCGAGGTG AATACCGGGG TGTCGCCTCT AATTATTTAG CAGAATTGAA TACAGGTGAT  
     2641 GCAGCAGCTT GCTTCATTCG TACGCCGCAG TCCGGATTTC AGATGCCGAA TGATCCTGAA  
     2701 ACGCCTATGA TTATGGTCGG GCCGGGCACA GGAATTGCGC CATTCAGAGG CTTTATTCAG  
     2761 GCAAGATCGG TTTTGAAGAA GGAAGGAAGC ACCCTTGGTG AAGCACTTTT ATACTTCGGC  
     2821 TGCCGCCGCC CGGACCATGA CGACCTTTAC AGAGAAGAGC TGGATCAAGC GGAACAGGAC  
     2881 GGTTTGGTCA CAATCCGCCG ATGCTACTCG CGCGTCGAAA ACGAACCAAA AGGATATGTC  
     2941 CAGCACTTGC TCAAGCAAGA TACGCAGAAA TTGATGACAC TCATTGAAAA AGGGGCTCAT  
     3001 ATTTACGTAT GCGGTGATGG ATCGCAAATG GCTCCTGATG TAGAGAGAAC TTTGCGATTG  
     3061 GCATATGAAG CTGAAAAAGC AGCAAGTCAG GAAGAATCAG CTGTATGGCT GCAAAAGCTG  
     3121 CAAGATCAAA GACGTTATGT GAAAGACGTT TGGACAGGAA TG 
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CYP102A1 Holoenzyme F87A 
        1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA TTTACCGTTA  
       61 TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG CGGATGAATT AGGAGAAATC  
      121 TTTAAATTCG AGGCGCCTGG TCGTGTAACG CGCTACTTAT CAAGTCAGCG TCTAATTAAA  
      181 GAAGCATGCG ATGAATCACG CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT  
      241 GATTTTGCAG GAGACGGGTT GGCCACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG  
      301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA TGCGATGATG  
      361 GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC TAAATGCAGA TGAGCATATT  
      421 GAAGTACCGG AAGACATGAC ACGTTTAACG CTTGATACAA TTGGTCTTTG CGGCTTTAAC  
      481 TATCGCTTTA ACAGCTTTTA CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT  
      541 GCACTGGATG AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT  
      601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT AGATAAAATT  
      661 ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT TATTAACGCA TATGCTAAAC  
      721 GGAAAAGATC CAGAAACGGG TGAGCCGCTT GATGACGAGA ACATTCGCTA TCAAATTATT  
      781 ACATTCTTAA TTGCGGGACA CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC  
      841 TTAGTGAAAA ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA  
      901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT GGTCTTAAAC  
      961 GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC TATATGCAAA AGAAGATACG  
     1021 GTGCTTGGAG GAGAATATCC TTTAGAAAAA GGCGACGAAC TAATGGTTCT GATTCCTCAG  
     1081 CTTCACCGTG ATAAAACAAT TTGGGGAGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT  
     1141 GAAAATCCAA GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG  
     1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT GATGCTAAAA  
     1261 CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTGGATA TTAAAGAAAC TTTAACGTTA  
     1321 AAACCTGAAG GCTTTGTGGT AAAAGCAAAA TCGAAAAAAA TTCCGCTTGG CGGTATTCCT  
     1381 TCACCTAGCA CTGAACAGTC TGCTAAAAAA GTACGCAAAA AGGCAGAAAA CGCTCATAAT  
     1441 ACGCCGCTGC TTGTGCTATA CGGTTCAAAT ATGGGAACAG CTGAAGGAAC GGCGCGTGAT  
     1501 TTAGCAGATA TTGCAATGAG CAAAGGATTT GCACCGCAGG TCGCAACGCT TGATTCACAC  
     1561 GCCGGAAATC TTCCGCGCGA AGGAGCTGTA TTAATTGTAA CGGCGTCTTA TAACGGTCAT  
     1621 CCGCCTGATA ACGCAAAGCA ATTTGTCGAC TGGTTAGACC AAGCGTCTGC TGATGAAGTA  
     1681 AAAGGCGTTC GCTACTCCGT ATTTGGATGC GGCGATAAAA ACTGGGCTAC TACGTATCAA  
     1741 AAAGTGCCTG CTTTTATCGA TGAAACGCTT GCCGCTAAAG GGGCAGAAAA CATCGCTGAC  
     1801 CGCGGTGAAG CAGATGCAAG CGACGACTTT GAAGGCACAT ATGAAGAATG GCGTGAACAT  
     1861 ATGTGGAGTG ACGTAGCAGC CTACTTTAAC CTCGACATTG AAAACAGTGA AGATAATAAA  
     1921 TCTACTCTTT CACTTCAATT TGTCGACAGC GCCGCGGATA TGCCGCTTGC GAAAATGCAC  
     1981 GGTGCGTTTT CAACGAACGT CGTAGCAAGC AAAGAACTTC AACAGCCAGG CAGTGCACGA  
     2041 AGCACGCGAC ATCTTGAAAT TGAACTTCCA AAAGAAGCTT CTTATCAAGA AGGAGATCAT  
     2101 TTAGGTGTTA TTCCTCGCAA CTATGAAGGA ATAGTAAACC GTGTAACAGC AAGGTTCGGC  
     2161 CTAGATGCAT CACAGCAAAT CCGTCTGGAA GCAGAAGAAG AAAAATTAGC TCATTTGCCA  
     2221 CTCGCTAAAA CAGTATCCGT AGAAGAGCTT CTGCAATACG TGGAGCTTCA AGATCCTGTT  
     2281 ACGCGCACGC AGCTTCGCGC AATGGCTGCT AAAACGGTCT GCCCGCCGCA TAAAGTAGAG  
     2341 CTTGAAGCCT TGCTTGAAAA GCAAGCCTAC AAAGAACAAG TGCTGGCAAA ACGTTTAACA  
     2401 ATGCTTGAAC TGCTTGAAAA ATACCCGGCG TGTGAAATGA AATTCAGCGA ATTTATCGCC  
     2461 CTTCTGCCAA GCATACGCCC GCGCTATTAC TCGATTTCTT CATCACCTCG TGTCGATGAA  
     2521 AAACAAGCAA GCATCACGGT CAGCGTTGTC TCAGGAGAAG CGTGGAGCGG ATATGGAGAA  
     2581 TATAAAGGAA TTGCGTCGAA CTATCTTGCC GAGCTGCAAG AAGGAGATAC GATTACGTGC  
     2641 TTTATTTCCA CACCGCAGTC AGAATTTACG CTGCCAAAAG ACCCTGAAAC GCCGCTTATC  
     2701 ATGGTCGGAC CGGGAACAGG CGTCGCGCCG TTTAGAGGCT TTGTGCAGGC GCGCAAACAG  
     2761 CTAAAAGAAC AAGGACAGTC ACTTGGAGAA GCACATTTAT ACTTCGGCTG CCGTTCACCT  
     2821 CATGAAGACT ATCTGTATCA AGAAGAGCTT GAAAACGCCC AAAGCGAAGG CATCATTACG  
     2881 CTTCATACCG CTTTTTCTCG CATGCCAAAT CAGCCGAAAA CATACGTTCA GCACGTAATG  
     2941 GAACAAGACG GCAAGAAATT GATTGAACTT CTTGATCAAG GAGCGCACTT CTATATTTGC  
     3001 GGAGACGGAA GCCAAATGGC ACCTGCCGTT GAAGCAACGC TTATGAAAAG CTATGCTGAC  
     3061 GTTCACCAAG TGAGTGAAGC AGACGCTCGC TTATGGCTGC AGCAGCTAGA AGAAAAAGGC  
     3121 CGATACGCAA AAGACGTGTG GGCTGGGCAT CATCATCATC ATCAT 
 
CYP102A2 Holoenzyme F88A 
        1 ATGAAGGAAA CAAGCCCGAT TCCTCAGCCG AAGACGTTTG GGCCGCTCGG CAATTTGCCT  
       61 TTAATTGATA AAGACAAACC GACGCTTTCG CTGATCAAAC TGGCGGAAGA ACAGGGCCCG  
      121 ATTTTTCAAA TCCATACACC CGCGGGCACG ACCATTGTAG TGTCCGGCCA TGAATTGGTG  
      181 AAAGAGGTTT GTGATGAAGA ACGGTTTGAT AAAAGCATTG AAGGCGCCTT GGAAAAGGTT  
      241 CGCGCATTTT CCGGTGACGG ATTGGCCACT AGTTGGACGC ATGAGCCTAA CTGGAGAAAA  
      301 GCGCACAACA TTCTGATGCC GACGTTCAGC CAGCGGGCCA TGAAGGACTA TCATGAGAAA  
 240
      361 ATGGTCGATA TCGCTGTTCA GCTCATTCAA AAATGGGCAA GGCTCAACCC GAATGAAGCA  
      421 GTCGATGTCC CGGGAGATAT GACCCGGCTG ACGCTCGACA CCATTGGGCT ATGCGGGTTT  
      481 AACTACCGCT TTAACAGTTA CTACAGAGAA ACGCCCCACC CGTTTATCAA CAGCATGGTG  
      541 CGGGCGCTTG ATGAAGCGAT GCATCAAATG CAGCGGCTTG ATGTTCAAGA TAAGCTTATG  
      601 GTCAGAACAA AGCGGCAATT CCGCTATGAT ATTCAAACGA TGTTTTCGTT AGTCGACAGC  
      661 ATTATTGCAG AGCGCAGGGC GAATGGAGAC CAGGATGAAA AAGATTTGCT CGCCCGCATG  
      721 CTGAATGTGG AAGATCCGGA AACTGGTGAA AAGCTCGACG ACGAAAATAT CCGCTTTCAG  
      781 ATCATCACGT TTTTGATTGC CGGCCATGAA ACAACGAGCG GCCTGCTTTC CTTTGCGACT  
      841 TACTTTTTAT TGAAGCATCC TGACAAACTG AAAAAGGCGT ATGAAGAGGT CGATCGGGTG  
      901 CTGACGGATG CAGCGCCGAC CTATAAACAA GTGCTGGAGC TTACATACAT ACGGATGATT  
      961 TTAAATGAAT CACTGCGCTT ATGGCCGACA GCTCCGGCTT TCAGCCTTTA TCCAAAAGAA  
     1021 GACACAGTCA TTGGCGGAAA ATTTCCGATC ACGACGAATG ACAGAATTTC TGTGCTGATT  
     1081 CCGCAGCTTC ATCGTGATCG AGACGCTTGG GGAAAGGACG CAGAAGAGTT CCGGCCGGAA  
     1141 CGGTTTGAGC ATCAGGACCA AGTGCCTCAT CATGCGTACA AACCATTCGG AAATGGACAA  
     1201 CGGGCCTGTA TCGGCATGCA GTTTGCCCTT CATGAAGCCA CACTTGTGTT AGGCATGATT  
     1261 CTAAAATATT TCACATTGAT TGATCATGAG AATTATGAGC TTGATATCAA ACAAACCTTA  
     1321 ACACTTAAGC CGGGCGATTT TCACATCAGT GTTCAAAGCC GTCATCAGGA AGCCATTCAT  
     1381 GCAGACGTCC AGGCAGCTGA AAAAGCCGCG CCTGATGAGC AAAAGGAGAA AACGGAAGCA  
     1441 AAGGGTGCAT CGGTCATCGG TCTTAACAAC CGCCCGCTTC TCGTGCTGTA CGGCTCAGAT  
     1501 ACCGGCACCG CAGAAGGCGT CGCCCGGGAG CTTGCTGATA CTGCCAGTCT TCACGGCGTA  
     1561 AGGACAAAGA CAGCACCTCT GAACGACCGG ATTGGAAAGC TGCCGAAAGA GGGAGCGGTT  
     1621 GTCATTGTGA CCTCGTCTTA TAATGGAAAG CCGCCAAGCA ATGCCGGACA ATTCGTGCAG  
     1681 TGGCTTCAAG AAATCAAACC GGGTGAGCTT GAGGGCGTCC ATTACGCGGT ATTTGGCTGC  
     1741 GGCGACCACA ACTGGGCGAG CACGTATCAA TACGTGCCGA GATTCATTGA TGAGCAGCTT  
     1801 GCGGAGAAAG GCGCGACTCG GTTTTCTGCG CGCGGGGAAG GGGATGTGAG CGGTGATTTT  
     1861 GAAGGGCAGC TTGACGAGTG GAAAAAAAGC ATGTGGGCGG ATGCCATCAA AGCATTCGGA  
     1921 CTTGAGCTTA ATGAAAACGC TGATAAGGAA CGAAGCACGC TGAGCCTTCA GTTTGTCAGA  
     1981 GGGCTGGGCG AGTCTCCGCT CGCTAGATCG TACGAAGCCT CTCACGCATC CATTGCCGAA  
     2041 AATCGTGAAC TCCAGTCCGC AGACAGCGAT CGAAGCACTC GCCATATCGA AATTGCATTG  
     2101 CCGCCGGATG TTGAATATCA AGAGGGCGAC CATCTTGGCG TATTGCCAAA AAACAGCCAA  
     2161 ACCAATGTCA GCCGGATTCT TCACAGATTC GGTCTGAAGG GAACCGACCA AGTGACATTG  
     2221 TCGGCAAGCG GCCGCAGTGC GGGGCATCTG CCATTGGGCC GTCCTGTCAG CCTGCATGAT  
     2281 CTTCTCAGCT ACAGCGTCGA GGTGCAGGAA GCAGCCACAA GAGCGCAAAT ACGTGAACTG  
     2341 GCGTCATTTA CAGTGTGTCC GCCGCATAGG CGCGAATTAG AAGAACTGTC AGCAGAGGGT  
     2401 GTTTATCAGG AGCAAATATT GAAAAAACGA ATTTCCATGC TGGATCTGCT TGAAAAGTAT  
     2461 GAAGCGTGTG ACATGCCGTT TGAACGATTT TTAGAGCTTT TACGGCCGTT AAAACCGAGA  
     2521 TACTATTCGA TTTCAAGCTC TCCAAGAGTG AATCCGCGGC AAGCATCGAT CACAGTCGGT  
     2581 GTCGTGCGCG GCCCGGCGTG GAGCGGCCGT GGCGAATACA GGGGTGTGGC ATCAAATGAT  
     2641 TTAGCTGAGC GTCAAGCCGG TGATGATGTC GTGATGTTTA TCCGCACACC GGAATCCCGG  
     2701 TTTCAGCTTC CGAAAGACCC TGAAACGCCA ATTATTATGG TCGGGCCAGG CACGGGAGTC  
     2761 GCGCCATTTC GCGGTTTCCT TCAAGCCCGC GATGTTTTAA AGCGGGAGGG CAAAACGCTC  
     2821 GGTGAGGCTC ATCTCTATTT TGGATGCAGG AACGATCGGG ATTTTATTTA CCGAGATGAG  
     2881 CTTGAGCGGT TTGAAAAAGA CGGAATCGTC ACTGTCCACA CAGCCTTTTC CCGAAAAGAG  
     2941 GGCATGCCGA AAACATATGT CCAGCATCTC ATGGCTGACC AAGCAGATAC ATTAATATCA  
     3001 ATCCTTGACC GCGGTGGCAG GCTTTATGTA TGCGGTGATG GCAGCAAAAT GGCCCCGGAT  
     3061 GTGGAGGCGG CACTTCAAAA AGCGTATCAG GCTGTCCATG GAACCGGGGA ACAAGAAGCG  
     3121 CAAAACTGGC TGAGACATCT GCAGGATACC GGTATGTACG CTAAGGATGT CTGGGCAGGG  
     3181 ATA 
 
CYP102A3 Holoenzyme F88A 
        1 ATGAAACAGG CAAGCGCAAT ACCTCAGCCC AAAACATACG GACCTTTAAA AAATCTTCCG  
       61 CATCTGGAAA AAGAACAGCT TTCTCAATCC TTATGGCGGA TAGCTGATGA ATTGGGACCG  
      121 ATTTTCCGTT TTGATTTTCC GGGAGTATCC AGTGTTTTTG TGTCCGGCCA CAATCTTGTG  
      181 GCTGAAGTGT GTGATGAAAA ACGCTTTGAC AAGAACCTTG GCAAAGGCTT GCAAAAGGTG  
      241 CGTGAGTTCG GGGGAGATGG CTTAGCCACT AGTTGGACGC ACGAACCGAA CTGGCAAAAA  
      301 GCCCACCGCA TTTTGCTGCC GAGTTTTAGT CAAAAAGCGA TGAAAGGCTA TCATTCTATG  
      361 ATGCTGGATA TCGCAACCCA GCTGATTCAA AAGTGGAGCC GGTTAAACCC CAATGAAGAA  
      421 ATTGATGTAG CGGACGATAT GACACGTCTG ACGCTTGATA CGATTGGGTT ATGCGGGTTT  
      481 AACTATCGAT TCAACAGCTT TTACCGTGAT TCACAGCATC CGTTTATCAC CAGTATGCTC  
      541 CGTGCCTTAA AAGAGGCGAT GAATCAATCG AAAAGACTGG GCCTGCAAGA TAAAATGATG  
      601 GTGAAAACGA AGCTGCAGTT CCAAAAGGAT ATAGAAGTCA TGAACTCCCT GGTTGATAGA  
      661 ATGATAGCGG AGCGAAAGGC GAATCCGGAT GAAAACATTA AGGATCTCTT GTCTCTCATG  
      721 CTTTATGCCA AAGATCCAGT AACGGGTGAA ACGCTGGATG ACGAAAACAT TCGATACCAA  
 241
      781 ATCATCACAT TTTTAATTGC TGGACATGAG ACAACAAGCG GGTTGCTATC CTTTGCGATT  
      841 TATTGTCTGC TTACACATCC GGAAAAACTG AAAAAAGCTC AGGAGGAAGC GGATCGCGTG  
      901 TTAACGGATG ACACGCCTGA ATATAAACAA ATCCAGCAGC TCAAATACAT TCGGATGGTT  
      961 TTAAATGAAA CCCTCAGACT GTATCCAACA GCTCCGGCTT TTTCTCTATA TGCGAAGGAG  
     1021 GATACTGTTC TTGGCGGGGA ATATCCGATC AGCAAAGGGC AGCCAGTCAC TGTTTTAATT  
     1081 CCAAAACTGC ACCGGGATCA AAACGCTTGG GGACCGGATG CGGAAGATTT CCGTCCGGAA  
     1141 CGGTTTGAAG ATCCTTCAAG TATCCCTCAC CATGCGTATA AGCCGTTTGG AAACGGACAG  
     1201 CGCGCTTGTA TTGGCATGCA GTTTGCTCTT CAAGAAGCGA CAATGGTTCT CGGTCTTGTA  
     1261 TTAAAGCATT TTGAATTGAT AAACCATACT GGCTACGAAC TAAAAATCAA AGAAGCATTA  
     1321 ACGATCAAGC CGGATGATTT TAAAATTACT GTGAAACCGC GAAAAACAGC GGCAATCAAT  
     1381 GTACAGAGAA AAGAACAGGC AGACATCAAA GCAGAAACAA AGCCAAAAGA AACCAAACCT  
     1441 AAACACGGCA CACCTTTACT TGTTCTTTTT GGTTCAAATC TTGGGACAGC TGAGGGAATA  
     1501 GCCGGTGAAC TGGCTGCTCA AGGCCGCCAG ATGGGCTTTA CAGCTGAAAC GGCTCCGCTT  
     1561 GATGATTATA TCGGCAAGCT CCCTGAAGAA GGGGCAGTCG TCATTGTAAC GGCTTCTTAT  
     1621 AATGGGGCGC CGCCTGATAA TGCTGCCGGA TTTGTAGAGT GGCTGAAAGA GCTTGAGGAA  
     1681 GGCCAATTGA AAGGTGTTTC CTATGCGGTA TTCGGCTGCG GAAACCGGAG CTGGGCCAGC  
     1741 ACGTATCAGC GGATTCCCCG CCTGATTGAT GACATGATGA AAGCAAAGGG GGCATCGCGT  
     1801 TTAACAGCGA TTGGGGAAGG TGACGCCGCC GATGATTTTG AAAGCCACCG CGAGTCTTGG  
     1861 GAAAACCGCT TCTGGAAGGA AACGATGGAC GCATTTGATA TTAACGAAAT AGCCCAGAAA  
     1921 GAAGACAGGC CTTCATTATC GATTACTTTT CTCAGTGAAG CGACGGAAAC GCCGGTTGCT  
     1981 AAAGCATATG GCGCGTTTGA AGGGATTGTG TTAGAGAATC GAGAACTCCA GACAGCTGCC  
     2041 AGCACGCGTT CAACCCGCCA TATTGAATTG GAAATTCCGG CTGGTAAAAC ATATAAAGAA  
     2101 GGCGATCATA TCGGAATCCT GCCAAAGAAC AGCAGGGAGC TTGTTCAGCG GGTTCTCAGC  
     2161 CGATTCGGTT TGCAGTCCAA TCATGTGATA AAAGTAAGCG GAAGCGCTCA TATGGCTCAT  
     2221 CTGCCGATGG ATCGGCCAAT CAAAGTAGTG GATTTATTGT CGTCCTATGT AGAGCTGCAG  
     2281 GAACCGGCAT CAAGGCTTCA GCTTCGGGAG CTGGCCTCTT ATACAGTTTG TCCGCCGCAT  
     2341 CAAAAAGAGC TGGAACAGCT CGTTTCAGAT GATGGCATTT ACAAAGAGCA GGTACTTGCA  
     2401 AAACGTCTTA CCATGCTTGA TTTTTTAGAG GATTATCCTG CTTGCGAAAT GCCGTTTGAA  
     2461 CGGTTTTTAG CACTTTTGCC ATCACTAAAA CCGAGATACT ATTCCATTTC AAGCTCACCG  
     2521 AAAGTTCATG CAAATATCGT GAGCATGACG GTAGGAGTTG TGAAAGCCTC AGCATGGAGC  
     2581 GGCCGAGGTG AATACCGGGG TGTCGCCTCT AATTATTTAG CAGAATTGAA TACAGGTGAT  
     2641 GCAGCAGCTT GCTTCATTCG TACGCCGCAG TCCGGATTTC AGATGCCGAA TGATCCTGAA  
     2701 ACGCCTATGA TTATGGTCGG GCCGGGCACA GGAATTGCGC CATTCAGAGG CTTTATTCAG  
     2761 GCAAGATCGG TTTTGAAGAA GGAAGGAAGC ACCCTTGGTG AAGCACTTTT ATACTTCGGC  
     2821 TGCCGCCGCC CGGACCATGA CGACCTTTAC AGAGAAGAGC TGGATCAAGC GGAACAGGAC  
     2881 GGTTTGGTCA CAATCCGCCG ATGCTACTCG CGCGTCGAAA ACGAACCAAA AGGATATGTC  
     2941 CAGCACTTGC TCAAGCAAGA TACGCAGAAA TTGATGACAC TCATTGAAAA AGGGGCTCAT  
     3001 ATTTACGTAT GCGGTGATGG ATCGCAAATG GCTCCTGATG TAGAGAGAAC TTTGCGATTG  
     3061 GCATATGAAG CTGAAAAAGC AGCAAGTCAG GAAGAATCAG CTGTATGGCT GCAAAAGCTG  
     3121 CAAGATCAAA GACGTTATGT GAAAGACGTT TGGACAGGAA TG 
 
 
 
 
Amino acid sequences 
Methionine in sequence is cleaved and is not included in standard numbering of 
CYP102A1.   
 
 
CYP102A1 Heme F87A 
            1 TIKEMPQPKT FGELKNLPLL NTDKPVQALM KIADELGEIF KFEAPGRVTR YLSSQRLIKE  
       61 ACDESRFDKN LSQALKFVRD FAGDGLATSW THEKNWKKAH NILLPSFSQQ AMKGYHAMMV  
      121 DIAVQLVQKW ERLNADEHIE VPEDMTRLTL DTIGLCGFNY RFNSFYRDQP HPFITSMVRA  
      181 LDEAMNKLQR ANPDDPAYDE NKRQFQEDIK VMNDLVDKII ADRKASGEQS DDLLTHMLNG  
      241 KDPETGEPLD DENIRYQIIT FLIAGHETTS GLLSFALYFL VKNPHVLQKA AEEAARVLVD  
      301 PVPSYKQVKQ LKYVGMVLNE ALRLWPTAPA FSLYAKEDTV LGGEYPLEKG DELMVLIPQL  
      361 HRDKTIWGDD VEEFRPERFE NPSAIPQHAF KPFGNGQRAC IGQQFALHEA TLVLGMMLKH  
      421 FDFEDHTNYE LDIKETLTLK PEGFVVKAKS KKIPLGGIPS PST 
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CYP102A2 Heme F88A 
      1 KETSPIPQP KTFGPLGNLP LIDKDKPTLS LIKLAEEQGP IFQIHTPAGT TIVVSGHELVK  
       61 EVCDEERFD KSIEGALEKV RAFSGDGLAT SWTHEPNWRK AHNILMPTFS QRAMKDYHEKM  
      121 VDIAVQLIQ KWARLNPNEA VDVPGDMTRL TLDTIGLCGF NYRFNSYYRE TPHPFINSMVR  
      181 ALDEAMHQM QRLDVQDKLM VRTKRQFRYD IQTMFSLVDS IIAERRANGD QDEKDLLARML  
      241 NVEDPETGE KLDDENIRFQ IITFLIAGHE TTSGLLSFAT YFLLKHPDKL KKAYEEVDRVL  
      301 TDAAPTYKQ VLELTYIRMI LNESLRLWPT APAFSLYPKE DTVIGGKFPI TTNDRISVLIP  
      361 QLHRDRDAW GKDAEEFRPE RFEHQDQVPH HAYKPFGNGQ RACIGMQFAL HEATLVLGMIL  
      421 KYFTLIDHE NYELDIKQTL TLKPGDFHIS VQSRHQEAIH ADVQAAE 
 
CYP102A3 Heme F88A 
        1 KQASAIPQPK TYGPLKNLPH LEKEQLSQSL WRIADELGPI FRFDFPGVSS VFVSGHNLVA  
       61 EVCDEKRFDK NLGKGLQKVR EFGGDGLATS WTHEPNWQKA HRILLPSFSQ KAMKGYHSMM  
      121 LDIATQLIQK WSRLNPNEEI DVADDMTRLT LDTIGLCGFN YRFNSFYRDS QHPFITSMLR  
      181 ALKEAMNQSK RLGLQDKMMV KTKLQFQKDI EVMNSLVDRM IAERKANPDE NIKDLLSLML  
      241 YAKDPVTGET LDDENIRYQI ITFLIAGHET TSGLLSFAIY CLLTHPEKLK KAQEEADRVL  
      301 TDDTPEYKQI QQLKYIRMVL NETLRLYPTA PAFSLYAKED TVLGGEYPIS KGQPVTVLIP  
      361 KLHRDQNAWG PDAEDFRPER FEDPSSIPHH AYKPFGNGQR ACIGMQFALQ EATMVLGLVL  
      421 KHFELINHTG YELKIKEALT IKPDDFKITV KPRKTAAINV QRKEQA 
 
CYP102A1 Holoenzyme F87A 
        1 TIKEMPQPKT FGELKNLPLL NTDKPVQALM KIADELGEIF KFEAPGRVTR YLSSQRLIKE  
       61 ACDESRFDKN LSQALKFVRD FAGDGLATSW THEKNWKKAH NILLPSFSQQ AMKGYHAMMV  
      121 DIAVQLVQKW ERLNADEHIE VPEDMTRLTL DTIGLCGFNY RFNSFYRDQP HPFITSMVRA  
      181 LDEAMNKLQR ANPDDPAYDE NKRQFQEDIK VMNDLVDKII ADRKASGEQS DDLLTHMLNG  
      241 KDPETGEPLD DENIRYQIIT FLIAGHETTS GLLSFALYFL VKNPHVLQKA AEEAARVLVD  
      301 PVPSYKQVKQ LKYVGMVLNE ALRLWPTAPA FSLYAKEDTV LGGEYPLEKG DELMVLIPQL  
      361 HRDKTIWGDD VEEFRPERFE NPSAIPQHAF KPFGNGQRAC IGQQFALHEA TLVLGMMLKH  
      421 FDFEDHTNYE LDIKETLTLK PEGFVVKAKS KKIPLGGIPS PSTEQSAKKV RKKAENAHNT  
      481 PLLVLYGSNM GTAEGTARDL ADIAMSKGFA PQVATLDSHA GNLPREGAVL IVTASYNGHP  
      541 PDNAKQFVDW LDQASADEVK GVRYSVFGCG DKNWATTYQK VPAFIDETLA AKGAENIADR  
      601 GEADASDDFE GTYEEWREHM WSDVAAYFNL DIENSEDNKS TLSLQFVDSA ADMPLAKMHG  
      661 AFSTNVVASK ELQQPGSARS TRHLEIELPK EASYQEGDHL GVIPRNYEGI VNRVTARFGL  
      721 DASQQIRLEA EEEKLAHLPL AKTVSVEELL QYVELQDPVT RTQLRAMAAK TVCPPHKVEL  
      781 EALLEKQAYK EQVLAKRLTM LELLEKYPAC EMKFSEFIAL LPSIRPRYYS ISSSPRVDEK  
      841 QASITVSVVS GEAWSGYGEY KGIASNYLAE LQEGDTITCF ISTPQSEFTL PKDPETPLIM  
      901 VGPGTGVAPF RGFVQARKQL KEQGQSLGEA HLYFGCRSPH EDYLYQEELE NAQSEGIITL  
      961 HTAFSRMPNQ PKTYVQHVME QDGKKLIELL DQGAHFYICG DGSQMAPAVE ATLMKSYADV  
     1021 HQVSEADARL WLQQLEEKGR YAKDVWA 
 
CYP102A2 Holoenzyme F88A 
        1 KETSPIPQPK TFGPLGNLPL IDKDKPTLSL IKLAEEQGPI FQIHTPAGTT IVVSGHELVK  
       61 EVCDEERFDK SIEGALEKVR AFSGDGLATS WTHEPNWRKA HNILMPTFSQ RAMKDYHEKM  
      121 VDIAVQLIQK WARLNPNEAV DVPGDMTRLT LDTIGLCGFN YRFNSYYRET PHPFINSMVR  
      181 ALDEAMHQMQ RLDVQDKLMV RTKRQFRYDI QTMFSLVDSI IAERRANGDQ DEKDLLARML  
      241 NVEDPETGEK LDDENIRFQI ITFLIAGHET TSGLLSFATY FLLKHPDKLK KAYEEVDRVL  
      301 TDAAPTYKQV LELTYIRMIL NESLRLWPTA PAFSLYPKED TVIGGKFPIT TNDRISVLIP  
      361 QLHRDRDAWG KDAEEFRPER FEHQDQVPHH AYKPFGNGQR ACIGMQFALH EATLVLGMIL  
      421 KYFTLIDHEN YELDIKQTLT LKPGDFHISV QSRHQEAIHA DVQAAEKAAP DEQKEKTEAK  
      481 GASVIGLNNR PLLVLYGSDT GTAEGVAREL ADTASLHGVR TKTAPLNDRI GKLPKEGAVV  
      541 IVTSSYNGKP PSNAGQFVQW LQEIKPGELE GVHYAVFGCG DHNWASTYQY VPRFIDEQLA  
      601 EKGATRFSAR GEGDVSGDFE GQLDEWKKSM WADAIKAFGL ELNENADKER STLSLQFVRG  
      661 LGESPLARSY EASHASIAEN RELQSADSDR STRHIEIALP PDVEYQEGDH LGVLPKNSQT  
      721 NVSRILHRFG LKGTDQVTLS ASGRSAGHLP LGRPVSLHDL LSYSVEVQEA ATRAQIRELA  
      781 SFTVCPPHRR ELEELSAEGV YQEQILKKRI SMLDLLEKYE ACDMPFERFL ELLRPLKPRY  
      841 YSISSSPRVN PRQASITVGV VRGPAWSGRG EYRGVASNDL AERQAGDDVV MFIRTPESRF  
      901 QLPKDPETPI IMVGPGTGVA PFRGFLQARD VLKREGKTLG EAHLYFGCRN DRDFIYRDEL  
      961 ERFEKDGIVT VHTAFSRKEG MPKTYVQHLM ADQADTLISI LDRGGRLYVC GDGSKMAPDV  
     1021 EAALQKAYQA VHGTGEQEAQ NWLRHLQDTG MYAKDVWAG 
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CYP102A3 Holoenzyme F88A 
        1 KQASAIPQPK TYGPLKNLPH LEKEQLSQSL WRIADELGPI FRFDFPGVSS VFVSGHNLVA  
       61 EVCDEKRFDK NLGKGLQKVR EFGGDGLATS WTHEPNWQKA HRILLPSFSQ KAMKGYHSMM  
      121 LDIATQLIQK WSRLNPNEEI DVADDMTRLT LDTIGLCGFN YRFNSFYRDS QHPFITSMLR  
      181 ALKEAMNQSK RLGLQDKMMV KTKLQFQKDI EVMNSLVDRM IAERKANPDE NIKDLLSLML  
      241 YAKDPVTGET LDDENIRYQI ITFLIAGHET TSGLLSFAIY CLLTHPEKLK KAQEEADRVL  
      301 TDDTPEYKQI QQLKYIRMVL NETLRLYPTA PAFSLYAKED TVLGGEYPIS KGQPVTVLIP  
      361 KLHRDQNAWG PDAEDFRPER FEDPSSIPHH AYKPFGNGQR ACIGMQFALQ EATMVLGLVL  
      421 KHFELINHTG YELKIKEALT IKPDDFKITV KPRKTAAINV QRKEQADIKA ETKPKETKPK  
      481 HGTPLLVLFG SNLGTAEGIA GELAAQGRQM GFTAETAPLD DYIGKLPEEG AVVIVTASYN  
      541 GAPPDNAAGF VEWLKELEEG QLKGVSYAVF GCGNRSWAST YQRIPRLIDD MMKAKGASRL  
      601 TAIGEGDAAD DFESHRESWE NRFWKETMDA FDINEIAQKE DRPSLSITFL SEATETPVAK  
      661 AYGAFEGIVL ENRELQTAAS TRSTRHIELE IPAGKTYKEG DHIGILPKNS RELVQRVLSR  
      721 FGLQSNHVIK VSGSAHMAHL PMDRPIKVVD LLSSYVELQE PASRLQLREL ASYTVCPPHQ  
      781 KELEQLVSDD GIYKEQVLAK RLTMLDFLED YPACEMPFER FLALLPSLKP RYYSISSSPK  
      841 VHANIVSMTV GVVKASAWSG RGEYRGVASN YLAELNTGDA AACFIRTPQS GFQMPNDPET  
      901 PMIMVGPGTG IAPFRGFIQA RSVLKKEGST LGEALLYFGC RRPDHDDLYR EELDQAEQDG  
      961 LVTIRRCYSR VENEPKGYVQ HLLKQDTQKL MTLIEKGAHI YVCGDGSQMA PDVERTLRLA  
     1021 YEAEKAASQE ESAVWLQKLQ DQRRYVKDVW TGM 
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Appendix B 
Data set for Chapter 5 
 
Table B.1.  955 chimeric and parent P450 heme domain sequences with their folding 
state, 12-pNCA activity state and number of sequence changes. 
 
 
 
Folding 
State2 
12-pNCA 
activity3 m4  Sequence1 
Folding 
State2 
12-pNCA 
activity3 m4 
11111111 1 1 0  31233233 1 -- 37 
11112212 1 1 62  31233333 1 -- 21 
11113233 1 -- 86  31311231 1 1 81 
11113311 1 1 36  31311233 1 0 67 
11131313 1 -- 73  31311332 1 1 80 
11133231 1 -- 75  31312113 1 1 88 
11212112 1 1 51  31312133 1 1 70 
11212333 1 1 91  31312212 1 0 100 
11213133 1 -- 75  31312222 1 -- 76 
11213231 1 1 63  31312231 1 -- 95 
11232111 1 -- 44  31312233 1 1 66 
11232232 1 -- 91  31312323 1 1 71 
11232333 1 -- 70  31312332 1 1 79 
11311233 1 1 79  31312333 1 1 50 
11312233 1 1 93  31313111 1 -- 59 
11313233 1 1 85  31313131 1 1 77 
11313333 1 1 69  31313132 1 1 84 
11331312 1 0 78  31313133 1 -- 55 
11331333 1 0 64  31313223 1 -- 72 
11332212 1 0 92  31313232 1 1 80 
11332233 1 0 79  31313233 1 -- 51 
11332333 1 -- 63  31313333 1 1 35 
11333212 1 0 94  31331331 1 -- 62 
12112333 1 1 97  31331333 1 0 30 
12113221 1 1 77  31332131 1 0 81 
12211232 1 1 91  31332133 1 -- 49 
12211333 1 1 96  31332232 1 0 74 
12212112 1 -- 68  31332233 1 0 45 
12212211 1 1 60  31332312 1 -- 76 
12212212 1 1 80  31332322 1 -- 79 
12212332 1 1 93  31332323 1 -- 50 
12213212 1 1 90  31332333 1 -- 29 
12232111 1 1 61  31333233 1 0 30 
12232112 1 -- 89  31333322 1 -- 64 
12232232 1 0 74  31333332 1 0 43 
12232233 1 0 90  31333333 1 0 14 
12232332 1 0 90  32111333 1 1 64 
12233212 1 0 92  32112212 1 -- 85 
12313331 1 1 80  32112321 1 -- 105 
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12322333 1 1 86  32113131 1 0 85 
12331123 1 -- 103  32113232 1 1 93 
12331333 1 1 68  32113233 1 1 64 
12332223 1 -- 89  32131133 1 -- 63 
12332233 1 1 83  32132232 1 0 79 
12332333 1 -- 67  32132233 1 -- 58 
12333331 1 -- 84  32132331 1 0 74 
12333333 1 1 52  32133111 1 -- 88 
13113311 1 0 50  32133232 1 -- 72 
13213131 1 -- 57  32133233 1 -- 43 
13222212 1 -- 76  32133331 1 -- 59 
13233212 1 0 104  32211323 1 0 83 
13332333 1 0 49  32212133 1 0 81 
13333122 1 -- 104  32212231 1 0 101 
13333131 1 -- 78  32212232 1 0 73 
13333211 1 0 80  32212233 1 1 77 
21111321 1 0 78  32212321 1 0 96 
21111323 1 0 107  32212323 1 1 82 
21111333 1 0 90  32212332 1 0 89 
21112122 1 1 68  32212333 1 1 61 
21112123 1 0 97  32213123 1 -- 87 
21112132 1 1 89  32213132 1 -- 95 
21112212 1 1 72  32213231 1 0 94 
21112222 1 1 48  32213333 1 1 46 
21112232 1 1 69  32232131 1 -- 92 
21112311 1 0 68  32232322 1 -- 65 
21112312 1 1 88  32232331 1 -- 72 
21112322 1 1 64  32232333 1 -- 40 
21112332 1 1 85  32233222 1 -- 64 
21113111 1 0 50  32233332 1 -- 54 
21113112 1 1 78  32311131 1 -- 78 
21113122 1 1 83  32311323 1 1 76 
21113133 1 1 94  32312212 1 -- 83 
21113211 1 0 70  32312231 1 1 102 
21113212 1 1 87  32312233 1 -- 70 
21113221 1 -- 91  32312311 1 -- 94 
21113223 1 0 92  32312322 1 1 75 
21113312 1 1 98  32312323 1 -- 75 
21113322 1 1 79  32312331 1 -- 86 
21131121 1 0 79  32312332 1 -- 83 
21132112 1 1 89  32312333 1 1 54 
21132113 1 0 101  32313133 1 -- 59 
21132212 1 1 69  32313231 1 0 87 
21132222 1 0 45  32313232 1 0 84 
21132311 1 0 89  32313233 1 1 55 
21132313 1 -- 86  32313313 1 -- 57 
21132321 1 0 89  32313332 1 -- 68 
21132323 1 0 89  32313333 1 1 39 
21133112 1 1 99  32332133 1 0 53 
21133113 1 0 91  32332223 1 -- 70 
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21133131 1 -- 89  32332231 1 0 81 
21133211 1 0 91  32332232 1 0 77 
21133222 1 1 60  32332322 1 0 72 
21133223 1 -- 89  32332323 1 0 54 
21133232 1 1 81  32332331 1 0 65 
21133233 1 0 69  32332332 1 0 62 
21133312 1 1 100  32332333 1 1 33 
21133313 1 0 71  32333223 1 -- 55 
21133321 1 -- 104  32333232 1 1 63 
21133322 1 -- 76  32333233 1 -- 34 
21133331 1 0 85  32333312 1 -- 65 
21133332 1 0 82  32333323 1 0 39 
21211223 1 0 82  32333333 1 -- 18 
21211321 1 -- 87  33113111 1 -- 64 
21212111 1 0 57  33113211 1 0 84 
21212112 1 1 83  33113212 1 -- 93 
21212122 1 -- 59  33113233 1 -- 46 
21212123 1 0 88  33131333 1 -- 25 
21212133 1 1 107  33133131 1 -- 61 
21212212 1 1 63  33133333 1 -- 9 
21212213 1 0 92  33212213 1 1 77 
21212231 1 0 88  33212311 1 -- 91 
21212321 1 0 83  33212333 1 0 43 
21212332 1 1 76  33213211 1 -- 93 
21212333 1 0 87  33213232 1 -- 73 
21213121 1 0 83  33213333 1 0 28 
21213212 1 1 78  33232233 1 -- 38 
21213223 1 0 83  33232312 1 -- 69 
21213231 1 0 97  33232333 1 -- 22 
21213321 1 0 98  33233131 1 -- 59 
21213332 1 1 91  33233233 1 -- 23 
21222112 1 0 61  33233333 1 -- 7 
21231233 1 0 83  33311231 1 -- 85 
21232112 1 0 80  33312133 1 0 56 
21232122 1 -- 56  33312322 1 -- 86 
21232132 1 0 77  33312333 1 0 36 
21232212 1 0 60  33313233 1 0 37 
21232222 1 0 36  33313323 1 -- 42 
21232231 1 0 85  33313333 1 0 21 
21232232 1 0 57  33331232 1 -- 61 
21232233 1 0 82  33331233 1 -- 32 
21232321 1 0 80  33331333 1 -- 16 
21232322 1 0 52  33332131 1 -- 67 
21232323 1 0 81  33332133 1 -- 35 
21232332 1 0 73  33332232 1 -- 60 
21233111 1 0 80  33332233 1 -- 31 
21233132 1 0 92  33332323 1 -- 36 
21233212 1 1 75  33332333 1 0 15 
21233221 1 -- 79  33333231 1 0 48 
21233233 1 0 67  33333232 1 -- 45 
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21233312 1 -- 91  33333233 1 -- 16 
21233321 1 -- 95  33333323 1 -- 21 
21311122 1 1 80  33333333 1 0 0 
21311223 1 0 89  11313223 0* -- 101 
21311331 1 0 81  11333323 0* -- 69 
21312111 1 0 57  12212223 0* -- 85 
21312112 1 1 85  12331221 0* -- 91 
21312122 1 1 66  12332123 0* -- 108 
21312123 1 0 95  13132333 0* -- 58 
21312211 1 0 77  13311311 0* -- 43 
21312222 1 1 46  13331123 0* -- 91 
21312223 1 0 75  13331333 0* -- 50 
21312321 1 0 90  13332332 0* -- 78 
21312322 1 1 62  13333123 0* -- 75 
21312323 1 0 91  13333223 0* -- 71 
21313111 1 0 59  13333233 0* -- 50 
21313112 1 1 87  13333323 0* -- 55 
21313122 1 1 81  21113222 0* -- 63 
21313221 1 0 89  21133123 0* -- 94 
21313231 1 1 97  21233322 0* -- 67 
21313311 1 0 79  21312121 0* -- 81 
21313312 1 1 101  21331112 0* -- 92 
21313313 1 0 83  22232213 0* -- 72 
21313322 1 1 77  23231121 0* -- 99 
21331223 1 0 86  23232221 0* -- 65 
21331332 1 0 89  23313322 0* -- 78 
21331333 1 0 60  23333122 0* -- 79 
21332111 1 0 78  31131323 0* -- 60 
21332112 1 0 87  31212132 0* -- 103 
21332113 1 0 97  31233111 0* -- 80 
21332122 1 0 63  32111211 0* -- 71 
21332131 1 0 96  32212122 0* -- 72 
21332212 1 0 67  32232222 0* -- 49 
21332221 1 0 71  32333322 0* -- 68 
21332223 1 0 72  33112112 0* -- 90 
21332231 1 0 92  33133323 0* -- 30 
21332233 1 0 75  33232322 0* -- 72 
21332312 1 0 83  33331223 0* -- 53 
21332322 1 0 59  33331321 0* -- 69 
21332323 1 -- 80  33332221 0* -- 84 
21332331 1 0 91  33333321 0* -- 53 
21332332 1 0 80  11112123 0 -- 70 
21332333 1 -- 59  11113223 0 -- 92 
21333111 1 0 80  11132223 0 -- 108 
21333122 1 0 78  11132232 0 -- 100 
21333131 1 0 96  11132323 0 -- 93 
21333132 1 -- 93  11231232 0 -- 96 
21333211 1 0 100  11232323 0 -- 91 
21333212 1 1 82  11331123 0 -- 86 
21333221 1 0 86  11332221 0 -- 88 
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21333223 1 0 81  11333122 0 -- 98 
21333233 1 0 60  12133223 0 -- 98 
21333312 1 0 91  12211222 0 -- 70 
21333321 1 0 97  12231231 0 -- 85 
21333333 1 1 44  12233112 0 -- 91 
22111223 1 0 74  12233323 0 -- 80 
22111332 1 1 82  12311333 0 -- 89 
22112111 1 -- 65  12331211 0 -- 67 
22112131 1 0 83  13132223 0 -- 95 
22112211 1 0 83  13132322 0 -- 96 
22112223 1 0 60  13133323 0 -- 64 
22112321 1 -- 75  13212122 0 -- 89 
22112323 1 0 76  13212321 0 -- 81 
22112331 1 0 96  13231332 0 -- 86 
22113111 1 0 67  13232123 0 -- 97 
22113211 1 -- 87  13232311 0 -- 78 
22113223 1 0 75  13232323 0 -- 77 
22113232 1 1 67  13233133 0 -- 61 
22113233 1 0 94  13233233 0 -- 57 
22113313 1 -- 96  13233322 0 -- 91 
22113323 1 0 91  13332223 0 -- 86 
22113332 1 1 83  13333222 0 -- 93 
22131221 1 0 70  21111112 0 -- 62 
22132112 1 1 72  21111212 0 -- 82 
22132113 1 0 101  21111312 0 -- 82 
22132212 1 1 52  21111322 0 -- 78 
22132231 1 0 77  21131111 0 -- 55 
22132233 1 0 78  21131212 0 -- 83 
22132312 1 -- 68  21131321 0 -- 99 
22132323 1 0 73  21132121 0 -- 93 
22132331 1 0 93  21133212 0 -- 84 
22133112 1 1 87  21211113 0 -- 75 
22133211 1 0 95  21211122 0 -- 73 
22133212 1 1 67  21211211 0 -- 63 
22133232 1 1 64  21211222 0 -- 53 
22133312 1 0 83  21233112 0 -- 95 
22133322 1 1 59  21311111 0 -- 43 
22133323 1 1 78  21311311 0 -- 63 
22212111 1 0 74  21311333 0 -- 81 
22212123 1 0 71  21312212 0 -- 70 
22212131 1 0 91  21331111 0 -- 64 
22212212 1 1 46  21331131 0 -- 82 
22212232 1 1 43  21331312 0 -- 97 
22212312 1 -- 62  21331313 0 -- 78 
22212321 1 0 66  21333121 0 -- 104 
22212322 1 1 38  21333133 0 -- 64 
22213111 1 -- 76  21333331 0 -- 76 
22213112 1 0 81  21333332 0 -- 73 
22213132 1 1 78  22111231 0 -- 89 
22213212 1 1 61  22113132 0 -- 87 
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22213222 1 1 37  22121331 0 -- 88 
22213223 1 0 66  22131111 0 -- 72 
22213233 1 0 87  22131112 0 -- 86 
22213312 1 0 77  22131132 0 -- 83 
22213321 1 -- 81  22131133 0 -- 93 
22222121 1 0 48  22131222 0 -- 42 
22222222 1 1 0  22131321 0 -- 86 
22231221 1 0 61  22211132 0 -- 77 
22231223 1 -- 62  22211222 0 -- 36 
22232112 1 -- 63  22211331 0 -- 98 
22232121 1 0 67  22211332 0 -- 73 
22232122 1 0 39  22231113 0 -- 106 
22232123 1 0 68  22231122 0 -- 53 
22232212 1 1 43  22231211 0 -- 85 
22232222 1 1 19  22231212 0 -- 57 
22232223 1 0 48  22231232 0 -- 54 
22232232 1 1 40  22231311 0 -- 101 
22232233 1 0 69  22231312 0 -- 73 
22232311 1 0 87  22231333 0 -- 71 
22232312 1 0 59  22233331 0 -- 87 
22232322 1 0 35  22233333 0 -- 55 
22232323 1 -- 64  22311121 0 -- 84 
22232331 1 0 84  22311212 0 -- 67 
22232333 1 0 70  22311231 0 -- 92 
22233112 1 1 78  22311332 0 -- 80 
22233211 1 0 86  22313333 0 -- 69 
22233212 1 1 58  22331121 0 -- 88 
22233221 1 0 62  22331133 0 -- 84 
22233222 1 -- 34  22331211 0 -- 92 
22233223 1 -- 63  22331212 0 -- 64 
22233312 1 -- 74  22331222 0 -- 40 
22233323 1 0 76  22331321 0 -- 84 
22233332 1 -- 71  22333111 0 -- 97 
22311123 1 0 92  23111112 0 -- 76 
22312111 1 0 74  23111212 0 -- 87 
22312123 1 0 78  23112123 0 -- 98 
22312132 1 1 70  23112222 0 -- 49 
22312133 1 0 99  23131332 0 -- 84 
22312211 1 0 81  23132322 0 -- 62 
22312221 1 -- 57  23133312 0 -- 86 
22312222 1 1 29  23211121 0 -- 81 
22312223 1 0 58  23211131 0 -- 75 
22312231 1 0 78  23211222 0 -- 54 
22312232 1 1 50  23211311 0 -- 77 
22312311 1 0 94  23211332 0 -- 91 
22312312 1 -- 69  23212312 0 -- 80 
22312322 1 1 45  23213231 0 -- 104 
22312332 1 0 66  23231212 0 -- 75 
22312333 1 0 84  23231323 0 -- 74 
22313122 1 1 64  23232223 0 -- 66 
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22313212 1 0 68  23233322 0 -- 68 
22313221 1 0 72  23311112 0 -- 85 
22313222 1 -- 44  23311221 0 -- 89 
22313232 1 1 65  23311222 0 -- 61 
22313233 1 0 85  23311313 0 -- 85 
22313323 1 1 89  23313121 0 -- 97 
22313331 1 0 101  23313231 0 -- 99 
22313332 1 0 81  23331112 0 -- 102 
22323313 1 0 85  23331212 0 -- 82 
22331123 1 0 89  23331232 0 -- 79 
22331221 1 -- 68  23332322 0 -- 60 
22331223 1 0 69  31112121 0 -- 72 
22331323 1 0 85  31113321 0 -- 94 
22331332 1 0 77  31131312 0 -- 86 
22332112 1 1 70  31132221 0 -- 103 
22332113 1 0 99  31132223 0 -- 75 
22332121 1 0 74  31132311 0 -- 88 
22332123 1 0 75  31132312 0 -- 85 
22332132 1 1 67  31133112 0 -- 90 
22332211 1 0 78  31133123 0 -- 64 
22332221 1 0 54  31133212 0 -- 86 
22332222 1 1 26  31211122 0 -- 95 
22332223 1 0 55  31211132 0 -- 89 
22332232 1 -- 47  31211211 0 -- 63 
22332233 1 0 76  31211312 0 -- 91 
22332312 1 0 66  31212113 0 -- 89 
22332321 1 -- 70  31212211 0 -- 77 
22332322 1 0 42  31213122 0 -- 104 
22332332 1 0 63  31213223 0 -- 79 
22333112 1 0 85  31231211 0 -- 84 
22333122 1 0 61  31231311 0 -- 84 
22333131 1 0 100  31231323 0 -- 58 
22333132 1 0 82  31232322 0 -- 82 
22333133 1 0 68  31233122 0 -- 91 
22333211 1 0 93  31233133 0 -- 41 
22333212 1 1 65  31233222 0 -- 81 
22333221 1 0 69  31311112 0 -- 71 
22333222 1 -- 41  31311122 0 -- 95 
22333223 1 0 70  31311212 0 -- 91 
22333231 1 0 90  31311312 0 -- 91 
22333311 1 0 98  31312221 0 -- 101 
22333313 1 -- 66  31313123 0 -- 76 
22333321 1 0 85  31313222 0 -- 91 
22333323 1 -- 69  31313321 0 -- 88 
22333332 1 0 77  31331221 0 -- 99 
23112213 1 0 102  31331222 0 -- 87 
23112221 1 0 77  31331223 0 -- 67 
23112223 1 0 78  31331332 0 -- 59 
23112233 1 0 91  31332112 0 -- 96 
23112323 1 0 94  31332132 0 -- 78 
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23112333 1 0 75  31332221 0 -- 98 
23113111 1 0 64  31333112 0 -- 81 
23113112 1 0 92  31333222 0 -- 80 
23113121 1 0 88  31333223 0 -- 51 
23113131 1 0 82  31333232 0 -- 59 
23113212 1 -- 88  31333311 0 -- 64 
23113311 1 0 84  32111112 0 -- 79 
23113312 1 0 104  32111121 0 -- 75 
23113323 1 0 81  32111123 0 -- 105 
23113332 1 0 89  32111311 0 -- 71 
23122212 1 -- 51  32112232 0 -- 82 
23131323 1 -- 76  32112311 0 -- 85 
23132111 1 0 83  32113112 0 -- 95 
23132121 1 -- 94  32131212 0 -- 96 
23132212 1 -- 70  32131311 0 -- 92 
23132221 1 0 74  32132211 0 -- 106 
23132231 1 0 95  32132212 0 -- 82 
23132232 1 0 67  32132221 0 -- 86 
23132233 1 0 70  32133113 0 -- 65 
23132311 1 0 103  32133122 0 -- 93 
23132323 1 -- 75  32133212 0 -- 90 
23133112 1 -- 105  32133223 0 -- 64 
23133113 1 0 77  32133311 0 -- 77 
23133121 1 0 109  32133312 0 -- 74 
23133233 1 0 55  32133321 0 -- 80 
23133311 1 0 89  32133323 0 -- 48 
23133321 1 -- 92  32211111 0 -- 60 
23133331 1 0 71  32211112 0 -- 88 
23133333 1 -- 39  32211133 0 -- 82 
23211132 1 -- 95  32211212 0 -- 90 
23212112 1 -- 84  32212111 0 -- 74 
23212211 1 0 91  32212311 0 -- 94 
23212212 1 0 64  32213311 0 -- 96 
23212221 1 0 68  32213312 0 -- 93 
23212222 1 0 40  32231122 0 -- 83 
23212231 1 0 89  32231222 0 -- 63 
23212332 1 -- 77  32231332 0 -- 70 
23212333 1 0 73  32232111 0 -- 95 
23213112 1 0 99  32232133 0 -- 60 
23213121 1 0 97  32232212 0 -- 73 
23213123 1 -- 99  32232213 0 -- 74 
23213211 1 0 93  32232221 0 -- 77 
23213212 1 1 79  32233112 0 -- 92 
23213223 1 -- 84  32233122 0 -- 84 
23213232 1 0 76  32233123 0 -- 66 
23213311 1 0 93  32233232 0 -- 70 
23213322 1 -- 71  32233233 0 -- 41 
23213333 1 0 58  32311132 0 -- 104 
23231233 1 0 69  32311212 0 -- 97 
23232113 1 -- 90  32311221 0 -- 101 
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23232131 1 0 104  32311322 0 -- 89 
23232211 1 0 89  32313122 0 -- 94 
23232212 1 -- 61  32313212 0 -- 98 
23232233 1 0 68  32313222 0 -- 74 
23232311 1 -- 102  32331111 0 -- 81 
23232323 1 -- 73  32331112 0 -- 101 
23233212 1 0 76  32331122 0 -- 90 
23233221 1 -- 80  32331132 0 -- 83 
23233231 1 0 85  32331212 0 -- 94 
23233232 1 -- 73  32331221 0 -- 98 
23233312 1 -- 84  32331222 0 -- 70 
23233333 1 -- 37  32331311 0 -- 84 
23311233 1 -- 83  32331313 0 -- 52 
23311323 1 0 88  32332111 0 -- 95 
23312111 1 0 71  32332112 0 -- 100 
23312112 1 0 91  32332123 0 -- 74 
23312121 1 0 95  32332211 0 -- 99 
23312122 1 -- 67  32332212 0 -- 80 
23312123 1 0 96  32332222 0 -- 56 
23312131 1 0 89  32333122 0 -- 88 
23312223 1 -- 76  32333212 0 -- 81 
23312311 1 0 91  32333311 0 -- 68 
23312312 1 0 87  33111122 0 -- 100 
23312323 1 0 87  33111212 0 -- 96 
23313111 1 0 73  33111222 0 -- 93 
23313133 1 -- 71  33111312 0 -- 93 
23313212 1 0 86  33113121 0 -- 88 
23313222 1 0 62  33113223 0 -- 67 
23313232 1 0 83  33131122 0 -- 95 
23313233 1 0 67  33131123 0 -- 66 
23313323 1 0 72  33131332 0 -- 54 
23313333 1 0 51  33132222 0 -- 76 
23331233 1 0 62  33132223 0 -- 61 
23331323 1 -- 67  33132322 0 -- 74 
23332112 1 0 88  33133121 0 -- 82 
23332221 1 0 72  33133223 0 -- 46 
23332222 1 -- 44  33133233 0 -- 25 
23332223 1 0 73  33133321 0 -- 62 
23332231 1 0 93  33133332 0 -- 38 
23332311 1 0 95  33211112 0 -- 85 
23332323 1 0 66  33211211 0 -- 77 
23332331 1 0 77  33211312 0 -- 91 
23333111 1 0 94  33211321 0 -- 97 
23333123 1 -- 71  33212222 0 -- 70 
23333131 1 0 82  33212312 0 -- 90 
23333211 1 -- 96  33212313 0 -- 61 
23333212 1 0 83  33213112 0 -- 95 
23333213 1 0 64  33231212 0 -- 86 
23333222 1 -- 59  33231221 0 -- 92 
23333223 1 0 67  33231312 0 -- 70 
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23333232 1 0 75  33231333 0 -- 23 
23333233 1 0 46  33232112 0 -- 89 
23333312 1 0 77  33232122 0 -- 87 
23333323 1 -- 51  33232123 0 -- 63 
31111233 1 -- 76  33232222 0 -- 67 
31112231 1 0 86  33232223 0 -- 59 
31112333 1 1 59  33232323 0 -- 43 
31113131 1 1 68  33233112 0 -- 74 
31113132 1 1 93  33233221 0 -- 76 
31113222 1 -- 93  33233222 0 -- 73 
31113323 1 -- 65  33233223 0 -- 44 
31113331 1 1 76  33233323 0 -- 28 
31113332 1 -- 73  33311122 0 -- 107 
31131233 1 -- 55  33311223 0 -- 74 
31132231 1 0 86  33311311 0 -- 77 
31132232 1 0 83  33311312 0 -- 84 
31132333 1 -- 38  33311322 0 -- 87 
31133233 1 -- 39  33311332 0 -- 66 
31133331 1 -- 55  33312233 0 -- 52 
31211131 1 0 61  33312312 0 -- 83 
31211232 1 0 103  33312323 0 -- 57 
31212112 1 -- 85  33313122 0 -- 91 
31212212 1 0 93  33313223 0 -- 58 
31212232 1 0 90  33313311 0 -- 71 
31212321 1 0 101  33331122 0 -- 86 
31212323 1 0 78  33331133 0 -- 36 
31212331 1 1 89  33331311 0 -- 66 
31212332 1 0 86  33331331 0 -- 48 
31212333 1 1 57  33332112 0 -- 82 
31213232 1 -- 87  33332121 0 -- 88 
31213233 1 1 58  33332123 0 -- 56 
31213323 1 -- 63  33332211 0 -- 81 
31213331 1 1 74  33332223 0 -- 52 
31213332 1 1 71  33333133 0 -- 20 
31232231 1 -- 84  33333222 0 -- 66 
31232312 1 -- 83  33333223 0 -- 37 
31232332 1 0 65  33333311 0 -- 50 
31232333 1 0 36  33333332 0 -- 29 
31233221 1 -- 90           
1Sequence listed as parent sequence (A1 = 1, A2 =2, A3 = 3) at each block. 
2Folding state is 1 for P450s and 0 for no P450; * signifies significant P420 peak. 
3Chimeras with at least 25% of total product formed by A1 in 30 minutes are active = 1, not 
active = 0, -- = did not meet minimum P450 concentration requirement of 500 nM. 
4m is number of sequence changes relative to the closest parent sequence. 
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Appendix C 
 
Substrates tested with the 4-AAP assay 
 
This table lists the substrates tested for activity with members of the chimeric library 
described in Chapter 5, 6 and 7. An x in activiy column designates the appearance of a 
red color over background as well an increase in absorbance near 500 nm. 
 
 
Table C.1. Substrates used for activity tests with chimeric P450s with the 4-AAP assay. 
Substrate Activity Notes 
1,2-methylenedioxybenzene     
1,2-methylenedioxybenzene   
11-phenoxyundecanoic acid x fatty acid analog 
1-phenyldecane x  
1-phenyloctane x  
2,3-(methylenedioxy)benzaldehyde   
2,6-dichlorobenzonitrile   
2-phenoxyethanol x bactericide 
3-phenoxytoluene x  
4-aminobiphenyl x carcinogenic 
4-chromanone   
5α-cholestane  cholesterol derivative 
9-amino-1,2,3,4-tetrahydroacridine  drug, cholinesterase inhibitor, a.k.a. Tacrine, Cognex 
allyloxybenzene x a.k.a. allyl phenyl ether, background with 4-AAP 
anthracene   
benzene  carcinogenic 
benzofuran-2-carboxylic acid   
benzyl ether  flavoring agent 
benzylacetone   
chlorzoxazone x drug, muscle relaxant 
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cinnamaldehyde  flavoring agent 
cinnamic acid   
coumarone  a.k.a. Benzofuran, high-background with 4-AAP 
diclofenac  drug-like, anti inflammatory 
diphenyl ether x a.k.a. 2-methylbenzofuran 
diphenyl ether   
DL-mandelic acid   
DL-α-phenylglycine   
dopamine  neurotransmitter 
ethyl-4-phenylbutyrate x  
ethylphenoxyacetate x  
isosafrol   
melatonin  neurotransmitter 
methoxychlor  insecticide 
methylphenoxyacetate x  
naphthalene  holoenzyme 
naproxen  drug, non-steroidal anti-inflammatory, a.k.a. Aleve 
p-acetophenetidide  a.k.a phenacetin 
phenethyl alcohol  holoenzyme 
ethoxybenzene x a.k.a. phenetole 
propranolol x drug, beta blocker 
pseudocumene   
serotonin  neurotransmitter 
tolbutamide x drug, stimulates insulin secretion 
warfarin  drug, anticoagulent 
zoxazolamine x drug, muscle relaxant, a.k.a. 2-amino-5-chlorobenzoxazole 
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Appendix D 
 
Spectra of drug compounds and their products 
 
 
 
 
 
 
Figure D.1. UV-Vis spectra of chlorzoxazone (A) and 6-hydroxychlorzoxazone (B). 
 
 
 
 
Figure D.2. UV-Vis spectra of zoxazolamine (A) and 6-hydroxyzoxazolamine (B). 
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Figure D.3. UV-Vis spectra of tolbutamide (A), carboxytolbutamide (B) and 4-
hydroxytolbutamide (C). 
 
 
Figure D.4. UV-Vis spectra of  4-aminobiphenyl (A) and 4,4’-azobis(biphenyl) (B). 
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Figure D.5. UV-Vis spectra of propranolol (A), 4’-hydroxypropranolol (B), 5’-
hydroxypropranolol (C), desisopropylpropranolol (D), 1-nphthol (E). 
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Appendix E 
 
Creating chimeras of more distantly related P450s 
 
 
 
To begin to explore the methodology of recombining more distantly related P450s, two 
chimeras between CYP102A1 and CYP101 (15% amino acid identity) were constructed. 
Chimeras made from P450s with low sequence identity (< 30%) have been successfully 
constructed before but have only contained single crossovers near the N- or C-termini of 
the enzyme [1,2]. In order to create large libraries between distantly related P450s, one 
must address the main issue of decreased accuracy in the sequence alignment due to 
lower sequence identity and a larger number of insertions and deletions. A sequence 
alignment alone, such as ClustalW [3], would likely yield little success since the aligned 
sequences may not structurally correlate. To remedy this, a structure-based alignment 
such as 3D-Coffee [4] or combinatorial extension [5] can be employed to correctly align 
elements of the core structure.  
 
Two chimeras were designed by first aligning their structures using combinatorial 
extension and generating a structure-based sequence alignment (Figure E.1). This was 
done using PDB’s 1JPZ [7] and 1AKD [8] for CYP102A1 and CYP101, respectively. 
Using this alignment, two structural elements were swapped to create two chimeras. The 
first chimera, named 172-224, has the F and G helices from CYP101 swapped into 
CYP102A1 (Figure E.2A). This resulted in 31 mutations and a deletion of 16 amino acids 
relative to CYP102A1. Chimera 234-266 has a direct replacement of the I-helix in 
CYP102A1 with the I helix from CYP101 resulting in 24 mutations (Figure E.2B).  
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A. 
 
CYP102A1    ALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKN--LSQALKFVRDFAGDG     85 
CYP101      AWAVLQESNVPDLVWTRCNGGHWIATRGQLIREAYEDYRHFSSECPFIPREAGEA--YDF     99 
 
CYP102A1    LATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPE-D    144 
CYP101      IPTSMDPPE-QRQFRALANQVVGMPVVDKLENRIQELACSLIESLRPQ---GQCNFTEDY    155 
 
CYP102A1    MTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQ    204 
CYP101      AEPFPIRIFMLL-AGLPEED-----IPHLKYLTDQMTRPD----------------GSMT    193 
 
CYP102A1    FQEDIKVMNDLVDKIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIA    264 
CYP101      FAEAKEALYDYLIPIIEQRR--QKPGTDAISIVANGQVN--GRPITSDEAKRMCGLLLVG    249 
 
CYP102A1    GHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRL    324 
CYP101      GLDTVVNFLSFSMEFLAKSPEHRQELIQRP-----------------ERIPAACEELLRR    292 
 
CYP102A1    WPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFENPSA    384 
CYP101      FSLVADGRILTSDYEFH--GVQLKKGDQILLPQMLSGLDERENAC-PMHVDFSRQ----K    345 
 
CYP102A1    IPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTN-YELDIKETLTLKPEG    443 
CYP101      V---SHTTFGHGSHLCLGQHLARREIIVTLKEWLTRIPDFSIAPGAQIQHKSGIVSGVQA    402 
  
CYP102A1    FVVKAK---SKKI                                                   453 
CYP101      LPLVWDPATTKAV                                                   415 
 
B. 
 
CYP102A1    ALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQALKFVRDFAGDGLF     87 
CYP101      AWAVLQESNVPDLVWTRCNGGHWIATRGQLIREAYEDYR---HFSSECPFIPREAG----     94 
 
CYP102A1    TSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIA-VQLVQKWERLNADEHIEVPEDMT    146 
CYP101      ----------EAYDFIPTSMDPPEQRQFRALANQVVGMPVVDKLENRIQELACSLIESLR    144 
 
CYP102A1    RLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQ    206 
CYP101      -----PQGQCNFTEDYAEPFPIR----IFMLLAGLPEEDIPHLKYLTDQMTRPDGSMTFA    195 
 
CYP102A1    EDIKVMNDLVDKIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGH    266 
CYP101      EAKEALYDYLIPIIEQRRQ--KPGTDAISIVANG--QVNGRPITSDEAKRMCGLLLVGGL    251 
 
CYP102A1    ETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWP    326 
CYP101      DTVVNFLSFSMEFLAKSPEHRQELIQRPERIPAA-----------------CEELLRRFS    294 
 
CYP102A1    TAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFENPSAIP    386 
CYP101      LVADGRILTSDYEFHG--VQLKKGD--QILLPQMLSG----LDERENACPMHVDFS--RQ    344 
 
CYP102A1    QHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHF-DFEDHTNYELDIKETLT--LKPEG    443 
CYP101      KVSHTTFGHGSHLCLGQHLARREIIVTLKEWLTRIPDFSIAPGAQIQHKSGIVSGVQALP    404 
 
CYP102A1    FVVKAKSKKI-                                                     453 
CYP101      LVWDPATTKAV                                                     415 
 
Figure E.1. Sequence alignments of CYP102A1 and CYP101 based on structure (A) 
using combinatorial extension [5] and sequence (B) using ClustalW [3]. 
 
 
 
 261
 
 
Figure E.2 Structural alignments of sequence elements swapped in CYP102A1-CYP101 
chimeras. (A) Structural alignment of the F and G helices from CYP102A1 (blue) and 
CYP101 (purple) in 172-224. (B) Structural alignment of the I helices from CYP102A1 
and CYP101 in 234-266. 
 
 
Chimeras were assembled using SOEing from the heme domain of CYP102A1 with the 
F87A mutation and the wild-type sequence of CYP101 [6]. They were then expressed 
and analyzed as discussed in Chapter 3. Carbon monoxide difference spectroscopy 
showed that chimera 172-224 was able to correctly bind its heme cofactor and thus 
correctly fold into a cytochrome P450. Chimera 234-266, however, did not. Since it 
folded into a P450, 172-224 was tested for activity on 12-pNCA but showed no 
production of p-nitrophenol in the presence of 1 and 20 mM H2O2. Residue 87 was 
mutated back to phenylalanine, the residue present in the wild-type CYP102A1 seqence, 
and tested for activity on 12-pNCA. It was still inactive. Other tests could include testing 
for activity on camphor, the ‘natural’ substrate of CYP101 or the use of a reductase 
domain and NADPH in place of H2O2 to supply reducing equivalents.  
 
Figure E.3 shows the alignments of the F and G helices that were swapped between 
CYP102A1 and CYP101 in chimera 172-224. Comparison of the structural and 
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sequence-based alignments shows a very different correspondence between amino acids. 
Figure E.2A shows that the insertion was correctly aligned in the structural alignment and 
that CYP101 has shortened F and G helices relative to CYP102A1. The sequence 
alignment using ClustalW does not identify this alignment and would likely result in the 
swapping of structurally incompatible elements. Further experiments would need to be 
performed to confirm this. Chimera 234-266 was likely unsuccessful since the I helix 
makes up the core of the P450 structure and the sequence changes are highly disruptive. 
Obviously more work is needed here but these methodologies could be extended to 
choose swappable elements for the creation of a large library in conjunction with 
computational algorithms to minimize structural disruption (i.e. SCHEMA [9]).  
 
 
Structural alignment 
CYP102A1    FITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRK  
CYP101      LKYLTDQMTRPD----------------GSMTFAEAKEALYDYLIPIIEQRR 
 
Sequence alignment 
CYP102A1    FITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRK 
CYP101      -IFMLLAGLPEEDIPHLKYLTDQMTRPDGSMTFAEAKEALYDYLIPIIEQRR 
      
Figure E.3. The structural alignment compared to the sequence alignment for the F and 
G helices swapped in chimera 172-224. 
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Appendix F 
 
Miscellaneous laboratory methods 
 
 
 
This appendix includes laboratory methods used in this research that are unpublished 
since they were not part of the primary methodologies. They were frequently requested 
by other lab members and are thus included here. 
 
Preparation of electrocompetent cells 
Materials 
1.   1 L of LB media with appropriate antibiotics (Fernbock) 
2.   10 mL of LB media (in a 100 or 250 ml flask) 
3.   1.75 L ice-cold 10% glycerol (autoclaved and stored at 4°C) 
4.   Two large centrifuge bottles (autoclaved and stored at 4°C) 
5.   Fifty 1.7 ml microcentrifuge tubes (autoclaved and stored at 4°C) 
 
Methods 
Keep all materials as close to 4 ºC as possible throughout the preparation. Resuspend 
cells gently with pipette. Do not vortex. 
1. Inoculate a 10 ml culture of LB with your cell strain. Grow overnight at 30ºC. 
2.Subculture the 10 ml into 1 liter of fresh LB. Grow at 30ºC until the OD reaches 0.8 
to 0.9 (generally 3-4 hours). 
3. Put on ice or in refrigerator for 10 minutes. 
4.Spin down cells at 5,000 xg for 10 minutes. You will lose some of the cells here 
(~10%) if you only use two bottles. 
5. Resuspend in 1 growth volume of ice-cold 10% glycerol. 
6. Spin down at 5,000 xg for 10 minutes. 
7. Resuspend in ½ growth volume of ice-cold 10% glycerol. 
8. Spin down at 5,000 xg for 10 minutes. 
9. Resuspend in 1/500 growth volume of ice-cold 10% glycerol. 
10. Flash freeze in 100 µL aliquots in cold eppendorf tubes. Makes about 30 tubes. 
11. Store at -80ºC. 
 
Stripping blots for probe hybridization 
Blots refer to nitrocellulose paper with bound DNA used for DNA probe hybridization 
(southern blots). They were used here for high-throughput sequencing. 
 
Materials 
1.   Old blots 
2.   400 ml 0.1% SDS per blot to be stripped 
3.   Hybridization oven set at 80°C 
4.   TE buffer, pH 8.0 (10 mM Tris (pH 8.0), 1 mM EDTA (pH 8.0)) 
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Methods 
1. Boil 0.1% SDS. 
2. Add boiling 0.1% SDS to blot in hybridization bottle (100 ml per bottle works 
well). 
3. Put hybridization bottle in hybridization oven (set at 80°C) for 10 minutes. 
4. Repeat a total of four times. 
5. Wash each blot once in 20 ml TE buffer, pH 8.0. 
6. Store blots in small volume of TE buffer pH 8.0 (enough to cover blot). 
 
Storage of cells in 96-well microtiter plates 
This method is useful for storing libraries or large numbers of individual clones for long 
periods of time. 
 
Materials 
1.   Sterilized 96-well plates 
2.   LB media with appropriate antibiotics 
3.   50% glycerol (sterilized) 
4.   96-well plates with the clones that are to be stored 
 
Methods 
1.  Label sterilized 96-well plates. It is suggested that the plates be labeled on the 
edge and the top or bottom for easy identification and in case a label is lost or 
destroyed. 
2.  In a sterile hood, fill each well of the 96-well microtiter plate with 120 µl of LB  
media with the appropriate antibiotics. 
3.  Using a 96-well replicator, transfer small amounts of culture from an existing 96-
well plate with saturated cultures of the clones to be stored. 
4. Wrap plate with parafilm and grow for 14 to 20 hours. 
5. Remove from shaker and add 60 µl of 50% glycerol to each well of the 96-well 
microtiter plate in a sterile hood. 
6. Shake at 100 rpm for 10 minutes at room temperature. 
7. Store at -80°C. 
 
